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The iminosugar N-butyl-1-deoxynojirimycin (nB-DNJ) has reversible, non-
hormonal contraceptive effects on C57B/L6 mice at micromolar concentrations.  
In order to increase the potency and bioavailability of this lead compound, a 
series of novel iminosugars was synthesized as inhibitors of two potential target 
enzymes – ceramide-specific glucosyltransferase (CGT) and β-glucosidase 2 
(GBA2).  The new derivatives were shown to be inactive as inhibitors of CGT and 
are awaiting testing in a GBA2 assay. Efforts were made to identify additional 
protein targets of the iminosugars by preparing two iminosugar affinity labels that 
were used to isolate a potential new iminosugar target. 
A method was developed to functionalize 2,3-dihydropyridin-4(1H)-ones 
by taking advantage of the nitrogen-induced nucleophilicity of the beta-carbon 
(C5) of the enamine moiety.  Reaction of 2,3-dihydropyridin-4(1H)-ones with 
aliphatic and aromatic aldehydes under acidic conditions furnished 5,5’-
(methylene)bis(2,3-dihydropyridin-4(1H)-ones). In the presence of the reducing 




chemistry was extended to 4-(pyrrolidin-1-yl)furan-2(5H)-one, an enaminone with 
an exocyclic nitrogen.  A three-component Mannich aminomethylation of 2,3-
dihydropyridin-4(1H)-ones and 4-(pyrrolidin-1-yl)furan-2(5H)-one, carbamates, 
and formaldehyde was achieved when lithium perchlorate was present in the 
reaction mixture. This chemistry was extended to the reaction of exocyclic 
enaminones with formaldehyde and malonates to furnish the corresponding 
methylmalonates. Mechanist studies suggest that this reaction proceeds via the 
formation of 2-methylenemalonates (Knoevenagel condensation), which is 
followed by a nucleophilic (Michael) addition of the enaminone to the 
methylenemalonates.  The methylmalonate reaction products were cyclized 
under acidic conditions to form bicyclic lactams (octahydroquinoline-3-
carboxylates and cyclopenta[b]pyridine-3-carboxylates).  Oxidation of the 
octahydroquinoline-3-carboxylates furnished 2,5-dioxo-1,2,5,6,7,8-
hexahydroquinoline-3-carboxylates, a class of compounds known to possess 
ionotropic properties. In a related reaction, 3-aminocyclohex-2-enones, 
formaldehyde and methyl cyanoacetate directly furnished the corresponding 
bicyclic 2,5-dioxo-1,2,3,4,5,6,7,8-octahydroquinoline-3-carbonitriles.  In this case 
the reaction was catalyzed by a phosphine, which promoted both, the 
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Figure 1. Use of male contraceptives in developed and developing countries, 










 Use of modern contraceptives benefits women and their partners in many 
ways.  Access to contraceptives allows couples to make responsible decisions 
and to reduce unintended pregnancies, unplanned births and abortions.2 Despite 
a negative stereotype of men being irresponsible regarding birth control, a 
positive attitude toward male contraception has been acknowledged on a cross-
cultural basis.3 However, compared to the broad availability of female options, 
methods of male contraception are limited (Figure 1).1  
Among the most common existing male methods, withdrawal is known as 
unreliable;4 condoms are often not accepted as a long-term contraceptive 




alternative method, vasectomy has significant drawbacks, because the reversal 
procedure (vasovasectomy) is costly and effective in achieving pregnancy in only 
~50% of cases.6,7 Male hormonal contraceptives are often linked to side effects 
caused by synthetic androgen in the regimen, including acne, muscle gain and 
cardiovascular risks.8-10 To develop a new, safe, effective and reversible male 
contraceptive is clearly a great need.  Given the high cost of development, 
biological approaches (vaccines, antibodies, proteins, etc.) are less likely to be 
commercially viable in the market compared to small molecule therapeutics.  
Therefore, the strategy is to focus on obtaining small molecules that interact with 
targets present in the male reproductive system, which could potentially lead to a 
male contraceptive agent.   
Yet, there are obstacles in the path to discovering an ideal male 
contraceptive.  First of all, its efficacy should be at least equal to that of the 
current female oral contraceptives.  In order to meet this requirement, a male 
contraceptive has to be potent enough to inactivate 250 × 106 sperms in one 
ejaculate, while female hormonal agents only need to suppress ovulation of one 
or a few occytes.  Secondly, an ideal “male pill” is supposed to take action 
without displaying adverse effects.  And lastly, a good pharmacokinetic profile is 
necessary to deliver the contraceptive to its site of action, in particular, to 
traverse the blood-testis barrier. 
In 2002, van der Spoel et al. reported that an alkylated iminosugar, N-butyl 
1-deoxynojirimycin (nB-DNJ) achieved reversible infertility in male mice.11 The 




suggested that the hurdles listed previously were not insurmountable with this 
class of compounds.  
  Iminosugars, first isolated and synthesized in the 1960’s,12,13 differ from 
monosaccharides in that the endocyclic oxygen atom is replaced by a basic 
nitrogen. They are widespread in plants and microorganisms and are often 
inhibitors of glycosidases.  Iminosugars structurally resemble the sugar moiety of 
the natural enzyme substrates (Figure 2).14 Since the protonated nitrogen atom 
mimicks the positive charge of the oxocarbenium transition state of the natural 
substrate, in the enzyme catalytic process, the iminosugar is incorporated into 
















1.1.1 CGT as target of nB-DNJ 
The N-alkylated iminosugar, nB-DNJ (Miglustat, Zavesca), is used to 
treat glycosphingolipids (GSLs) storage disorders such as Gaucher’s disease.15 
The pharmacological mechanism of action involves the inhibition of ceramide-
specific glucosyltransferase (CGT),16,17 a key enzyme that occupies a bridging 
position in the GSLs metabolic pathway, and connects glucose with complex 
lipids.  GSLs are also abundant in sperm18,19 and appear to be crucial in the 




biosynthetic pathway are infertile.20,21 Thus, the GSLs biosynthetic pathway is 
thought to provide a good target for small molecule-induced male fertility control, 
mainly via the inhibition of CGT, as depicted in Figure 3.  


























As demonstrated in van der Spoel’s research, C57BL/6 mice treated with 
nB-DNJ showed reversible inhibition of fertility, starting 3 weeks after daily oral 
administration of 15 mg/kg. Fertility returned 4 weeks after cessation of 
administration.  Based upon histological analysis, the major effect of nB-DNJ is 
malformation of the acrosomal cap, sperm head and the mitochondrial sheath.  
The reproductive hormones including LH, FSH and testosterone are not affected 
by nB-DNJ at that dose.  Body weight, testicular weight and mating behavior are 
not altered either.  Supported by these results, nB-DNJ appeared to be a 
promising lead compound toward the development of male contraceptives for 
humans.  However, a recent study involving five human subjects failed to show 
any impact on sperm concentration, motility, morphology and the ability to 
undergo the acrosome reaction, after treatment with 100 mg of nB-DNJ twice 




spermatogenesis in rabbits, as well as in other strains of mice.23 The mechanism 
underlying the species specificity remains largely unknown, although it could be 
partially attributed to the relatively poor potency of nB-DNJ against CGT (IC50 = 
~20 µM), and the short half-life, a result of its hydrophilicity.  With improved 
potency and pharmacokinetic profile, iminosugars may still hold promise as 
candidates for male fertility control.  Structure-activity relationship (SAR) 
information is usually pivotal, in order to achieve such improvements.  Yet, not 
many nB-DNJ analogues have been tested as CGT inhibitors, and neither is 
adequate structure-activity relationship (SAR) data available.  Table 1 
summarizes the available data. 
Table 1. Inhibitory activities of iminosugars on CGT from literature24,25 
Structure Name CGT IC50 
(µM) 






































































nN-6-Me-DGJ 400  




Based on the available data, the lead molecule nB-DNJ is a micromolar 
inhibitor of CGT, while DNJ, which lacks an alkyl group at the nitrogen, is not an 
inhibitor, demonstrating that an alkyl group at the nitrogen is crucial for inhibition. 
However, variations of the N-alkyl groups are seemingly possible.  A longer alkyl 
chain, such as a nonyl group, is especially favorable.  Since both the glucose- 
and galactose-derived iminosugars nB-DNJ and nB-DGJ are active compounds, 
the stereochemistry at position 4 is deemed not to be important for activity.  N-
Butyl-α-homo-nojirimycin and other C1 substituted analogues are inactive, 
indicating that the C1 position needs to be left unsubstituted.  Methylether 
formation at O-3 is detrimental, suggesting that a free hydroxyl group at that 
position is necessary for enzyme inhibition.  Removal or acetylation of the C6 
hydroxyl group results in a large decrease in activity, therefore an intact hydroxyl 
group needs to remain at that position when new analogues are designed.  A 






























1.1.2 GBA2 as target of nB-DNJ 
As discussed in the previous section, the sterility induced by nB-DNJ is 
species specific, which suggests that there may be other targets of nB-DNJ than 
CGT.  In a more recent study, it was proposed by Walden and coworkers that 
nB-DNJ induces infertility in C57BL/6 mice through interaction with a different 
target than CGT.26 The derailed acrosome formation was linked to an enzyme 
known as β-glucosidase 2 (GBA2). 
This enzyme was first identified and cloned as microsomal β-glucosidase, 
or bile acid β-glucosidase.27,28 It had long been known that GlcCer is primarily 
hydrolyzed into glucose and ceramide by the lysosomal enzyme 
glucocerebrosidase (GBA1).  A non-lysosomal glucosylceramidase had also 
been defined but had never been characterized, until it was recently discovered 
that the non-lysosomal glucosylceramidase was identical to the previously 
mentioned GBA2, which governs the GlcCer catabolic pathway in extralysosomal 
locations,29 as depicted in Figure 5. The lack of non-lysosomal 
glucosylceramidase activity leads to the accumulation of GlcCer.  Indeed, 
genetically modified (GBA2–/–) male C57BL/6 mice have increased levels of 
GlcCer in their testis, liver and brain.  More importantly, GBA2-deficient male 
mice produced round-headed spermatozoa with abnormal acrosomes along with 
reduced fertility similar to those treated with nB-DNJ.30 This implied that, 
perhaps, an elevation of GlcCer in the testis would have a disrupting effect on 
spermatogenesis.  In addition to that, the glucosylceramidase activity of GBA2 




including nB-DNJ.31 Taken together, the available information suggested that the 
elevation of GlcCer caused by the inhibition of GBA2, could be the first step of 
the cascade through which nB-DNJ and other iminosugars would cause C57BL/6 
mice to produce impaired spermatozoa.   



















In order to investigate the biochemical basis of this notion, Walden and 
coworkers studied the variation of GlcCer levels in C57BL/6 mice caused by 
administration of nB-DNJ.26 Interestingly, a biphasic relationship between oral 
dose of nB-DNJ and the testicular level of GlcCer was observed  (Figure 6).   





















Figure 6.    Relationship between dose of iminosugar and testicular GlcCer level





As shown in Figure 6, at lower doses (up to 15 mg/kg/day), GlcCer levels 
correlated with drug dose, reaching a maximum of six times control value at 15 
mg/kg/day.  At high doses (150-2400 mg/kg/day), the correlation was negative.  
At the highest dose used, the GlcCer level became similar to that of untreated 
animals.   
This paradoxical relationship was explained by the difference in sensitivity 
of CGT and GBA2 toward inhibition by nB-DNJ.  In vitro data showed that GBA2 
was more sensitive than CGT toward inhibition by the iminosugar (IC50 values = 
0.14 µM, 22.9 µM, respectively).  Therefore it was believed that, in vivo, drug 
dosage determined which enzyme(s) was/were inhibited.  At lower doses (up to 
15 mg/kg/day), serum level of nB-DNJ (~ 0.5 µM) exceeded the in vitro IC50 
toward GBA2 (0.14 µM), but remained well below the corresponding IC50 toward 
CGT; hence, nB-DNJ primarily inhibited GBA2 and rendered an increased 
testicular GlcCer level.  At higher doses (150 - 2400 mg/kg/day, serum levels 1.7 
- 21.5 µM), activities of both CGT and GBA2 were reduced, so that less GlcCer 
was produced, resulting in an overall decrease in GlcCer levels.    
Even after the paradoxical relationship between the dose of nB-DNJ and 
GlcCer levels was explained, Walden’s hypothesis still remains somewhat 
questionable.  In his hypothesis, an elevated level of testicular GlcCer triggers 
the cascade that induces impaired spermatogenesis.  If this hypothesis stands, 
one would expect to observe an increased level of GlcCer at any dose that 
induces infertility.  However, the experimental data showed no increase of 




doses of nB-DNJ can certainly induce infertility (the minimum dose required is 15 
mg/kg/day).  To further support his theory, Walden proposed a model in which 
the higher amount of GlcCer that hampers spermatogenesis is localized in a 
particular (sub)cellular site.  Therefore, at higher iminosugar doses, although the 
overall testicular GlcCer level is reduced, the amount of GlcCer in this particular 
location can still be high enough to trigger the cascade.  Knowledge about the 
(sub)cellular location of GBA2 will support this model, yet the current data on the 
location of this enzyme are not in agreement with the theory.29-31   
Moreover, Walden’s hypothesis does not explain the species dependency 
of nB-DNJ’s contraceptive effect.  GlcCer levels were measured in ten inbred 
strains of mice other than C57BL/6.  After treating males of these strains with low 
dose nB-DNJ, GlcCer levels were found to increase in all strains, to as high as 
the drug-treated C57BL/6 mice.  Yet, males of these strains didn’t show the 
reproductive phenotype, suggesting a possibility that other inbred strains may 
express allelic variants of the downstream enzymes/proteins that are less 
susceptible to GlcCer accumulation.32 The fact that elevated levels of GlcCer 
failed to induce infertility in these males could also suggest that accumulation of 
GlcCer in testis is not responsible for impairment of spermatogenesis.   
 
1.1.3 Summary of nB-DNJ’s male contraceptive effect 
In summary, the male contraceptive effect of nB-DNJ and other 
iminosugars on C57BL/6 mice is likely to be induced by inhibiting CGT and/or 




design and develop an iminosugar-based male contraceptive agent.  Also, the 
mechanism causing nB-DNJ’s species specificity remains obscure.  In order to 
clarify the basis of the species dependency, the potential unknown targets of the 
iminosugar remains to be investigated.   
 
1.2 Objectives 
Our goal is to synthesize nB-DNJ analogues targeting CGT and/or GBA2, 
and generate SAR data.  The SAR information will be utilized to prepare agents 
with higher potency and improved pharmacokinetic properties.  In addition, we 
propose to characterize and identify potential novel target proteins of nB-DNJ. 
 
1.2.1 Structural modification strategies 
The research described in this subsection describes the strategies that we 
applied to modify the iminosugar molecule, and the synthesis and evaluation of 
these analogues.  The approaches that we used to modify the structure of the 
iminosugar included new N-substituents, changing the molecular geometry, 
deoxygenation, stereoisomers of the -OH groups, ring contraction and ring 










change of molecular geometry,
increase distance between nitrogen











Figure 7.  Medicinal chemistry approaches
 
 Among these approaches, changing N-substituents has been frequently 
practiced because C-N bonds can be made easily.  In order to explore the 
relationship between conformational flexibility and activity, we proposed to 
append relatively bulky substituents onto the nitrogen in order to restrict 
conformational flexibility.33,34 The effect of reduced basicity on activity was to be 
evaluated by appending aromatic groups onto the nitrogen atom.  The removal of 
one or more hydroxyl groups, that is (are) not relevant to activity, was expected 
to preclude phase II-type metabolism and therefore improve the half-life of the 
compounds.  Changing molecular geometry, as depicted in Figure 8,35,36 was to 
move the nitrogen atom toward an exo-cyclic position, increasing the distance 
between the nitrogen and the hydroxyl groups while retaining the composition of 




contraction/expansion analogues were prepared by other researchers in the 
Georg group, and not included in this section.    














   PKB IC50 (µM)
= 12











* This figure shows an example of a molecular geometry change in medicinal chemistry,
   in which the kinase inhibitory activity of the pyrrolidine analogue was enhanced by ~
  15-fold compared to the piperazine compound - see text for reference.
 
 
1.3 Synthesis of analogues with modified N-substitution 
 The first modification was to prepare analogues with sterically demanding 
lipophilic groups as N-substitutes, and to investigate the effect on the enzyme 
inhibitory activity of these iminosugars.  The desired analogues were obtained in 





























a) LAH, THF, 0 °C to rt, overnight, 95%; b) oxalyl chloride, NEt3, DMSO, CH2Cl2, -78 °C;  




2 3 3-1           3-2/ 3-3
 
 
The diol 1 obtained from reduction of benzyl-protected D-glucose was 
subjected to a Swern oxidation to yield a chemically labile ketoaldehyde.  The 
very mild nature of the oxidation was the key to the success of this 
transformation.  Under Swern conditions, both the primary and secondary alcohol 
groups in diol 1 were oxidized, while with other oxidants (IBX, Ca(OCl)2) the 
primary alcohol was oxidized to the aldehyde first, which reacted with the 
secondary alcohol to form a hemi-acetal.  Subsequently, the hemi-acetal was 

































The ketoaldehyde intermediate was taken to the next step without 
isolation and subjected to a double reductive alkylation reaction with sodium 
cyanoborohydride to yield the O-benzyl-protected product 2. In this 
transformation, the primary amine first forms an imine with the aldehyde; the 
imine is then reduced to give a secondary amine.  The newly formed secondary 
amine then reacts intramoleculary with the ketone moiety to form a cyclic imine, 
which is subsequently reduced stereoselectively to yield the corresponding 
tertiary amine. The reagent sodium triacetoxyborohydride, which is also 
commonly used for reductive alkylations, was tried but produced an undesired 
dual-alkylated product and ring-closing was not achieved.  To introduce steric 
bulk to the nitrogen atom, isopropylamine, trans-nbutylcyclohexanamine and 
trans-nhexylcyclohexanamine were used in the double reductive alkylation 
reaction.  The protecting groups were removed via hydrogenolysis, and yielded 




The two non-commercially available amines that were employed in the 
double reductive alkylation were prepared as shown in Scheme 2.  The amino 
group of the starting material, trans-4-aminocyclohexynol hydrochloride, was 
liberated and Boc-protected using a literature method.38 The hydroxyl group in 4 
was subsequently replaced, yielding the iodo derivative 5.  Addition of cuprate 
reagents to 5 furnished 4-alkylated product 6.39 The Boc protecting group was 
then removed under acidic conditions and the HCl salts of the resulting amines 
were directly taken to the double reductive alkylation.  
Li2(nBu)2CuCN or Li2(nhexyl)2CuCN













toluene, 60 °C, 77%
NHBoc
I
R = nbutyl, nhexyl
Scheme 2
54
6 7  
 
Electron-withdrawing N-aryl substitutes (Figure 10) were also introduced, 
utilizing the same methodology depicted in Scheme 1. N-aryl groups were 
expected to reduce basicity of the nitrogen atom in the iminosugars and 











Figure 10.  N-aryl and N-morpholino analogues
3-4           3-5           3-6          3-7
nhex Ph
 
A N-morpholine group, which is a common building block in synthesis of 
therapeutics, was appended to the parent molecule in order to further probe the 
enzyme active site.  The N-morpholine group could provide additional H-bond 
interactions with the enzyme. 
 
1.4 Synthesis of analogues with Molecular Geometry Change 
Hydroxylated carbocyclic amines, possessing an exocyclic nitrogen atom, 
resemble nB-DNJ closely, with respect to atomic composition and 














We proposed that the hydroxylated aminocyclopentanes could mimic nB-
DNJ in its inhibitory activity based on structural similarities but would display 
increased basicity and less steric hindrance at the nitrogen atom.  The four 




configurations with nB-DNJ and are oriented in space similarly to those of nB-
DNJ.  Although the hydroxylated aminocyclopentane resembles nB-DNJ, the 
difference in geometry between these two structures is significant due to the 
alteration of the ring size.  Therefore, hydroxylated aminocyclopentanes were 
anticipated to occupy the enzyme active center in a slightly different manner, and 
to possess altered inhibitory activities compared to nB-DNJ.  The synthetic route 










































a) TBS-Cl, imidazole, DMF, 0 °C to rt, 90%; b) BnBr, NaH, DMF, 0 °C to rt, 85%; c) TsOH, MeCN/
H2O, 65%; d) PPh3, imidazole, I2, THF, reflux, 97%; e) Zn, THF/H2O, sonication, 94%; f) NH2OH•HCl,
NaHCO3, MeOH, reflux, 20h, 85%; g) Toluene, reflux, 70%; h) 1. Zn, HOAc/H2O, 87%, 2. HCl in ether;
i) Butyraldehyde/nonylaldehyde, NaB(OAc)3H, DCE, ~70%; j) Pd/C, HCOONH4, MeOH, reflux, 42% 
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 Our synthesis started with a selective protection of the primary alcohol of 
methyl-alpha-D-glucopyranoside as a tert-butyldimethylsilyl (TBS) ether.40 The 
remaining free hydroxyl groups of 8 were protected as benzyl ethers to generate 
9.  The TBS group was removed under acidic conditions to unmask the primary 
hydroxyl group of 10, which was subsequently converted to iodo compound 11.  
Aldehyde 12 was obtained via a reductive ring opening of 11, which is known as 
the Vasella fragmentation reaction.41 Initially a reported method was applied to 
achieve the fragmentation, which utilized Vitamin B12 as a catalyst in the zinc-
mediated reaction.42 In efforts to lower the cost, we discovered that a comparable 
yield could be obtained by performing the reaction in a THF/H2O medium under 
ultrasonic conditions, without the need of a catalyst.  Treatment of aldehyde 12 
with hydroxylamine hydrochloride in warm methanol in the presence of sodium 
bicarbonate furnished oxime 13, as a mixture of E and Z isomers.   
An intramolecular oxime-olefin cycloaddition (IOOC) was used as the key 
step in our synthesis toward the stereochemically defined hydroxylated amino-
cyclopentanes.43,44 In this key transformation, two new stereogenic centers were 
created at the ring fusion, as shown in Figure 12. Literature data had shown that, 
when the glucose-derived oxime olefin was subjected to IOOC, the two hydrogen 
atoms at the ring junctions would be cis and reside on the alpha-face exclusively.  
























The 1,3-dipolar cycloaddtion of oxime 13 in refluxing toluene for 15 hours 
led to cis-fused isoxazolidine 14.  The N-O bond was cleaved with activated zinc 
under acidic aqueous conditions to furnish amine 15.45 The reductive alkylation 
reaction of the purified amine 15 with aldehyde gave a mixture of mono- and di-
alkylated products, which were difficult to separate. As a consequence, the 
isolated yield of the mono-alkylated amine was relatively poor.  In an effort to 
improve the yield and simplify the handling of amine 15, the HCl salt was 
prepared.  The semi-crude residue from the organic extraction of 15 was 
dissolved in a solution of hydrochloric acid in ether.  The salt precipitated and 
was then filtered, rinsed with ether and dried under reduced pressure to afford 
the HCl salt of amine 15.  When the salt (pre-dissolved in the presence of 
triethylamine) was taken to the reductive alkylation step, to our surprise the 
reaction produced monoalkylated products exclusively, providing an 
improvement in yields (49→73% and 41→70%, respectively).  Following that, the 
protecting groups of the N-butyl carbocyclic amine were removed under 
hydrogenolysis conditions to yield 17-1, while Birch conditions46,47 were needed 




1.5 Synthesis of analogues with modified -OH groups 
 Polar drugs, such as nB-DNJ, can have relatively poor pharmacokinetic 
parameters, which can potentially jeopardize their effectiveness.  In humans, the 
half-life of the iminosugar was observed to be 6.5 hours after the first dose of 100 
mg, with a maximum serum concentration of only 0.86 µg/mL.48 The relatively 
short half-life of nB-DNJ is due to rapid renal clearance, which is most likely a 
result of the hydrophilicity of the compound and the presence of several hydroxyl 
groups that can be subjected to phase II-type metabolism.  It was expected that 
the half-life of the analogues could be incresed by removing one or two hydroxyl 
groups deemed to be unnecessary, while retaining activity. 
 
1.5.1  2,4-Dideoxygenated analogue of DNJ 
Based on currently available information, little is known about the role that 
the 2-OH group plays in iminosugars.  In order to address this issue, the 2-












As discussed previously, 4-epi-nB-DNJ (nB-DGJ) is an active inhibitor of 
CGT, suggesting that the 4-OH group perhaps contributes less to the inhibitory 




4-OH may have little impact on the effectiveness of the corresponding analogue.  
Thus, the 2,4-dideoxy DNJ analogue, in which both hydroxyl groups are 
removed, would also be a good candidate for biological evaluation, with regards 
to testing the importance of the 2-OH group as well as the 4-OH group.   
 We envisioned that both the 2-deoxy- and 2,4-dideoxy-DNJ analogues 
could be derived from a common enaminone intermediate, as shown in Figure 
14.  The 4-OH was envisioned being installed via α-hydroxylation at the position 
that is α to the carbonyl group of the enaminone intermediate.  A subsequent 
reduction was to furnish the 3-hydroxy functionality in the target molecule. 

















Regarding the preparation of the enaminone intermediate, the Georg 
group has developed a practical method to generate such useful synthons.49  
Prior to this discovery, the techniques utilized to prepare enaminones 
primarily originated from a method developed by the Comins group.50,51 This 
method employs acylpyridinium salts prepared in situ from 4-methoxy-pyridines 


















R = Ph, etc;  R*= aryl, alkyl, H
 
The pyridinium salts are treated with Grignard reagents or sodium 
borohydride, and the resultant enol ethers are hydrolyzed to afford the 
corresponding enaminones. 
Although the above method had proven enormously effective, the Georg 
group methodology provided a more direct route toward the same desired 
synthon and also in optically active form.  In this method, the amino group of an 
amino-ynone system which can be easily prepared from β-amino acids, adds into 
an ynone to afford the enaminone moiety rapidly under basic conditions, as 
shown in Figure 16.  Mechanistic studies revealed that the ring closure took 
place via the addition of the amino group into a vinylogous halide species, 
followed by elimination of the halogen, rather than through a direct Michael 
addition into the ynone (6-endo-dig). 
Figure 16.  Enaminone synthesis developed in the Georg group
















To synthesize our targeted 2-deoxy and 2,4-dideoxy-DNJ analogues, a β-
amino acid derived from D-serine was envisioned as the starting material for the 
synthetic route.  Although this β-amino acid derivative 18 was commercially 
available, it was rather expensive.  Therefore, we chose to prepare 18 via an 





















a) 1. ClCO2Et, 2. CH2N2, 3. CF3CO2Ag, 86%; b) EDCI, MeNHOMe•HCl, NMM, 92%  
The homologation reaction converted the N,O-protected α-D-serine to 18 
in a two-step, one-flask fashion.  The amino acid was reacted with ethyl 
chloroformate to furnish the corresponding carboxylic acid chloride, which was 
subsequently transformed into a diazo intermediate upon treatment with 
diazomethane.  Safety was a concern, especially when the experiment was 
performed on large scale, since the highly explosive diazomethane was used.  
The diazo intermediate was purified via organic extraction.  The semi-crude 
material was then treated with the silver salt of trifluroacetic acid, which catalyzed 
the Wolff rearrangement, to furnish a ketene species.  The resultant ketene 




Weinreb amide 19,54 as depicted in Scheme 4.  The amide formation was rapid, 
clean and almost quantitative.  
Efforts to directly introduce the alkyl chain onto the Boc-protected amine in 
compound 19 turned out to be unsuccessful under various conditions.  The 
difficulty of the alkylation can be attributed to steric hindrance from both the Boc 
group and the alkyl halides.  We then sought to accomplish the alkylation by 
utilizing a reductive alkylation reaction, although that lengthened the synthetic 
route by two additional steps.  As a consequence, the Boc protecting group was 
removed under acidic conditions and the HCl salt of the crude product was taken 
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The HCl salt was suspended in dichloroethane (DCE) and neutralized with 
one equivalent of triethylamine.  The pH value of the reaction medium was then 
adjusted to be slightly acidic using acetic acid.  Nonylaldehyde and sodium 
triacetoxyborohydride were added to the reaction in sequence.  The reaction was 
was completed within two hours at room temperature.  Dialkylation of the primary 




alkylated product 20.  The dialkylation was suppressed by the using an equal 
molar amount or less of the aldehyde, which increased the yield to 85%.  The 
secondary amine was then re-protected with di-tert-butyl dicarbonate (Boc2O) to 
provide compound 21 in moderate yield.  The ynone 22 was easily obtained upon 
treatment of the Weinreb amide 21 with the commercially available Grignard 
reagent ethynylmagnesium bromide.  We also attempted to switch the order of 
the above two steps, hence the ynone formation was carried out prior to the 
reductive alkylation, as shown in Figure 17.  The incentive was to enhance the 
yield of the Boc re-protection step, in that the ynone molecule was significantly 
less sterically congested than the counterpart Weinreb amide.  However, no 
clean separation of the mono- and dialkylated amines could be achieved, and 
this alternative route was therefore not pursued further. 
BnO
ONHR













To obtain the enaminone intermediate 23, ynone 22 was dissolved in a 
solution of 4N hydrochloric acid in dioxane at room temperature.  Within 20 
minutes, all the starting material was consumed.  After the dioxane was removed 
under reduced pressure, the remaining crude salt was dissolved in methanol at 




closure was completed instantly and the crude material was purified using flash 
chromatography, yielding the coveted cyclic enaminone 23 in excellent yield, as 











a) 1. HCl, dioxane, rt; 2. K2CO3, MeOH, 90%  
For the synthesis of the desired 2,4-dideoxy-DNJ analogue 24, vinylogous 
amide 23 was subjected to a two-step, one-pot reduction.55 An excess amount of 
sodium borohydride was used to reduce the carbonyl group and the double bond 
simultaneously, yielding the cis-hydroxyl derivative diastereoselectively. The 
excess reducing agent was then removed by organic extraction, and the 
structure of the intermediate was confirmed with 1H NMR.  The semi-crude 
material was subsequently hydrogenolyzed to cleave the benzyl ether protecting 
group, yielding the desire product 24, as shown in Scheme 7.  The NMR spectra 
of 24 were identical to those of a standard sample derived from a commercially 
available pipecolic acid derivative ((2S,4R)-N-Boc-4-hydroxypiperidine-2-
carboxylic acid methyl ester, 98% ee).  The specific rotation of diol 24 was 
comparable to that of the standard sample ([α]D25 -22, c 0.75, MeOH, and [α]D25 -
21, c 0.97, MeOH, respectively), suggesting that no racemization took place 
during the cyclization step shown in Scheme 6.  It was occasionally observed 
that the stereochemical integrity can be compromised when 6/6 and 6/5 bicyclic 














a) 1. NaBH4, EtOH, rt; 2. H2, Pd/C, 45%; b) 1. 4M HCl, 2. nonylaldehyde,
NaB(OAc)3H, TEA, DCE, 96%; c) DIBAL-H, toluene, 40%







Targeting the 2-deoxy-DNJ analogue, we attempted α-hydroxylation on 
the vinylogous amide 23, as depicted in Figure 18.  A regio- and stereoselective 
α-acetoxylation, using lead (IV) tetra-acetate as the oxidant, was reported by 
Comins,56 although the substrates used in this methodology differed from 23, 
where electron-withdrawing groups were present on the nitrogen atoms.  When 
enaminone 23 was subjected to the oxidation with Pb(OAc)4 in refluxing toluene, 
only decomposition of the starting material was observed.  Mechanistically, α-
acetoxylation undergoes a key enolization step.  The N-alkyl substituent in 23 
presumably decreases the electrophilicity of the carbonyl group, making it less 
likely for the enolization to take place.  
The difficulty in enolizing the carbonyl group was encountered again when 
we attempted to apply the Rubottom reaction57,58 to 23.  No signs of the 
formation of the silyl-enol ether intermediate were observed (1H NMR).  Thus, the 
synthesis of the 2-deoxy-DNJ analogue was not pursued further. 
To summarize this subsection, we completed the synthesis of the 2,4-
dideoxy-DNJ analogue 24 in six steps, employing the amino-ynone cycloaddition 


























R1 = Me, nPr, tBu, Ph, Bn, etc 























1.5.2   3-epi-DGJ analogue of DNJ 
Only a few iminosugars containing hydroxyl group with inverted 
configuration have been prepared, and the properties of these “unnatural” 
iminosugars are not well understood.  The stereochemistry of hydroxyl groups at 
carbons 2, 3 and 4 of nB-DNJ may all be systemically modified, and the effect of 
such modification on the ability to inhibit target enzymes can be measured.  For 
example, N-butyldeoxygalactonojirimycin (nB-DGJ), which has an inverted 
hydroxyl group at C4, was tested against CGT and GBA2 and proved to be an 
active inhibitor of both enzymes (Figure 19).  A comparison of the IC50 values of 
nB-DNJ and nB-DGJ indicated that inversion of the 4-OH stereochemistry had no 




configuration of the C2 and/or C3 hydroxyl group(s) was unknown, even though 










IC50 CGT   =  30.0  µM 
        GBA2 =   5.3   µM
OH
! nB-DGJ nB-DNJ
IC50 CGT   =  20.4  µM 
        GBA2 =  0.14  µM
4
 
In order to generate SAR data that can be examined, the inversion of the 
2- and 3-OH groups should be conducted one at a time.  Since the importance of 
the 2-OH group was unclear (seen in the previous section), we decided to 
prepare and study the 3-OH inverted analogue, leaving the 2-OH 
stereochemistry intact.  
We envisioned that two of the α-hydroxyl groups of the 3-epi-DGJ 
analogue could be introduced in a stereoselective fashion (Figure 20), taking 
advantage of the directing effect of an endocyclic allylic alcohol.  The allylic 
alcohol was envisaged to arise from a 1,2-reduction of an enone intermediate.  
The C-C double bond of the enone moiety was to be generated via a ring-closing 
metathesis reaction (RCM).  The retrosynthetic product of the RCM was 
envisaged to come from the starting material N,O-protected D-serine, which was 
































The installation of an allyl group onto the Boc-protected nitrogen of the 
amino acid turned out to be an obstacle (Figure 21).  We first attempted to 
repeat a reported method,59 in which N,O-protected serine was directly alkylated 
with allyl iodide in the presence of sodium hydride at low temperature for three 
days.  Although this method was reported to give the product in high yield and 
purity, we found that additional purification was necessary before the N-allyl 
amino acid could be taken to the next step.  Furthermore the isolated yield was 
not satisfying.  We also tried to apply the alkylation to the corresponding Weinreb 


























b) NaH, allyl bromide, 0 °C, THF, 24%
 
We then slightly modified the route so that we could obtain better yields, 
achieve a more convenient purification and reduce the risks of epimerization 
(Scheme 8).  N,O-protected-D-serine was converted to Weinreb amide 25 using 
an EDCI-mediated coupling reaction.  The Boc protecting group of 25 was then 
removed under acidic conditions.  Without purification, the resultant HCl salt was 
dissolved in methanol and then Hünig’s base (diisopropylethylamine, DIPEA).  










 25                                               26                                            27
a) MeNH(OMe)•HCl, EDCI, NMM, 0 °C to rt, 90%; b) 1. HCl/dioxane, 0 °C; 2. DIPEA, allyl bromide, MeOH











The reaction was stirred at 50 °C for five hours, providing the N-allyl 
intermediate 26 in 50% yield over two steps. Although the yield was only 




dialkylated product, was easy to remove.  The allylamino group of 26 was then 
protected with di-tert-butyl dicarbonate (Boc2O) in freshly distilled ethyl acetate 
(EtOAc) at room temperature to afford 27 in excellent yield.   
Treatment of 27 with vinylmagnesium bromide at low temperature gave 
Weinreb ketone 28, in excellent yield as shown in Scheme 9.  The cyclic enone 
29 was then obtained in 75% by treatment of the diene 28 with the second-






















a) vinylmagnesium bromide, THF, -78 to 0 °C, 90%; b) G-II, DCM, reflux, 75%  
 
The subsequent step was the 1,2- reduction of the resultant enone 29.  
We chose the Luche protocol,62 to selectively reduce the conjugated ketone.  
With regards to the diastereoselectivity reduction of chiral ketones under Luche 
conditions, we expected that an axial hydride delivery would take place on enone 
29, which would generate an equatorial allylic hydroxyl group, as depicted in 
Figure 22.  Since an axial hydroxyl group was needed for the following 
dihydroxylation, a Mitsunobu reaction was planned in advance, in order to invert 
























 The 1,2-reduction of 29 was carried out with sodium borohydride in 
combination with cerium trichloride (CeCl3) at low temperature, and was 
completed within 15 minutes, yielding a cis-alcohol, to our surprise, as the 











a) NaBH4, CeCl3, MeOH, -78 °C to rt, 15 min, 92%; b) 1. PPh3, 
pNO2C6H4CO2H, DIAD, THF, 0 °C, 81%, 2. K2CO3, MeOH, rt, 60%









The stereochemical outcome was verified through 1H, 13C and 2-
dimensional NMR experiments.  The allylic proton H5 (δ = 4.53 ppm) appears 
further downfield compared to its counterpart (δ = 4.11 ppm) obtained from a 
Mitsunobu reaction.  This observation indicates that H5 is located in the de-
shielding cone of the C4-C5 bond, suggesting H5 orients as an equatorial 
proton.63 A NOESY experiment further confirmed the configuration of H5, in that 
strong correlations were observed between H5 and H4, and even between H5 


















 The stereochemical outcome was clearly different from what was 
predicted.  To explain the unexpected result, we propose that, prior to hydride 
delivery, the cyclic enone adopts a conformation in which the methylene 
benzylether side chain is in a pseudoaxial orientation, as depicted in Figure 
24.64,65 Thus, the steric hinderance rendered by the methylene benzylether side 
chain blocks the attack of the hydride from the β-face.  As a result, delivery of the 
nucleophile from the α-face is favored, furnishing the cis-alcohol.  






























 In contrast to the favored cis-alcohol formation, the hypothetical trans-
alcohol formation would have to overcome an energy barrier caused by a 
conformational change (from gauche to eclipse).  Therefore, the formation of a 




 To further confirm the stereochemical outcome of the Luche reduction, the 
allylic alcohol 30 and the Mitsunobu reaction product were N-alkylated and 
reduced to diols as shown in Figure 25, and NMR spectra of these 
diastereomers were analyzed.  



















! = 4.24 ppm, s
! = 4.13 ppm, m
R = nBu






 The stereochemistry was further confirmed via comparison of the vicinal 
coupling constant value of proton H5 (δ = 4.24 ppm) of the Luche reduction 
product to its counterpart (δ = 4.13 ppm) derived from the Mitsunobu reaction.  
The equatorial H5 of the diol directly derived from the Luche reduction appears 
as a singlet, suggesting H5 is not coupled to other hydrogens, which can be 
partially explained by the small dihedral angels between H5e and the neighboring 
hydrogen atoms.  Conversely, in the product derived from the Mitsunobu 
reaction, these dihedral angels are increased due to the inversion of H5.  As a 
result, the axial H5 appears as a multiplet in the spectrum as anticipated.  We 
further deciphered the H5 multiplet utilizing the Hoye method,66,67 and 




The large coupling constants suggested the increased dihedral angels between 
H5 and neighboring hydrogens and therefore confirmed the relative positions of 
these coupled hydrogen nuclei. 
 The cis-allylic alcohol 30 was next subjected to dihydroxylation under 
Upjohn conditions, as shown in Scheme 11.  The Upjohn dihydroxylation allows 
the syn-selective preparation of a diol from the alkene by using a catalytic 
amount of the toxic and volatile osmium tetroxide (OsO4) and a stoichiometric 
amount of N-methylmorpholine N-oxide (NMO) as an oxidant, which can re-














30                                                     31
 
 OsO4 behaves as a large reagent, which attacks the C=C bond from the 
least hindered side, as shown in Figure 26.  Thus, the dihydroxylation was highly 









































The stereochemistry of the newly introduced hydroxyl groups was also 
confirmed by a NOESY experiment on derivative 33-2, where no correlation was 
observed between the axial H2a and H4, suggesting little through-space 
interaction was present between these two hydrogen atoms.  H4 was then 
assigned as an equatorial proton, which is further away from H2a in space 
compared to a H4a would be.  Thus, the 3- and 4-OH groups were confirmed to 



















R = nBu, nNonyl
Scheme 12
 31                                        32-1, 32-2                          33-1, 33-2
a) 1. HCOOH, rt, 2. NaB(OAc)3H, butyraldehyde/nonylaldehyde, rt, 73%, 71%; b) Pd/C, HCOONH4, 




The Boc protecting group of triol 31 was removed under acidic conditions, 
and a following reductive alkylation reaction produced N-alkyl compounds 32-1 
and 32-2, as shown in Scheme 12.  The desired 3-epi-DGJ analogues 33-1 and 
33-2 were obtained after hydrogenolysis of the O-benzyl ethers, and purification 
by column chromatography. 
 
1.5.3   3-epi-4-deoxy-DNJ analogue 
We hypothesized in the previous section that the 4-OH group of nB-DGJ 
contributed little to its bioactivity.  Removal of such hydrophilic hydroxyl group(s) 
could decrease the hydrophilicity of the resultant analogues and potentially 
reduce renal clearance caused by phase-II type metabolism, therefore providing 
an extended half-life.  Based upon this hypothesis, we reasoned that the 3-epi-4-
deoxy analogue (Figure 27) could display a better pharmacokinetic profile than 
the parent compound and also serve as a probe to further illustrate the effect of 


















 We envisaged that the syn-diol of the target compound could be 
introduced via dihydroxylation (Figure 28).  The olefin intermediate could be 




derived from D-serine.  Although this route seemed feasible, as the allylic alcohol 
was successfully synthesized in the previous section, the cost of the starting 
material, D-serine, appeared to be a major drawback of this approach.  
 An alternative method was selected, employing a less costly starting 
material, as shown in Figure 28.  Thus, the cyclic alkene was envisioned to 
come from a ring closing metathesis (RCM) of a diene.  The diene could be 
derived from a regioselective epoxide ring opening with allylamine.  The 
enantioenriched epoxide could be obtained from a Sharpless asymmetric 
epoxidation (SAE) of the resultant allylic alcohol, which could be prepared in 
large quantities from readily available reagents.   

































 The starting asymmetric oxirane was prepared on gram scale, following 
reported procedures70,71 as shown in Figure 29.  Propargyl alcohol was alkylated 
with allyl bromide in the presence of copper bromide (CuBr) at 70 ºC in a slightly 
basic aqueous solution, to yield hex-5-en-2-yn-1-ol.  The product was then 
reduced with lithium aluminum hydride (LAH) to give the trans-allylic alcohol.  




asymmetric epoxidation72 (SAE) in the presence of diethyl-D-(-)-tartrate (D-(-)-
DET), titanium tetraisoproxide (Ti(OiPr)4) and cumene hydroperoxide, to furnish 
(2R,3R)-epoxyhex-5-en-1-ol on gram scale.  The reaction was carried out at low 
temperature and was kept free of moisture.  The tartrate catalyst was prepared 
by mixing the titanium, tartrate and the hydroperoxide for over 30 minutes at -20 
°C prior to the addition of the allylic alcohol, in order to achieve high 
enantioselectivity ([α]22D 26.4, c 1.0, MeOH; lit. [α]22D 23.2, c 10, MeOH). 










a) CuBr, H2O, NaOH, pH = 8 to 9, 70 °C, 84%; b) LAH, THF, 0 °C ! rt ! 45 °C ! 0 °C, 37%; 
c) cumene hydroperoxide, Ti(OiPr)4, 4Å MS, D-(-)-DET, -25 °C, 60%
 
 The enantioenriched oxirane was then subjected to a regioselective ring 
opening with allylamine,73,74 followed by protection of the secondary amine with 
Boc2O (Scheme 13) in order to avoid unwanted side reactions in the ring-closing 









                                                       34
a) 1. Ti(OiPr)4, allylamine, DCM, reflux, 44%; 2. Boc2O, NaHCO3, 





The chelation-facilitated nucleophilic attack of the epoxide ring produced a 
mixture of regioisomers using Crotti’s conditions,75,76 which required a large 
access of reagents (15 equiv of LiClO4 and 10 equiv of allylamine in acetonitrile).  
Due to the difficulties to separate the isomers, we resorted to the Sharpless 
conditions77 which utilized smaller amounts of reagents (2 equiv of Ti(OiPr)4, and 
1 equiv of allylamine in DCM).  To our delight, the Ti-mediated reaction provided 
the C3 openened aminodiol selectivity (Figure 30), although the yield was only 
moderate.   










rigid, bidentate coordination to the metal center
(iPrO)3Ti
 
The following Boc protection of the resultant secondary amine turned out 
to be not so straightforward.  The reaction was extremely slow under regular 
conditions for Boc- protection.  Fortunately, we found the reaction could be 
accelerated with ultrasonic treatment and the completion of the reaction was 
achieved after 6 days.  
Treatment of diene 34 with the second-generation Grubbs’ catalyst (GII) in 
DCM at room temperature gave the key intermediate 35, as shown in Scheme 



















a) Grubbs II, DCM, rt, 74%; b) 1. NaIO4, THF/H2O; 2. NaBH4, EtOH, 60%
34                                      35                                           36
 
 It turned out to be cumbersome to directly subject 36 to dihydroxylation 
and the following reductive alkylation, as it was difficult to isolate the aminotriol 
reaction product because of its polarity.  In addition, the aminotriol was not 
reactive enough for the reductive alkylation.  Thus, in order to solve these 
problems, the primary alcohol of compound 36 was first protected as a silyl ether 
with t-butyldiphenylsilyl chloride, and then subjected to Upjohn conditions to 
afford diol 37 as the major diastereomer (Scheme 15).78 The hydrophobic silyl-
protecting group enabled a more convenient isolation of the product.  We also 
investigated the t-butyldimethylsilyl (TBS) silyl ether derivative of 36, but that 














a) 1.TBDPSCl, imidazole, DCM, rt; 2. OsO4, NMO, DCM/H2O, 0 °C to rt, 60%;  b) 1. HCOOH,
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nNonyl nNonyl
 
The Boc protecting group of diol 37 was then removed under acidic 




reaction to furnish tertiary amine 38.  Finally, the silyl protecting group was 
removed by treatment with tetrabutylammonium fluoride (TBAF) to yield the 
desired product 39. The polar aminotriol 39 was initially contaminated with 
tetrabutylammonium salts, which could not be removed by chromatography.  The 
contaminants were removed by passing through a Dowex ion-exchange column 
using water as the eluent, to yield pure 39.  
 
 
1.6 Biological evaluation 
The biological evaluation of the iminosugars was conducted by our 
collaborators, Dr. Tash and his group, at the University of Kansas, Medical 
Center. 
 
1.6.1 CGT inhibitory assay  
The iminosugar analogues were first screened as CGT inhibitors. 
 
1.6.1.1  Assay development  
The published assay procedures were found unreliable and not 
reproducible.15,24,25 Thus, new assays were designed and standardized, utilizing 
labeled reagents as reporters of the enzymatic reaction progress.  The general 










 CGT catalyzes the glycosidation reaction of ceramide, yielding C14-
labelled glucosylceramide (C14-GlcCer) as the product.  C14-GlcCer can be 
separated utilizing thin layer chromatography (TLC) and be quantified by 
autoradiography.  Active iminosugars inhibit the enzymatic reaction, resulting in a 
decrease in the formation of C14-GlcCer.  Thus, the potency of the analogues 
correlates negatively with the intensity of signals detected.   
Prior to addition of inhibitors, strong and consistent C14-GlcCer signals 
were expected, serving as the positive control for the following screen.   
However, no readable signals were detected for C14-GlcCer on the X-ray film.  
Numerous efforts were made to troubleshoot the problems, but no improvements 
could be made.  Hence, a new assay was developed in order to evaluate the 
inhibitory activities of the synthesized iminosugars. 
A practical in vitro assay was set up, using a ceramide derivative, NBD-
C6-tagged ceramide ((6-((N-(7-nitrobenz-2-oxa-1,3-diazol-4-
yl)amino)hexanoyl)sphingosine)) as a fluorescent reporter of the enzymatic 




provides a method for detecting ceramide and the reaction product GlcCer after 
separation on silica gel thin layer plates (TLC).  
NBD-C6-ceramide glucosyl-NBD-C6-ceramide
UDP-glucose UDP




As shown in Figure 32, active iminosugars inhibit the enzymatic reaction, 
inducing a decrease in product formation.  Therefore, the potency of the 
analogues correlates negatively with the intensity of fluorescent signals.   
Figure 33 shows the results when testis microsomes were incubated for 
2-30 minutes with NBD-C6-ceramide.  The starting substrate is indicated at the 
top of the TLC plate.  The reaction product migrates more slowly and resides in 
the middle of the plate after development of the plate was completed.  The NBD-
tagged ceramide and GlcCer fluoresce green and can be easily distinguished 
from other non-specific fluorescent spots on the plate.  The row of spots just 
above the GlcCer belongs to a fluorescent substance endogenous to the 
microsome preparation.  A time-dependent increase in GlcCer formation is also 





Figure 33.  TLC separation of NBD-C6-ceramide and NBD-C6-GlcCer in control 





2 min 2 min 5 min 10 min 20 min 30 min  
 Figure 34 illustrates a parallel incubation performed with and without an 
inhibitor of CGT.  In the presence of nB-DNJ, the formation of NBD-C6-GlcCer 
was clearly retarded and lower signal strength was observed at all time points. 
Figure 34.  Side-by-side comparison of NBD-C6-GlyCer produces in the 
absence (upper row) and the presence (lower row) of 100 µM nB-DNJ






 IC50 values for nB-DNJ were then determined, using both mouse and rat 




Table 2. IC50 of nB-DNJ and nB-DGJ on testicular CGT 
 Species \ Tissue Testis (µM) 
LE rat 32.0 ± 25.5 (n = 4) 
C57BL/6 51.0 ± 28.0 (n = 3) nB-DNJ 
C57BL/6 (lit.) 22.9 
LE rat 145.0 ± 97.7 (n = 3) 
C57BL/6 > 300 (n = 2) nB-DGJ 
C57BL/6 (lit.) 30.0 
 
The IC50 for nB-DNJ on mouse testicular CGT was higher than the 
reported value,24 but was within an acceptable range.  It is interesting to note that 
the IC50 was relatively higher in the mouse microsomes in comparison to the rat.  
This is opposite to the relative efficacy of nB-DNJ with respect to its 
contraceptive effect, as it is known that nB-DNJ does not induce infertility in rats.  
This observation could indicate differences in bioavailability and 
pharmacokinetics of the compound between mice and rats.  Another possibility is 
that CGT is not the target that leads to the contraceptive effect in the C57BL/6 
male mice. 
IC50 values for nB-DGJ were also determined under the same conditions. 
The CGT extracted from the rat microsomes also responded better to the 
inhibition induced by nB-DGJ than that obtained from the mice microsomes.  In 
addition to that, nB-DGJ was less potent than nB-DNJ as an inhibitor, which 






1.6.1.2  Screening of analogues as CGT inhibitors  
With the IC50 value for nB-DNJ determined as the positive control, we then 
conducted the IC50 value determinations for all iminosugar analogues.  However, 
none showed inhibition of CGT.  Figure 35 illustrates a representative image of 
the CGT inhibitory assay, in which no decrease of NBD-C6-GlcCer is observed at 
doses of the iminosugar analogues ranging from 0.5 to 300 µM. 




Lane             1           2          3           4           5            6            7          8
conc. (µM)  BLK       0.5        1          10         50         100         300      BLK  
 
1.6.1.3  Concluding remarks  
A CGT inhibitory assay was developed by our collaborators because 
reported assay conditions were not reproducible.  nB-DNJ was assayed against 
C57BL/6 and Long Evans rat testis microsomal CGT.  nB-DNJ showed inhibitory 




mouse enzyme.  None of the synthetic nB-DNJ analogues showed inhibition of 
CGT in this assay up to 300 µM.  The results suggest: a) steric bulk and/or 
aromatic substituents on the nitrogen atom are detrimental to CGT inhibitory 
activity; b) the 2- and/or 3-OH groups are important for CGT inhibition. 
Elimination of the 2-OH or inversion of the configuration of 3-OH leads to a loss 
of inhibitory activity; c) the negative results indicate the possibility that the 
iminosugars bind to targets other than CGT. 
 
1.6.2  GBA2 inhibitory assay 
GBA2 is the other proposed target that iminosugars could impact.26 The in 
vitro biochemical assay to test the inhibitory activity of the iminosugar analogues 
has been optimized and standardized in Dr. Tash’s group at the University of 
Kansas, Medical Center. 
 
1.6.2.1  Assay development  
The principle of the GBA2 assay is shown in Figure 36.  The use of a 
fluorometric method provides a sensitive and quantitative assay for GBA2 
inhibition.  Cleavage of 4-methylumbelliferyl-β-D-glucuronide (MUG) by GBA2 
yields 4-methylumbelliferone (MU), which is fluorescent above pH 8.  When 
excited by 360 nm light, MU emits light at 460 nm.  Active inhibitors of GBA2 
retard the production of MU, resulting in a decrease of the fluorescent 
absorbance at 460 nm.  Thus, the potency of the inhibitor is negatively correlated 

















 The assay has been optimized for incubation time, substrate concentration 
and microsome concentration.  Assay development has matured to the point that 
the Z-factor and r2 value are 0.88 and 0.97, respectively, over an 11 minute 
incubation period.  Figure 37-40 show the time course of GBA2 activity in the 
presence of different concentrations of nB-DNJ. 
 
Figure 37. GBA2 actitivity versus incubation time in the presence of nB-DNJ, 
with rat testicular microsome 
 





Figure 38. GBA2 actitivity versus incubation time in presence of nB-DNJ, with 
mice testicular microsome 
 
 As seen in Figure 37 and 38, the fluorescent absorbance declines with 
increasing concentration of nB-DNJ, indicating that nB-DNJ inhibits GBA2 
activity, in both C57BL/6 mice and Long Evans rat testis.  It is evident that 
C57BL/6 testicular GBA2 is more sensitive to nB-DNJ, when comparing the slope 
of the plot at 100 µM nB-DNJ (purple line) to that of the rat testicular GBA2 
assay. 
Figure 39 and 40 demonstrate the effect of nB-DNJ on C57BL/6 and Long 
Evans liver GBA2 activity.  Long Evans liver GBA2 is more sensitive to the 
inhibition than that of C57BL/6 mice. 
 


































Figure 40. GBA2 actitivity versus incubation time in presence of nB-DNJ, with 
mouse liver microsome 
 
 
Subsequently, the IC50 value of nB-DNJ was determined and compared to 
the literature data,26 as shown in Table 3.   
Table 3.  IC50 of nB-DNJ on microsomal GBA2 
Species \ Tissue Testis (µM) Liver (µM) 
LE rat 81.2 5.0 
C57BL/6 4.9 31.5 
C57BL/6 (lit.) 0.14 ~ 0.14 
 
Based on these data, nB-DNJ appears to be a relatively potent inhibitor of 
microsomal GBA2 (C57BL/6 testis and Long Evans liver, especially), although 
the IC50 values from Dr. Tash’s laboratory are higher than the reported ones.  




Tash’s assay also revealed species/tissue dependence, as the potency of nB-
DNJ varies when GBA2 from different organs is assayed.   
 
1.6.2.2 Concluding remarks and future directions  
An in vitro assay for GBA2 has been set up.  IC50 values of nB-DNJ have 
been determined using this assay, and nB-DNJ appears to be a relatively potent 
inhibitor of GBA2, which is consistent with the literature reports.  Comparing the 
IC50GBA2 to the IC50CGT, nB-DNJ appears roughly ten-fold more potent in inhibiting 
testicular GBA2 of C57BL/6 mice, suggesting inhibiting GBA2 might be a more 
effective approach to induce infertility in mice.  Screening of the synthetic 
iminosugars is underway, and the assay results will be available in the near 
future. 
 
1.6.3  Affinity labeling studies  
Given that the mechanism of nB-DNJ’s species dependency unsolved for 
its male contraceptive effect, we hypothesized that the iminosugar could possibly 
interact with a unique protein target(s) expressed in C57BL/6 mice to induce 
male infertility.  Based on our biological assay results, we postulated that this 
potential target is possibly different from CGT and GBA2.  Therefore, affinity 







1.6.3.1  Preparation of the affinity labels 
In order to isolate and characterize not yet identified targets, we prepared 
the affinity labels shown in Schemes 16 and 17.  Diol 1 was oxidized to the 
corresponding ketoaldehyde intermediate under Swern conditions. Without 
isolation, the crude material was subjected to a reductive alkylation with the linker 
t-butyl-5-aminopentylcarbamate (BocNH(CH2)5NH2).  Following deprotection of 
the Boc group, the free amine was coupled with biotin to yield the O-benzylated 
affinity probe.  The benzyl protecting groups were removed under hydrogenolysis 
conditions and the crude product was eluted through Dowex-50 to afford the 
desired DNJ-affinity label.  The biotin group is used for affinity purification, so that 







































41                                                                       42
a) oxalyl chloride, NEt3, DMSO, CH2Cl2; b) BocNH(CH2)5NH2, NaBH3CN, MeOH, 4Å MS, 52%;  
c) 1. 4M HCl in dioxane; 2. HATU, NMM, biotin, DMF, 92%; d) H2, PdCl2 (4 equiv), EtOH/H2O, 31%.  
A second-generation affinity label contains an aryl azide group, which 




specific binding takes place, increasing the chance of isolating iminosugar-
binding protein(s).  
Figure 41.  Mechanism of nucleophilic attack upon an irradiated phenyl azide
N3
irradiation N nucleophile NH
Nu
 
Azides are chemically inert compounds that upon irradiation form a highly 
reactive nitrene.  Alkyl nitrenes generated in a solution of hydrocarbons will insert 
into solvent C-H bonds.79 Aryl nitrenes, however, are far less reactive and do not 
react with hydrocarbons.  Upon irradiation, they rearrange to a 7-membered 
strained heterocumulene, as shown in Figure 41.80 This ketenimine intermediate 
can then react with nucleophiles in up to 70-80% quantum yields.  
The synthesis of the photo affinity label 45 is shown in Scheme 17. 
a) BocNH(CH2)3NH2, NaBH3CN, MeOH, 4Å MS, 58%; b) Pd/C, HCOONH2, EtOH, reflux, 77%; 















































t-Butyl-5-aminopropylcarbamate (BocNH(CH2)3NH2) was selected as the 
linker between the sugar moiety and the affinity label.  Following reductive 
alkylation, the O-benzyl protecting groups were removed under hydrogenolysis 
conditions.  Subsequently, the N-Boc group was removed and the free amine 
was subjected to the coupling reaction with the sulfo-SBED (Figure 42) to yield 






























1.6.3.2 Analysis of the affinity assay 
The affinity labeling studies were conducted following a protocol similar to 
the one that was used to identify the endogenous binding targets of 
gamendazole.81 Both iminosugar affinity labels were incubated with C57BL/6 
mice testicular cytosol and 45 was irradiated with UV light (254 nm) for 10 
minutes.   The following purification removed the non-specific binding proteins by 
eluting the cytosol through an avidin-agarose column.  In both experiments, a 
protein band of ~60 kDa was isolated (electrophoresis), utilizing either affinity 




could be competitively inhibited by nB-DNJ, indicating that nB-DNJ binds to this 
C57BL/6 cytosolic protein in a specific manner.  The protein will be identified by 
mass spectroscopic and and peptide sequence analysis. 
 
Figure 43.  Identication of iminosugar target(s) in C57BL/6 testis
Lane:   1               2                           4                       5                         7
            
        1  Rxn run-off (cytosol + BT-UV-nB-DNJ + DMSO
        2  Rxn run-off (cytosol + BT-UV-nB-DNJ)
        4  1.5 mM nB-DNJ elute (cytosol + BT-UV-nB-DNJ + nB-DNJ)
        5  1.5 mM nB-DNJ elute (cytosol + BT-UV-nB-DNJ + DMSO)
        7  3 mM nB-DNJ elute (cytosol + BT-UV-nB-DNJ + DMSO)  
 
1.6.3.3  Concluding remarks and future directions 
Two iminosugar affinity labels were prepared and utilized to isolate a 
potential protein target(s) in C57BL/6 mice for nB-DNJ interaction.  To date, the 




which specifically binds to nB-DNJ.  Mass spectroscopic and peptide sequence 
analysis are underway to identify and characterize this protein.  Following 
investigations will delineate the role this protein plays in spermatogenesis and 
illustrate downstream “events” upon its inhibition.  Therefore, we expect to have a 
better understanding of the mechanism that underlies the male contraceptive 
effect of nB-DNJ on C57BL/6 male mice, which could explain the species-specific 
























Enaminones are excellent precursors for alkaloid natural product 
synthesis and can be used as building blocks for synthetic nitrogen-containing 
bioactive agents (Figure 44).  This long-ago discovered, yet underexplored class 
of molecules demonstrates unique chemical properties that we found 
complementary to our interests in natural product and diversity oriented synthesis 
(DOS).82,83  

























* Total syntheses of the alkaloids and corresponding analogues have been achieved in the Georg group
 
Enaminones can be best described as β-acyl enamines or amides with an 
interpolated alkene (vinylogous amide), as shown in Figure 45.  Enaminones 
differ from enamines with respect to reactivity and stability, as the enaminone 
functionality is more stable against hydrolysis and oxidation than an enamine 
moiety.  The conjugate system formed by appending the enamine moieties to a 
carbonyl group, attenuates its reactivity and increases its stability, although the 














 Yet enaminones are highly polarized molecules and can be utilized in a 
variety of chemical transformations, as shown in Figure 46.   

































The electrophilic centers in the molecule are the carbonyl carbon (C4) and 
the carbon at the β-position relative to the carbonyl group (C5).  A selective 1,2 
reduction can be achieved under Luche conditions, and the double bond can be 
reduced with tri-sec-butyl(hydrido)borate (L-Selectride).   The resulting enolate of 
the 1,4-addition can be trapped with Comins’ reagent,84 to afford a vinyl triflate, 
which is a useful synthetic intermediate that can subsequently undergo 
palladium-catalyzed coupling reactions to generate 4-aryl substituted piperidines.  
The nucleophilic sites are the basic nitrogen, and more importantly of the sp2 




nucleophilicity, α-iodination reactions have been achieved in nearly quantitative 
yield under a variety of conditions.85,86 A subsequent Suzuki-Miyaura coupling of 
the α-iodo intermediates with aromatic boronic acids under microwave-assisted 
conditions87 afforded a wide range of 5-aryl enaminone analogues which share 
common structural features with many alkaloids.88 
 Recently, a more direct and concise protocol has been developed in the 
Georg group using organotrifluoroborates as coupling partners,89 in order to 
achieve the 5-arylation of enaminones (Figure 47).   


































This palladium(II)-catalyzed C-H functionalization methodology takes 




the 5-aryl-enaminones in one step, thus avoiding the need for preactivation of the 
enaminones. 
A wide variety of 5-substituted piperidine scaffolds have been constructed 
utilizing the powerful methodologies described above, however only aryl or 
alkene motifs could be successfully installed onto the enaminone C5 position. 
Thus, it has been our interest to develop additional efficient methodologies to 
furnish novel, modified enaminone scaffolds, taking advantage of the C5 
nucleophilicity. 
 
2.2 Preliminary studies concerning the C5 nucleophilicity 
 Several preliminary experiments were performed in order to explore the 
C5 nucleophilicity of enaminones. 
 
2.2.1 Installation of alkyl groups at the C5 position 
 Installation of a simple alkyl group at the C5 position of enaminones has 
not been successful, using the Pd(II)-catalyzed coupling methodology.  This is 
mostly due to the fact that normally alkyl halides do not react with palladium.  
Even if the oxidative addition occurs, facile β-hydride elimination takes place prior 
to the desired sequence of transmetalation and reductive elimination.90 We then 
set out to seek an alternative approach to prepare 5-alkyl-enaminones.  
 It was initially proposed to achieve our goal through an “aldol”-type 
reaction with aldehydes as the reaction partner, as the “aldol” formation and the 




N-acyl-enaminones under Nozaki-Hiyama reaction conditions, followed by a 
deoxygenation91 (Figure 48) furnished C5 alkyl derivatives. 
























When comparing N-acyl-enaminones and N-alkyl-enaminones, the 
resonance contribution of the nitrogen is greatly enhanced in the N-alkyl-
enaminones.  In turn, the nucleophilicity of the C5 position is significantly 
increased and therefore it was expected that N-alkyl enaminones could directly 
attack aldehydes as depicted in Figure 49.  The resultant α-hydroxylated 
intermediate could either be deoxygenated or could undergo β-elimination and 
hydrogenation in sequence, to complete the installation of the C5 alkyl group.  






















The reaction between enaminone and aldehydes was performed as 
proposed above but no reaction took place under either neutral or basic 
conditions.  Under slightly acidic conditions, rendered by the addition of TMSCl 




aldehyde toward nuceophilic attack.  However, instead of providing the desired 
aldol or β-elimination product, a bis-addition product was observed.  Presumably 
the “aldol” intermediate eliminated water to afford a vinylogous imine species, as 
a result of the resonance contribution of the nitrogen. The newly formed 
vinylogous imine then reacted with a second enaminone, forming bis-addition 







































Table 4. Bis-addition products from enaminones and aldehydes 
 
Product R1 R2 Yield (%) 
H Pr 86 
H Ph 90 
H 2-MeC6H4 83 















 Attempts to “trap” the “aldol”, by lowering the reaction temperature or by 
adding “trapping” reagents, such as acetic anhydride and triethylsilylchloride to 
the reaction were unsuccessful.  We also made efforts to facilitate the β-
elimination pathway in order to compete with the bis-addition process.  Limited 
success was achieved only when a sterically hindered aldehyde 
(isobutylaldehyde) was utilized in the presence of a metal chelating reagent 
(Ti(OiPr)4), as shown in Figure 51. 








O Ti(OiPr)4, DCM, rt
R = H 44%
R = Ph 77%R R
 
 Although the limited success was not synthetically useful, it demonstrated 
that the bis-addition process could be impeded, in this case, by steric hindrance 
from the gem-dimethyl groups.  It was then reasonable for us to speculate that 
hydride delivery prior to addition of a second equivalent of enaminone, could 
interrupt or even block the double addition. 
While some mild reducing agents, such as Pd/NH4O2CH and zirconocene 
hydrochloride (Schwartz’s reagent), were unsuccessful, the triethylsilane (TES-H) 
/trifluoroacetic acid (TFA) system91 proved to be an effective hydride source to 
quench the vinylogous iminium species and yield the desired C5-alkylated 

















a) butyraldehyde (1.2 equiv), TFA (4 equiv), TES-H (4 equiv), DCM, reflux, 30 min, 81%
46-a
 
The reaction scope of this one-flask method was then studied, and a 
library of 5-alkylenaminone scaffolds was prepared efficiently.  The products are 
listed in Table 5. 
Table 5. Library of 5-alkylenaminones 
Product Compound R Yield (%) 
   
46a nBu 81 






   
    
46c nBu 92 
46d Bn 86 
46e nNonyl 77 







46f iBu 93 
    
   
46g nBu 88 
46h Bn 93 
      
N
O
R     
    
46i nBu 89 
46j Bn 98 
46k iPr 88 
46l 2-MeC6H4CH2 97 





 46m 4-ClC6H4CH2 96 
 
 High yields were obtained and no dimer formation was observed with a 
variety of aliphatic and aromatic aldehydes.  Bicyclic enaminones were converted 
to the C5 alkylated products, giving comparable yields to those of the monocyclic 




(pyrrolidin-1-yl)furan-2(5H)-one in which the nitrogen is exocyclic.  Interestingly, 
4-(pyrrolidin-1-yl)furan-2(5H)-one also underwent the transformation efficiently 
despite the fact that it has been reported that iodination of the β-carbon does not 
proceed with tertiary (E)-enaminones.86  
 The facile introduction of alkyl groups to C5 of enaminones allows the 
synthesis of a new class of enaminone derivatives.  It should be feasible to 
introduce additional diversified substituents at the C5 position, and construct 
more complex enaminone derivatives.   
 
2.2.2  Aminomethylation at the C5 position and the utilization of LiClO4  
Encouraged by the result of the alkylation reaction, we investigated 
whether nucleophiles other than hydrides can participate in the three-component 
reaction, with enaminones and aldehydes.  Amines were selected as such 
nucleophiles.  Secondary and tertiary aminoalkylated derivatives of enaminones 
were expected from this Mannich reaction.92,93 Although such reaction did 
proceed, it was difficult to isolate the reaction products from the undesired bis-
addition products.  A clean separation was only possible when preparative TLC 
was utilized for isolation of products.   
We next resorted to acyl-protected amines (carbamates) as nucleophiles, 
with the expectation that the products of the multi-component reaction would be 
easier to isolate.  When the literature was surveyed, we were able to find only 




We also noticed in the literature that in the last decade, lithium perchlorate 
(LiClO4), an inexpensive Lewis acid has been utilized often as a useful reagent to 
facilitate Mannich type MCR reactions as seen in Figure 52.  LiClO4 was 
reported to promote the Mannich reaction of electron-rich aromatic compounds 
with in situ generated iminium salts.95 A one-flask three-component reaction with 
(trimethylsilyl)dialkylamine, aldehyde and a functionalized organo-lithium/zinc 
reagent was facilitated by LiClO4, yielding a variety of secondary, tertiary 
alkylamines and N,N-dialkylamino esters in good to moderate yields.96,97 When 
chiral amines were used in the one-flask reaction, high diastereoselectivity was 
achieved in the resultant N-alkylamino esters.98 By replacing the organozinc 
reagents with α-lithiated salts of sulfoxides and sulfones, β-(dialkylamino) 
sulfoxides and β-(dialkylamino) sulfones were obtained in the presence of 
LiClO4.99 With trialkylphosphites as the nucleophile, tertiary α-amino 
phosphonates could be prepared efficiently under similar conditions.100   














































Taking into account the above literature information, we then explored 




Tert-butyl carbamate was selected to participate in the test reaction with 
an (E)-enaminone and formaldehyde, as shown in Scheme 19.   We first 
assayed catalytic amounts of LiClO4 and were pleased to observe the formation 
of 34% of the desired product in the presence of 50 mol% of LiClO4.  Higher 

















a) LiClO4 (1.2 equiv), t-butyl carbamate (2 equiv), (HCHO)n (2 equiv), DCE, reflux, 74%
47-a
 
The reaction yielded 74% of product in refluxing dichloroethane (DCE) 
when 1.2 equivalents of LiClO4 were added.  No bis-addition product was 
observed.  More equivalents (up to 3 equiv) of the reagents did not further affect 
the yield.  Other lithium salts or metal chelating reagents (eg. LiCl, LiI, Ti(OiPr)4) 
were also tested, but no desired product was detected. 
With the standard conditions established, several carbamates were 










Table 6. Library of 5-aminomethylated enaminones 
Product Compound R1  R2 Yield (%) 
    
47a tBu H 74 
47b Ph H 99 
47c Bn Bn 86 
47d allyl Bn 99 
47e Bn allyl 74 









    
    
47g Ph H 54 
47h Bn Bn 62 
47i Bn 4-MeOC6H4CH2 51 
47j tBu H NR 








     
     
  
Typically higher yields were achieved when the (E)-enaminone was 
utilized as the reactant; even quantitative yields were obtained in some cases.  
With the (Z)-enaminone lower yields were observed under the same reaction 
conditions.  Bulky groups on the carbamates were not well tolerated with either 
(E) or (Z)-enaminones.  When benzyl (cyclohexylmethyl)carbamate and benzyl 
isopropylcarbamate (bulky groups as R2) were reacted with the (E)-enaminone, 
less than 10% of products were obtained.  The (Z)-enaminone did not react with 
t-butyl carbamate (bulky group as R1).  Nevertheless and more importantly, we 
discovered in this study that LiClO4 could be utilized to inhibit the adverse bis-
addition reaction and facilitate the desired multi-component reaction.  This 







 2.3 LiClO4-assisted synthesis of 2,5-dioxo-octahydroquinoline-3-
carboxylates 
 We had envisioned that the exploration of the reactivity of the nucleophilic 
β-carbon of the enaminones could potentially lead to more complex enaminone 
derivatives. For instance, we envisaged that scaffolds, containing a bicyclolactam 
nucleus, could be assembled from the (E)-enaminones with electrophiles under 










Figure 53.  2,5-Dioxo-octahydroquinoline-3-carboxylates
R1 = Alkyl; R2 = Me, Bn; 














Typically, a mixture of equimolar amounts of Meldrum’s acid, dimedone, 
aldehyde, and an excess of ammonium acetate (NH4OAc) or an amine are 
heated in a reaction vessel to construct such molecules.101-104 (Figure 54) 




















R1 = H, Me; R2 = H, alkyl; R3 = aryl, alkyl
+  CO2  +  (CH3)2C=O
 
 However, under such reaction conditions, the loss of one of the ester 
groups of Meldrum’s acid (loss of CO2 and acetone) is unavoidable.  Hence, it is 




Since our preliminary studies showed that LiClO4 could inhibit the double 
addition of enaminones to aldehydes, we proposed that we could achieve a 
multi-component reaction similar to the aminomethylation, by modifying the 
corresponding reaction conditions, more specifically by using a malonate as the 
replacement for a carbamate.   With such an adduct in hand, the C3 carboxylate 
could be potentially retained in the final cyclized product after a following 
annulation.   
 
2.3.1  LiClO4-assisted formation of enaminone methylmalonates 
We then carried out test reaction where an (E)-enaminone (derived from 
the condensation of dimedone and an amine),105 formaldehyde and dimethyl 
malonate were subjected to heating in acetonitrile, in the presence of one 
equivalent of LiClO4, as depicted in Scheme 20.  To our delight, the desired 










LiClO4 (1 equiv), dimethyl malonate (1.5 equiv),
 (HCHO)n (2 equiv), MeCN, 90 °C, 77%
48a  
 
 Optimization of the reaction conditions showed that an equal molar 
amount of LiClO4 was crucial and adequate to achieve a good yield.  Acetic 




one flask.  Although no cyclized product was detected, we observed that the yield 
of the MCR reaction had improved.  In addition, the presence of acetic anhydride 
allowed the completion of the reaction at lower temperature within a comparable 
amount of time, as shown in Table 7.  Several other Lewis acids were tested, 
however no satisfactory results were obtained. 
Table 7. Optimization of the LiClO4-assisted reaction 
 
Product Temperature (°C) LiClO4 (Ac2O) (equiv) Yield (%) 
         






 48a  
90                  / 12 
90                0.9  63 
90                1.0  77 
90                1.9  75 
90                10.0  62 
60          1.0 (1.0)   93* 
60  LiO2CCF3  / 1.0  57 
60  Ti(OiPr)4 / 1.0  / ** 
60  MgBr2•OEt2 / 1.0  / **  
*   used as the standard condition for following transformation;   
**  bis-addition product observed, no desired product formation.  
 
Next, several enaminones and malonates were subjected to this reaction, 






n = 0, 1














R1 = H, Me
R2 = Bn, Bu, Ph
R3 = Me, Et, Bn
 
 
The reaction products were obtained in moderate to excellent yields (66%-




malonate, dimethyl 2-methylmalonate) did not react under these conditions.  
Methyl acetoacetate and triethyl phosphonoacetate were tested as surrogates for 
malonates, but no product was detected under the standard conditions.  Attempts 
to replace formaldehyde with other aldehydes such as benzaldehyde, were not 
successful. 
Table 8. LiClO4-mediated MCR with enaminones, formaldehyde and malonates 
 
Product Yield (%) 
 
























Compound R1 = R2 =  
48b Ph Me 90 
48c Ph Bn 97 
48d Bn       Me, Bn 73 
48e Bn Bn 90 
48f         nBu Me 66 
48g         nBu Bn 83 
48h N-morpholine Me 72 
48i N-morpholine Bn 86 
    
    
48j Ph Me 83 
48k Ph Bn 87 
48l Bn Me 95 
48m Bn Bn 88 
48n         nBu Me 88 
    
    
48o Ph Me 96 








2.3.2  Mechanistic studies 
We proposed that the reaction proceeds through a Knoevenagel process 
producing dimethyl 2-methylenemalonate in situ, followed by a conjugate addition 





















To confirm this pathway, the proposed intermediate dimethyl 2-
methylenemalonate was prepared106 and subjected to reaction with an 



























 The results showed that the adduct was obtained with or without LiClO4, in 
a comparable yield compared to that of the one-flask reaction under the standard 
conditions, suggesting that the LiClO4-mediated three-component reaction likely 




and a conjugate addition step in sequence.  The results also revealed that LiClO4 
is not necessary for the Michael addition, indicating it is responsible for other 
aspects of this reaction. 
 Unlike methylenemalonate, even in the presence of LiClO4, dimethyl 
benzylidene-malonate107 was unreactive with the enaminone, which explains why 
no reaction occurred when benzaldehyde was used instead of formaldehyde.   
 We think that LiClO4 most likely plays a dual role in this reaction: firstly it 
prevents the equilibrium of the reaction from going toward the direction of the bis-
adduct formation; and secondly it facilitates the formation of the Michael acceptor 
in the one-flask reaction.   
H H
O




























The lithium cation of the weak Lewis acid presumably forms a chelate with 
the neighboring oxygen atoms,108-110 which possibly lowers the energy of the 




intermediate, which is highly susceptible toward bis-addition by a second 
enaminone molecule, is largely inhibited. Therefore, the equilibrium of the 
reaction is shifted toward the direction of the conjugate addition in which the 
enaminone adds to methylenemalonate, as shown in Figure 57.  Bivalent Lewis 
acids, such as Ti(OiPr)4 and MgBr2, facilitate the dehydration step due to their 
stronger acidity, and therefore generate the bis-addition derivative as the major 
product. 
Figure 58.  Proposed role of LiClO4 - facilitates methylenemalonate formation
synthetic preparation
MeO OMe
O O (HCHO)n, Cu(OAc)2
AcOH, reflux, 25% MeO OMe
O O
in the MCR (60 °C)
LiClO4  +  Ac2O CH3CO ClO4 +    LiOAc



























 LiClO4 probably also facilitates the formation of the Michael acceptor, as 




separate flask can only be achieved under rather harsh conditions,106 whereas 
the formation of the Michael acceptor in the one-flask reaction with LiClO4 and 
the additive acetic anhydride takes place under relatively ambient conditions.  It 
is worth noting that methylenemalonate was not detected in a control reaction to 
which the enaminone was not added, suggesting that elimination of the acetate is 
likely the rate-limiting step to yield the Michael acceptor.  The presence of the 
enaminone possibly provides a modest amount of electrostatic stabilization to the 
reaction’s transition state and consequently shifts the equlibrium towards the 
formation of the Michael addition product.  
 
2.3.3  Annulation of the adduct 
 Annulation of adducts was achieved under acidic conditions,111-113 yielding 
N-substituted 2,5-dioxo-1,2,3,4,5,6,7,8-octahydroquinoline-3-carboxylates, as 
shown in Scheme 22. 
n = 0, 1






















1 = H, Me
R2 = Bn, Bu, Ph
R3 = Me, Et, Bn
49
 
Adducts obtained from the three-component reaction were treated with 
excess trifluoroacetic acid (30 equiv) in dichloroethane (DCE) or toluene, under 
refluxing conditions.  Cyclized products were obtained in moderate yields.  A list 
of products is shown in Table 9.  The cyclization of dimethylmalonate adducts 




dibenzylmalonate adducts, with an aproximately 10% improvement in yields.  
Adducts containing a 1-morpholino group decomposed under the acidic 
conditions, thus cyclized products were not isolated. 
Table 9. Results of the annulation step 


















R1   
compound R1 = R2 = Solvent  
49a Bn Me DCE 79 
49b Bn Bn toluene 70 
49c Ph Me DCE 84 
49d Ph Bn toluene 49 
49e nBu Me DCE 57 
49f nBu Bn toluene 60 
     
49g Bn Me DCE 67 
49h Bn Bn toluene 64 
49i Ph Me DCE 64 
49j Ph Bn toluene 51 
49k nBu Me DCE 62 
     
49l Bn Me DCE 62 
49m Ph Me DCE 49 
 
2.3.4 Oxidation of 2,5-dioxo-octahydroquinoline-3-carboxylates  
The oxidation products of bicyclolactams 49 structually resemble a class 


























Milrinone and amirinone are prototypes of clinically useful “non-glycoside” 
inotropes, which are indicated for the short-term intravenous therapy of 
congestive heart failure (CHF).114 The main mechanism of these agents is 
inhibition of the cyclic GMP-inhibited camp phosphodiesterase (type 3 PDE), 
resulting in an elevation of camp levels in cardiac and vascular muscles.115 It has 
been suggested that the ionotropic effect of these drugs could also be attributed 
to the antagonism towards endogenous adenosine at the cardiac A1 receptor.116 
Owing to their unique mechanism of action, these cardiotonic agents display a 
better safety profile than the conventionally used digitalis glycosides that have a 
narrow therapeutic index and a tendency to cause life-threatening 
arrhythmogenic lability.117  
However, neither milrinone nor amirinone inhibits PDE3 or A1 with 
exclusive high affinity.  Thus, in a search for a new generation of cardiotonic 
agents with greater efficacy, these FDA approved agents have served as the 
prototypes of a series of analogues.  Among the derivatives synthesized using 
milrinone as the template, methyl 2,5-dioxo-1,2,5,6,7,8-hexahydroquinoline-3-




both guinea pig spontaneously beating atria and electronically driven left atria.118-
121  
With bicyclolactams 49 in hand, we performed an oxidation reaction in 
order to convert them to 2-pyridones.  2,5-dioxo-4,6,7,8-octahydroquinoline-2,5-
dione-3-carboxylate was discovered to be susceptible toward oxidation under 
basic condition. Methyl 1-benzyl-2,5-dioxo-1,2,5,6,7,8-octahydroquinoline-3-
carboxylate was converted to the oxidized product 50a in excellent yield, upon 
refluxing in oxygenated methanol, as shown in Scheme 23.  Additional 
analogues were obtained, however the reactions did not go to completion in all 














50a  R1 = Bn      94% 
50b  R1 = Ph      24%
50c  R1 = nBu    60%
50d  R1 = H        25%
49 50  
 
2.3.5 Synthesis of N-substituted 2,5-dioxo-octahydroquinoline-3-
carbonitriles 
 Encouraged by the successful construction of enaminone 
methylmalonates, we attempted to expand the scope of the LiClO4-assisted 
methodology.  Different malonate surrogates were screened, although no 
successful reactions were achieved with malonate surrogates, such as methyl 
acetoacetate, triethyl phsophonoacetate and methyl cyanoacetate, using acetic 




 Since it was reported that nucleophilic phosphines could be used as 
catalyst in internal cycloadditions to synthesize carbo- and heterocycles,122-125 we 
screened phosphines as additives in our test reactions. 
To our delight, with methyl cyanoacetate as a replacement for malonate, 
the reaction yielded the corresponding cyclized nitriles in one-flask in the 
presence of a catalytic amount of organophosphine.  Again, formaldehyde was 
the only viable aldehyde (Scheme 24) in this reaction.  A list of products is 
shown in Table 10. 
R1 = H, Me





a) LiClO4 (1.0 eq), (HCHO)n (2.0 equiv), methyl cyanoacetate













Table 10. 2,5-Dioxo-1,2,3,4,5,6,7,8-octahydroquinoline-3-carbonitriles 
 
Product compound R1 = R2 = Yield (%) 
51a H Bn 85 
51b H Ph 65 (PBu3) 
51c H Bu 73 (PBu3) 
51d Me Bn 68 
51e Me Pr 75 
         














 In this reaction no intermediate adduct was detected, suggesting that the 
phosphine-catalyzed Knoevenagel process126 was directly followed by an 
intramolecular amide forming step.   
A proposed formal [3 + 3] mechanism for the synthesis of the 2,5-dioxo-
1,2,3,4,5,6,7,8-octahydroquinoline-3-carbonitriles is outlined in Figure 60. 
































































LiClO4 initiates the C-C bond formation between the aldehyde and methyl 
cyanoacetate with the assitance of phosphine.   The Michael acceptor is then 
formed upon elimination of the hydroxyl group.  The enaminone, which is 
stabilized by LiClO4, attacks the Michael acceptor providing the adduct.  It is 




amidation/cyclization,127 giving the 2,5-dioxo-1,2,3,4,5,6,7,8-octahydroquinoline-
3-carbonitrile. 
Malonates were also subjected to the reaction conditions shown in 
Scheme 24.  However, no cyclized product was detected after 12 h.  The bis-
addition product was found to be the major product, accompied by only a small 
amount of the Michael addition product.  This result was not very surprising in 
that it was reported that Knoevenagel products were not obtained from 
malonates and aldehydes under phosphine-catalyzed conditions.126 As a result, 
the Michael acceptor could not be generated in situ, and the subsequent 
formation of enaminone methylmalonates could not take place.  
 
2.4 Concluding remarks 
In this chapter, we examined the nucleophilicity and chemical reactivity of 
enaminones.  A practical method was discovered to install alkyl groups at the C5 
position, and a LiClO4-assisted aminomethylation reaction was achieved taking 
advantage of the C5 nucleophilicity.  Susequent studies allowed us to develop a 
LiClO4-mediated two-step synthesis of 2,5-dioxo-octahydroquinoline-3-
carboxylates.  This facile method provides an operationally easy approach to 
synthesize a class of compounds, which are potentially ionotropically active for 
the treatment of congestive heart failure disease.  An organophosphine 








3.1 Material and Methods 
Proton nuclear magnetic resonance spectra were recorded using a 400 
MHz or 500 MHz spectrometer.  Carbon nuclear magnetic resonance spectra 
were recorded using a 100 MHz or 125 MHz spectrometer.  All Chemical shifts 
were recorded as parts per million (ppm), and all samples were dissolved in 
CDCl3 using residual solvent peak as internal standard unless otherwise noted. 
Mass spectra were obtained from a ZAB HS mass spectrometer equipped with a 
11/250 data system. Fast-atom bombardment mass spectrometry (FAB-MS) 
experiments were performed with a Xenon gun operated at 8 Kev energy and 0.8 
mA emission at the MS laboratory at the University of Kansas and the Institute 
for Therapeutic Discovery and Development at University of Minnesota. Fast-
atom bombardment high resolution mass spectra (FAB-HRMS) were recorded at 
1:10,000 resolution using linear voltage scans under data system control and 
collected in a multi-channel analyzer mode (MCA). A Recording Infrared 
Spectrophotometer or a FT-IR was used to record infrared spectra. Optical 
rotations were obtained using a polarimeter at room temperature.  Melting points 
are uncorrected. All moisture-sensitive reactions were performed using either 
oven or flame dried glassware under a positive pressure of argon unless 
otherwise noted. Solvents and reagents that are commercially available were 
used without further purification unless otherwise noted. Tetrahydrofuran and 




Methylene chloride was distilled freshly from calcium hydride under argon.  Silica 
gel (230-400 mesh) used for column chromatography. All compounds were 
concentrated using a standard rotory evaporator and high-vacuum techniques. 
 
3.2    Biological Procedures 
3.2.1 Microsome preparation from mouse and rat testes 
Testes in 5 g batches were placed in a 50 mL culture tube.  To the tube, 
reagent A (antipain (20 µL, 1 mg/mL), leupeptin (20 µL, 1 mg/mL), aprotinin (200 
µL, 1 mg/mL), APMSF (110 µL, 1 mg/mL), KCl (372 mg), deionized H2O (18.5 
mL)) and reagent B (25 mL, 0.5 M Tris, 2.0 M sucrose) were added.  The testes 
were minced with scissors then blended by 2-3 10 sec bursts at a time on Power 
Gen 700 (Fisher Scientific) at setting 5-6 while on ice. The homogenate was 
centrifuged at 7500 rpm for 10 min at 4 ºC using a SW28 rotor.  The resultant 
supernatant was collected and centrifuged at 23500 rpm for 1 h at 4 ºC in a 
SW40 rotor.  The supernatant was discarded and the pellet containing the 
microsomes was suspended in Reagent C (600 µL, 200 mM DTT, 0.1 M EDTA, 
10 mM UDP-glucose and 10% CHAPSO) and dispersed by passing through a 
25-gauge needle followed by an insulin needle.  The microsome suspension was 
stored as 100 µL aliquots in microcentrifuge tubes, flash frozen in liquid nitrogen 
for 1-2 min, and kept at -80 °C, and used as needed. 
 




The Enzymatic Reaction:  The following solutions were added to each tube: 
reagent A (295 µL, pH 7.4, containing 50mM HEPES, 5 mM MnCl2, 10mM 
phosphatidylcholine, 50 uM CBE, 1 mM EDTA and 10 mM UDP-Glucose), H2O 
(145 µL), iminosugar solution (50 µL) and testicular microsomes (100 µg).  
Control tubes contained the same components except microsome.  Reactions 
were initiated by the addition of BSA-ceramide (3 µL), and incubated at 37 °C for 
30 min, then terminated by addition of chloroform:methanol (1 mL, 2:1, v/v), 
vortexed and incubated at room temperature for 30-60 min to allow phase 
separation.  The upper phase and the mid-layer were removed and discarded, 
and chloroform:methanol:water (500 µL, 3:48:47, v/v/v) was added to the bottom 
layer, vortexed and allowed to sit for 15 min at room temperature.  The resultant 
upper phase was again removed and chloroform:methanol (100 µL, 2:1, v/v) was 
added and then sample tubes were dried in a vortex evaporator overnight. 
 
Thin layer chromatography (TLC):  TLC plates were pre-treated (Whatman silica 
gel 60 A, 20x20 cm, layer thickness 250 µm) by immersion in 
chloroform:methanol:water (50:50:15, v/v/v) for 5 min, air dried for 10 min, then 
immersed in 5% sodium borate (prepared in methanol) for 1 min, dried and 
heated at 120 °C for 1.5 h.  The dried sample tubes were reconstituted with 
chloroform:methanol (100 µL, 2:1, v/v) and vortexed, a sample (20 µL) was then 
spotted onto the plates at the origin.   The spotted plates were air-dried and 




(60:30:5, v/v/v) and run for approximately 1 h until solvent reached < 1 cm from 
top of plate. 
 
Detection and quantitation of substrate/product:  The TLC plate was documented 
using UV transilluminator (302 nm) and analyzed using AlphaEase (Fluorchem 
SP) software.  The IDV values were plotted against iminosugar concentration 
using Sigma Plot 10.  A linear regression plot was used to determine IC50 values. 
 
3.2.3  Non-lysosomal β-glucosidase 2 (GBA2) assay 
The inhibitory effects of nB-DNJ derivatives on the activity of the non-
lysosomal glucosylceramidase were determined in membrane preparations from 
various tissues.  Pooled mouse tissues were homogenized in water (1:3, w/v) 
using a Polytron PT1000 homogenizer (VWR) for 1 min.  Homogenates were 
centrifuged for 20 min at 15,000 g (4 °C).  The supernatant was removed and the 
pellet was resuspended in ice-cold 50 mM potassium phosphate buffer, pH 5.8. 
Membranes were washed three times in the phosphate buffer, resuspended in 
this buffer, and stored at -80 °C.   
For the enzyme assay aliquots of the membrane suspension were 
preincubated with conduritol epoxide (CBE) (Toronto Research Chemicals, 
Downsview, ON, Canada) at a final concentration of 2.5 mM for 15 min, 
supplemented with an iminosugar to the desired concentration, incubated for 15 
min, then diluted 3-fold in 4.5 mM 4-methylumbelliferyl-D-glucoside (Sigma) in 




of 30 µl, and incubated at 37 °C for 1 h. The reaction was stopped by adding 200 
µl of 500 mM sodium carbonate, pH 10.7.  Released 4-methylumbelliferone was 
detected using a Fluoroskan Ascent fluorometer (Thermo Electron Corp., 
Basingstoke, Hampshire, UK; excitation 355 nm, emission 460 nm). The IDV 
values were plotted against iminosugar concentration using Sigma Plot 10.  
Linear regression plot was used to determine IC50 values. 
 
3.2.4 Affinity labeling study 
Incubation:  A light-proof vessel containing pre-cleared cytosol (2.7 mL), affinity 
label (42 or 45, 150 µL, 10 mM stock solution diluted 1:1000) and nB-DNJ 
solution (150 µL, 5.2 mg/mL) was incubated at 4 °C in a dark room.  As a control, 
pre-cleared cytosol (2.7 mL), affinity label (150 µL) and DMSO (150 µL) were 
incubated on the side. 
 
Irradiation of the Affinity label:  The sealed vessel was exposed to a UV light (254 
nm) suspended at 10 cm height for 20 min.  The irradiated mixture was then 
loaded onto an avidin D agarose column. 
  
Separation:  The column was washed until background was reached and was 
subsequently eluted with 1.5 mM nB-DNJ, 3 mM nB-DNJ, 250 mM NaCl and 600 
mM NaCl in sequence.  Absorbance of all eluates measured and concentrated to 





Silver Stain:  Silver stain is compatible with mass-spectrometry analysis and has 
high signal to noise ratio.  The gel was fixed with 50% MeOH, 12% acetic acid, 
0.05% formalin, 2 h or overnight.  The gel was washed with 35% EtOH for (20 
min × 3).  The gel was subsequently subjected to sensitization with 0.02% 
Na2S2O3 for 2 min, followed by washing with H2O (5 min × 3).  The gel was then 
stained with 0.2% AgNO3, 0.076% formalin for 20 min.  Next, the gel was rinsed 
with H2O (5 min × 2), and developed with 6% Na2CO3, 0.05% formalin and 12% 
acetic acid for 5 min.  The gel was left at 4 ºC in 1% acetic acid. 
 
Preparation of samples from gel bands for Mass-spectrometry study:  The gel 
was destained till a clear background was observed.  Gel bands were excised 
precisely and placed into a washed, plain 1.5 mL Eppendorf tube; a band from a 
blank area was also collected as the control. The gel slice was washed with 50% 
HPLC Grade acetonitrile/H2O twice for 10 min with occasional vortex mixing.  
The Eppendorf tube was closed tightly after rinsing the cap off with the 50% 
HPLC Grade acetonitrile/H2O solution.  The samples were then submitted for 
mass-spectrometry analysis. 
 
3.3 Experimental Procedures 










material, 2,3,4,6-tetra-O-benzyl-D-glucopyranose (2.0 g, 3.7 mM) was dissolved 
in THF (20 mL) and then LiAlH4 (505 mg, 12.6 mmol) was added to the solution 
in portions over 20 min, at 0 °C.  After the reaction had warmed to room 
temperature, the reaction was quenched utilizing the 1+2+3 method: for each of 
1 g LiAlH4 used, H2O (1 mL) was added slowly, then 10% aqueous NaOH (2 mL), 
and lastly H2O (3 mL) were added.  The aluminum salts were easily filtered off on 
a Celite plug.  The filtrate was subjected to rotary evaporation and flash column 
chromatography on silica gel, using 10% EtOAc:hexanes (v/v) as the eluent, to 
give a colorless syrup (95%).  1H NMR (CDCl3, 400 MHz, ppm): δ 7.27 (m, 20H), 
4.6 (m, 8H), 4.02 (m, 1H), 3.89 (dd, J = 3.6, 6.2 Hz, 1H), 3.63 (d, J = 3.8 Hz, 2H), 
3.55 (dd, J = 4.5, 11.9 Hz, 1H); 13C NMR (CDCl3, 400 MHz, ppm): δ 138.3, 138.0, 
128.6, 128.3, 128.2, 128.1, 128.0, 127.1, 79.6, 79.2, 77.5, 74.7, 73.6, 73.4, 73.2, 
71.3, 70.8, 62.0; ESI-HRMS: calc’d m/e for [M+Na+] C34H38NaO6: 565.2566, 
found 565.2568; IR (neat, NaCl, cm-1): 3545, 2923, 2870, 1720, 1496, 1453, 









General Procedure for the Synthesis of (2R,3R,4R,5S)-3,4,5-Tris(benzyloxy)-
2-((benzyloxy)methyl)piperidines 2. A reaction vessel, containing dimethyl 




approximately, was cooled to -78 °C in a dry ice-acetone bath.  A solution of 
oxalyl chloride (4.4 equiv) in CH2Cl2 (0.2 mL/mmol) was subsequently added 
dropwise to the DMSO/CH2Cl2 solution.  The reaction was stirred at -78 °C for 30 
min.  Diol 1 was dissolved in CH2Cl2 at a concentration of 4 mL/mmol 
approximately, and the solution of the diol was added slowly to the reaction.  The 
reaction was kept at -78 °C for 1.5 h, followed by the dropwise addition of 
triethylamine (8 equiv) in CH2Cl2 (0.5 mL/mmol), and was allowed to warm to 
room temperature gradually.  Solvent and excess triethylamine were evaporated 
in vacuo at 40 °C.  The crude amorphous solid material was used in the double 
reductive alkylation without further purification. 
The above material was dissolved in MeOH (6 mL/mmol) and 4Å 
molecular sieves (0.4 g/mmol) were added.  A solution of the amine (3 equiv) in 
MeOH was then added to the reaction.  Next, sodium cyanoborohydride (2.5 
equiv) was added, and the pH of the reaction was kept < 7 by adding acetic 
acid.  (Caution: good ventilation is mandatory for the highly toxic HCN gas that 
is generated.)  The reaction was stirred at 50 °C overnight, and quenched with 1 
M NaOH.  The reaction mixture was filtered through a Celite plug and diluted 
with H2O (50 mL/mmol). The aqueous solution was then extracted with CH2Cl2 
(20 mL × 2).  The organic layers were combined, dried over MgSO4 and then 
concentrated in vacuo.  The N-alkylated products were purified via flash column 











isopropylpiperidine (2-1).  After chromatographic purification, a viscous yellow 
oil was obtained (60%).  1H NMR (CDCl3, 400 MHz, ppm): δ 7.74 - 7.27 (m, 18H), 
7.12 - 7.10 (m, 2H), 4.96 (d, J = 11.2 Hz, 1H), 4.86 (d, J = 10.9 Hz, 1H), 4.81 (d, 
J = 11.2 Hz, 1H), 4.68 (d, J = 10.3 Hz, 2H), 4.47 (d, J = 3.2 Hz, 2H), 4.42 (d, J = 
10.9 Hz, 1H), 3.69 (dd, J = 8.1, 2.4 Hz, 1H), 3.63 (m, 1H), 3.57 (m, 2H), 3.45 (t, J 
= 9.0 Hz, 1H), 3.26 (t, J = 9.0 Hz, 1H), 3.07 (dd, J = 6.2, 4.8 Hz, 1H), 2.37 (m, 
1H), 1.96 (t, J = 10.8 Hz, 1H), 1.08 (d, J = 6.7 Hz, 3H), 0.80 (d, J = 6.7 Hz, 3H); 
13C NMR (CDCl3, 400 MHz, ppm): δ 138.61, 138.55, 138.19, 138.12, 128.38, 
128.35, 128.10, 127.97, 127.87, 127.77, 127.63, 127.59, 104.71, 84.66, 82.34, 
77.89, 75.68, 75.02, 74.87, 74.75, 73.50, 68.95, 57.10, 29.70; ESI-HRMS: calc’d 
m/e for [M+H+] C37H44NO4: 566.3270, found 566.3302;  IR (neat, NaCl, cm-1): 
3062, 3030, 2924, 2863, 1724, 1604, 1583, 1497, 1453, 1360, 1312, 1274, 1212, 











butyl-cyclohexyl)piperidine (2-2).  After chromatographic purification, a 
colorless oil was obtained (55%).  1H NMR (CDCl3, 400 MHz, ppm): δ 7.36 - 7.27 
(m, 18H), 7.19 (d, J = 1.8 Hz, 1H), 7.17 (s, 1H), 4.95 (d, J = 11.3 Hz, 1H), 4.89 
(d, J = 10.9 Hz, 1H), 4.82 (d, J = 11.3 Hz, 1H), 4.66 (ddd, J = 6.2, 6.2, 6.2 Hz, 
2H), 4.60 (d, J = 12.3 Hz, 1H), 4. 51 (d, J = 10.9 Hz, 1H), 4.32 (d, J = 12.3 Hz, 
1H), 3.63 (m, 1H), 3.60 (m, 2H), 3.49 (m, 1H), 3.43 (t, J = 9.0 Hz, 1H), 3.14 (dd, J 
= 4.8, 11.0 Hz, 1H), 2.63 (t, J = 11.6 Hz, 1H), 2.42 (d, J = 9.5 Hz, 1H), 2.02 (t, J = 
10.7 Hz, 1H), 1.80 (d, J = 12.6 Hz, 1H), 1.53 - 1.26 (m, 14H), 0.96 (t, J = 6.7 Hz, 
3H); 13C NMR (CDCl3, 400 MHz, ppm): δ 139.21, 138.63, 137.70, 128.69, 
128.57, 128.40, 128.35, 128.25, 127.97, 127.90, 127.81, 127.71, 127.58, 127.53, 
127.31, 87.63, 79.51, 79.18, 75.17, 75.08, 73.29, 72.86, 72.69, 64.68, 64.43, 
62.65, 62.52, 56.81, 56.55, 47.94, 37.57, 36.71, 33.02, 32.28, 32.03, 31.53, 
30.55, 30.16, 29.71, 29.33, 29.08, 26.09, 23.58, 22.97, 22.70, 18.53, 14.23; ESI-
HRMS: calc’d m/e for [M+H+] C44H56NO4: 662.4209, found 662.4226;  IR (neat, 
NaCl, cm-1): 3089, 3064, 2922, 2855, 1726, 1605, 1586, 1496, 1454, 1361, 1316, 











hexyl-cyclohexyl)piperidine (2-3).  After chromatographic purification, a 
colorless oil was obtained (54%).  1H NMR (CDCl3, 400 MHz, ppm): δ 7.36 - 7.25 
(m, 18H), 7.18 (m, 2H), 4.95 (d, J = 11.3 Hz, 1H), 4.88 (d, J = 10.9 Hz, 1H), 4.82 
(d, J = 11.3 Hz, 1H), 4.66 (ddd, J = 11.6, 11.6, 11.6 Hz, 2H), 4.59 (d, J = 12.3 Hz, 
1H), 4.51 (d, J = 10.9 Hz, 1H), 4.31 (d, J = 12.3 Hz, 1H), 3.60 (m, 2H), 3.57 (m, 
1H), 3.49 (dd, J = 2.1, 10.4 Hz, 1H), 3.43 (t, J = 9.0 Hz, 1H), 3.14 (dd, J = 4.9, 
11.1 Hz, 1H), 2.63 (t, J = 11.6 Hz, 1H), 2.42 (d, J = 9.5 Hz, 1H), 2.02 (t, J = 10.8 
Hz, 1H), 1.79 (d, J = 12.7 Hz, 1H), 1.64 (dt, J = 2.8, 10.3 Hz, 2H), 1.58 (m, 2H), 
1.51 (d, J = 12.3 Hz, 1H), 1.40 - 1.25 (m, 9H), 1.13 - 1.01 (m, 4H), 0.89 (t, J = 6.9 
Hz, 3H); 13C NMR (CDCl3, 400 MHz, ppm): δ 139.22, 138.63, 137.70, 128.69, 
128.39, 128.35, 128.25, 127.97, 127.90, 127.81, 127.71, 127.58, 127.53, 127.31, 
87.63, 79.33, 79.18, 75.17, 75.08, 73.29, 72.69, 72.69, 64.42, 62.65, 56.55, 
47.93, 37.58, 37.03, 33.01, 32.03, 31.93, 29.61, 29.33, 27.04, 23.58, 22.97, 
22.69, 14.15; ESI-HRMS: calc’d m/e for [M+H+] C46H60NO4: 690.4522, found 
690.4520;  IR (neat, NaCl, cm-1): 3088, 3064, 3030, 2923, 2854, 1726, 1604, 
1586, 1497, 1454, 1361, 1315, 1270, 1207, 1173, 1096, 1028, 902, 820, 734, 











phenylpiperidine (2-4).  After chromatographic purification, a yellow oil was 
obtained (46%).  1H NMR (CDCl3, 400 MHz, ppm): δ 7.39 - 7.21 (m, 22H), 7.07 
(d, J = 8.5 Hz, 2H), 7.02 (t, J = 7.4 Hz, 1H), 4.90 (m, 1H), 4.85 (d, J = 5.5 Hz, 
1H), 4.81 (m, 2H), 4.70 (m, 2H), 4.58 (d, J = 11.2 Hz, 1H), 4.41 (d, J = 12.0 Hz, 
1H), 4.34 (d, J = 12.0 Hz, 1H), 4.02 (t, J = 6.9 Hz, 1H), 3.87 (m, 1H), 3.75 (t, J = 
7.7 Hz, 1H), 3.66 (dd, J = 2.0, 9.6 Hz, 1H), 3.47 (dd, J = 4.8, 11.4 Hz, 1H), 3.41 
(dd, J = 4.6, 9.8 Hz, 1H), 3.04 (m, 1H), 3.07 (t, J = 10.9 Hz, 1H); 13C NMR 
(CDCl3, 400 MHz, ppm): δ 150.45, 139.19, 138.85, 138.80, 138.53, 129.5, 
128.92, 128.83, 128.78, 128.38, 128.24, 128.19, 128.10, 128.03, 127.96, 127.73, 
122.44, 120.66, 85.77, 79.49, 78.11, 74.54, 74.22, 73.53, 72.79, 67.66, 63.12, 
52.72; ESI-HRMS: calc’d m/e for [M+H+] C40H42NO4: 600.3114, found 600.3113; 
IR (neat, NaCl, cm-1): 3060, 3027, 2922, 2852, 1721, 1599, 1497, 1453, 1364, 








hexylphenyl)-piperidine (2-5).  After chromatographic purification, a yellow oil 




7.09 (d, J = 8.4 Hz, 2H), 7.00 (d, J = 8.4 Hz, 2H), 4.89 (d, J = 11.3 Hz, 1H), 4.81 
(t, J = 12.4 Hz, 2H), 4.57 (d, J = 11.3 Hz, 1H), 4.41 (d, J = 12.4 Hz, 1H), 4.27 (d, 
J = 12.4 Hz, 1H), 3.98 (t, J = 9.1 Hz, 1H), 3.88 (m, 1H), 3.75 (t, J = 7.9 Hz, 1H), 
3.66 (d, J = 11.4 Hz, 1H), 3.45 (dd, J = 2.0, 9.6 Hz, 1H), 3.34 (d, J = 11.4 Hz, 
1H), 3.14 (m, 1H), 2.98 (t, J = 11.4 Hz, 1H), 2.57 (t, J = 9.1 Hz, 2H), 1.57 (m, 4H), 
1.30 (m, 6H), 0.88 (t, J = 6.6 Hz, 3H); 13C NMR (CDCl3, 400 MHz, ppm): δ 
147.77, 138.92, 138.53, 138.40, 138.08, 137.98, 128.94, 128.45, 128.37, 128.31, 
128.23, 128.04, 127.94, 127.90, 127.78, 127.75, 127.61, 127.54, 127.47, 127.44, 
127.30, 122.10, 116.30, 86.07, 83.09, 79.61, 78.93, 75.55, 74.55, 74.35, 73.20, 
73.07, 72.43, 66.74, 63.92, 58.76, 54.55, 35.32, 35.02, 34.97, 31.75, 31.57, 
29.70, 29.05, 22.63, 14.13; ESI-HRMS: calc’d m/e for [M+H+] C46H54NO4: 
684.4053, found 684.4028; IR (neat, NaCl, cm-1): 3431, 3351, 3217, 3017, 2956, 
2926, 2854, 1875, 1717, 1624, 1517, 1466, 1378, 1273, 1179, 1125, 1071, 1028, 








methyl)piperidine (2-6).  After chromatographic purification, a yellow oil was 




(d, J = 6.8 Hz, 2H), 4.77 (m, 2H), 4.72 (t, J = 5.0 Hz, 1H), 4.68 (m, 2H), 4.56 (d, J 
= 11.4 Hz, 1H), 4.41 (d, J = 12.1 Hz, 1H), 4.36 (d, J = 11.9 Hz, 1H), 4.01 (t, J = 
6.2 Hz, 1H), 3.86 (m, 1H), 3.75 (t, J = 6.6 Hz, 1H), 3.66 (dd, J = 2.3, 9.2 Hz, 1H), 
3.51 (d, J = 5.2 Hz, 1H), 3.48 (m, 2H), 3.15 (t, J = 9.4 Hz, 1H); 13C NMR (CDCl3, 
400 MHz, ppm): δ 128.69, 128.40, 128.33, 128.29, 127.91, 127.74, 127.64, 
127.53, 126.60, 118.89, 84.83, 76.55, 73.83, 73.40, 73.15, 72.30, 70.66, 65.19, 










yl)morpholine (2-7).  After chromatographic purification, a viscous yellow oil was 
obtained (65%).  1H NMR (CDCl3, 400 MHz, ppm): δ 7.35 - 7.18 (m, 20H), 4.96 
(d, J = 11.3 Hz, 1H), 4.87 (d, J = 10.8 Hz, 1H), 4.83 (d, J = 10.8 Hz, 1H), 4.70 
(ddd, J = 11.6, 11.6, 11.6 Hz, 2H), 4.59 (m, 1H), 4.52 (ddd, J = 12.4, 12.4, 12.4 
Hz, 2H), 4.07 (d, J = 9.4 Hz, 1H), 3.74 (t, J = 9.3 Hz, 1H), 3.62 (m, 6H), 3.42 (t, J 
= 9.0 Hz, 1H), 3.29 (dd, J = 4.6, 10.0 Hz, 1H), 2.68 (s, 2H), 2.57 (m, 1H), 2.54 
(m, 2H), 2.21 (t, J = 10.3 Hz, 1H); 13C NMR (CDCl3, 400 MHz, ppm): δ 138.99, 
138.52, 138.35, 128.46, 128.36, 128.30, 127.99, 127.85, 127.77, 127.69, 127.60, 




ESI-HRMS: calc’d m/e for (M+H+)] C38H45N2O5: 609.3328, found 609.3307; IR 
(neat, NaCl, cm-1): 3063, 3030, 2950, 2912, 2853, 1721, 1604, 1496, 1453, 1361, 








General Procedure for the Synthesis of (2R,3R,4R,5S)-2-(Hydroxymethyl)-1-
alkylpiperidine-3,4,5-triol (3).  Method A: The above tetrabenzyl derivatives 
were dissolved in MeOH (25 mL/mmol).  To the solution was added palladium 
chloride (0.68 equiv).  The reaction was shaken under hydrogen at 1 atmosphere 
until uptake of hydrogen ceased.  The reaction was then carefully filtered through 
a pressed pad of Celite and evaporated under vacuo.  The resultant residue was 
subsequently dissolved in a minimum amount of 30% aqueous MeOH and 
loaded onto a Dowex 50W × 8 (200 mesh) ion exchange column.  The column 
was first eluted with a large amount of H2O, followed by elution with 1M 
ammonium hydroxide.  The fractions containing the product were combined, and 
the H2O was evaporated.  The resultant residue was purified by flash column 
chromatography on silica gel, using 10% MeOH/ CH2Cl2 + 1% NH4OH (v/v) as 
the eluent.   
 Method B128: A mixture of the above tetrabenzyl derivatives, ammonium 




g per mmol of O-benzyl group) was refluxed in MeOH in a sealed reaction 
vessel.  The reaction was monitored by thin layer chromatography, and the 
catalyst was carefully filtered off by passing the reaction mixture through a Celite 
pad upon completion of the cleavage of the benzyl ether.  The solvent was 
subsequently removed under vacuum.  The neutral residue was purified by flash 
column chromatography on silica gel, using 10% MeOH/ CH2Cl2 + 1% NH4OH 








Method B:  After chromatographic purification, a colorless oil was obtained 
(73%).  1H NMR (MeOD, 400 MHz, ppm): δ 3.91 (d, J = 2.5 Hz, 2H), 3.52 (m, 
1H), 3.47 (m, 1H), 3.40 (t, J = 9.3 Hz, 1H), 3.15 (t, J = 9.0 Hz, 1H), 3.03 (dd, J = 
4.8, 11.1 Hz, 1H), 2.34 (dd, J = 9.6 Hz, 1H), 2.11 (t, J = 10.9 Hz, 1H), 1.19 (d, J = 
6.7 Hz, 3H), 0.98 (d, J = 6.5 Hz, 3H); 13C NMR (MeOD, 400 MHz, ppm): δ 80.7, 
79.3, 72.0, 71.0, 66.2, 58.5, 21.4, 13.1; ESI-HRMS: calc’d m/e for [M+H+] 











3,4,5-triol (3-2). Method A.  After chromatographic purification, a colorless oil 
was obtained (75%).  1H NMR (MeOD, 400 MHz, ppm): δ 3.95 (m, 1H), 3.82 (d, J 
= 2.5 Hz, 1H), 3.51 (m, 2H), 3.31 (m, 1H), 3.11 (m, 1H), 2.88 (m, 1H), 2.40 (m, 
1H), 2.18 (m, 1H), 1.83 (m, 2H), 1.76 (m, 6H), 1.06 (m, 7H), 0.86 (t, J = 10.2 Hz, 
3H); 13C NMR (MeOD, 400 MHz, ppm): δ 79.4, 70.5, 69.8, 63.7, 57.2, 56.3, 49.7, 
37.7, 36.7, 33.1, 32.3, 29.4, 23.0, 14.0; ESI-HRMS: calc’d m/e for [M+H+] 








3,4,5-triol (3-3). Method A:  After chromatographic purification, a colorless oil 
was obtained (60%).  1H NMR (MeOD, 400 MHz, ppm): δ 3.96 (d, J = 8.8 Hz, 
1H), 3.80 (d, J = 8.6 Hz, 1H), 3.65 (m, 2H), 3.33 (m, 1H), 3.12 (m, 1H), 2.89 (m, 




= 7.9 Hz, 1H), 1.25 (m, 8H), 1.16 (m, 4H), 1.01 (d, J = 9.6 Hz, 1H), 0.89 (t, J = 
10.4 Hz, 3H); 13C NMR (MeOD, 400 MHz, ppm): δ 79.1, 70.4, 69.6, 63.7, 57.7, 
57.0, 49.6, 37.7, 37.0, 33.0, 31.9, 31.0, 29.7, 27.2, 22.7, 14.1; ESI-HRMS: calc’d 








(2R,3R,4R,5S)-2-(Hydroxymethyl)-1-phenylpiperidine-3,4,5-triol (3-4). Method 
A:  After chromatographic purification, a colorless oil was obtained (78%).  1H 
NMR (MeOD, 400 MHz, ppm): δ 7.32 (d, J = 6.7 Hz, 2H), 7.22 (d, J = 6.7 Hz, 
2H), 7.09 (m, 1H), 3.75 (m, 1H), 3.72 (d, J = 4.5 Hz, 2H), 3.53 (d, J = 8.9 Hz, 1H), 
3.45 (t, J = 8.4 Hz, 1H), 3.25 (d, J = 11.2 Hz, 1H), 3.02 (m, 1H), 2.91 (t, J = 11.6 
Hz, 1H); 13C NMR (MeOD, 400 MHz, ppm): δ 151.8, 130.2, 125.1, 124.4, 78.8, 
72.6, 71.4, 66.4, 62.8, 60.4, 59.1; ESI-HRMS: calc’d m/e for [M+H+] C12H18NO4: 











5). Method A:  After chromatographic purification, a colorless oil was obtained 
(37%).  1H NMR (MeOD, 400 MHz, ppm): δ 7.05 (m, 4H), 3.85 (m, 2H), 3.71 (d, J 
= 11.0 Hz, 1H), 3.58 (t, J = 9.1 Hz, 1H), 3.44 (d, J = 10.5 Hz, 1H), 3.21 (d, J = 7.1 
Hz, 1H), 2.85 (d, J = 8.0 Hz, 1H), 2.78 (t, J = 9.5 Hz, 1H), 2.52 (t, J = 7.8 Hz, 1H), 
1.55 (m, 2H), 1.29 (m, 6H), 1.21 (t, J = 7.0 Hz, 1H), 0.88 (t, J = 6.6 Hz, 3H); 13C 
NMR (MeOD, 400 MHz, ppm): δ 147.1, 140.3, 129.3, 124.7, 78.7, 71.2, 69.9, 
65.9, 65.1, 60.1, 59.5, 35.5, 31.7, 31.4, 29.1, 22.6, 15.3, 14.1; ESI-HRMS: calc’d 









(3-6). Method A:  After chromatographic purification, a yellow oil was obtained 
(15%).  1H NMR (MeOD, 400 MHz, ppm): δ 7.60 - 7.09 (m, 9H), 3.79 (m, 1H), 
3.74 (m, 1H), 3.66 (m, 1H), 3.49 (t, J = 6.2 Hz, 1H), 3.18 (m, 1H), 3.04 (dd, J = 
2.8, 9.5 Hz, 1H), 1.83 (t, J = 7.0 Hz, 1H), 1.42 (d, J = 12.2 Hz, 1H); 13C NMR 
(MeOD, 400 MHz, ppm): δ 128.4, 127.2, 126.4, 126.2, 122.2, 76.7, 71.1, 70.1, 













Method B:  After chromatographic purification, a colorless oil was obtained 
(45%).  1H NMR (MeOD, 400 MHz, ppm): δ 4.11 (dd, J = 2.4, 11.2 Hz, 1H), 3.78 
(dd, J = 5.6, 13.6 Hz, 2H), 3.69 (m, 2H), 3.42 (m, 1H), 3.37 (m, 1H), 3.21 (m, 1H), 
3.15 (d, J = 8.6 Hz, 1H), 3.11 (t, J = 8.5 Hz, 1H), 2.91 (m, 2H), 2.70 (m, 2H), 2.60 
(m, 1H), 2.32 (t, J = 10.2 Hz, 1H); 13C NMR (MeOD, 400 MHz, ppm): δ 80.3, 
79.6, 72.1, 70.7, 68.9, 68.2, 65.6, 63.8; ESI-HRMS: calc’d m/e for [M+Na+] 




tert-Butyl (trans-4-Hydroxycyclohexyl)carbamate (4).38 The HCl salt of the 
starting primary amine (2.5 g, 16.6 mmol) was dissolved in H2O and dioxane (64 
mL, 1:3, v/v).  1N NaOH (17 mL, 17.0 mmol) was then added to the solution to 
neutralize the HCl salt.  After the addition was completed, the reaction was 




stirred in the open air for 2 h.  The reaction was quenched with 1N potassium 
bisulfate solution (20 mL) and then extracted with chloroform (100 mL × 2).  The 
organic layers were combined, dried over magnesium sulfate and subjected to 
rotary evaporation.  To the resultant crude white solid was added with a mixture 
of chloroform and hexanes (80 mL, 1:2, v/v).  The suspension was heated until 
fully dissolved, and was then stored in a 4 °C fridge.  The pure compound 
precipitated out overnight as a colorless feather-like solid (55%, mp: 169 - 170 
°C).  The observed spectroscopic data were in agreement with the data in the 
literature.  1H NMR (CDCl3, 400 MHz, ppm): δ 4.38 - 4.36 (br s, 1H), 3.64 (m, 
1H), 3.45 - 3.43 (br s, 1H), 2.01 (d, J = 15.6 Hz, 4H), 1.47 (s, 9H), 1.39 (m, 3H), 
1.19 (m, 2H); 13C NMR (CDCl3, 400 MHz, ppm): δ 155.3, 79.3, 69.8, 49.0, 34.0, 
31.1, 28.4; IR (neat, NaCl, cm-1): 3338, 2938, 2892, 1683, 1529, 1453, 1365, 




tert-Butyl (cis-4-Iodocyclohexyl)carbamate (5). Intermediate 5 was prepared 
according to a literature procedure129 using the above material tert-butyl (trans-4-
hydroxycyclohexyl)carbamate (4) as the starting material.  Triphenylphosphine 
(548.3 mg, 2.1 mmol) and imidazole (359.3 mg, 5.3 mmol) were successively 
dissolved in toluene (15 mL).  The resultant mixture was cooled to 0 °C, and 




then warmed to room temperature and stirred for 10 min.  A solution of 4 (223 
mg, 1.04 mmol) in toluene (5 mL) was cannuled into the reaction; the reaction 
was then heated to 60 °C and stirred for 1 h.  After cooling, the reaction was 
quenched with H2O (25 mL), and the aqueous layer was extracted with EtOAc 
(25 mL × 2).  The organic layers were combined, washed with 10% sodium 
thiosulfate, dried over magnesium sulfate and concentrated in vacuo.  The crude 
compound was purified by flash column chromatography on silica gel, using 10% 
EtOAc:hexanes (v/v) as the eluent to give a white solid (77%, mp: 95 - 96 °C).  
1H NMR (CDCl3, 400 MHz, ppm): δ 4.66 (s, 1H), 4.57 (s, 1H), 3.55 (s, 1H), 2.08 
(m, 2H), 1.82 (m, 2H), 1.66 (m, 4H), 1.44 (s, 9H); 13C NMR (CDCl3, 400 MHz, 
ppm): δ 155.2, 79.3, 48.1, 35.4, 30.1, 28.6; IR (neat, NaCl, cm-1): 3331, 2975, 
2938, 1697, 1522, 1455, 1440, 1390, 1365, 1348, 1320, 1249, 1227, 1166, 1066, 




General Procedure for the Synthesis of tert-Butyl (trans-4-
Alkylcyclohexyl)carbamates 6.  In a flame-dried flask was placed copper 
cyanide (CuCN).  The vessel was flushed with argon and then evacuated under 
high vacuum. The process was repeated three times, and the dry CuCN was 
kept under argon.  Dry THF (1 mL/mmol CuCN) was added via syringe and the 




suspension was added the organ lithium reagents (2 equiv relative to CuCN) 
dropwise.  The heterogeneous mixture was allowed to warm gradually to 0 °C 
until a clear solution was formed.  Next, the solution was re-cooled to -78 °C.  A 
solution of the iodo species 5 in THF was then added to the solution.  The 
reaction was stirred at -78 °C until all the starting material was consumed.  The 
reaction was then quenched with a solution of 10% concentrated NH4OH in 
saturated NH4Cl, and was allowed to stir at room temperature for 30 min.  The 
aqueous phase was then extracted with EtOAc (15 mL × 2).  The organic layers 
were combined, dried over MgSO4 and concentrated in vacuo.  The crude 
product was purified by flash column chromatography on silica gel, using 10% 




tert-Butyl (trans-4-Butylcyclohexyl)carbamate (6-1).  After chromatographic 
purification, a white solid was obtained (82%, mp: 98 - 99 °C).  1H NMR (CDCl3, 
400 MHz, ppm): δ 4.43 (s, 1H), 3.34 (s, 1H), 1.97 (d, J = 12.1 Hz, 2H), 1.76 (d, J 
= 12.1 Hz, 2H), 1.44 (s, 9H), 1.26 - 0.93 (m, 11H), 0.83 (t, J = 6.5 Hz, 3H); 13C 
NMR (CDCl3, 400 MHz, ppm): δ 154.2, 77.9, 49.0, 38.2, 36.0, 34.7, 32.6, 29.9, 
28.7, 21.7, 14.7; ESI-HRMS: calc’d m/e for [M+Na+] C15H29NNaO2: 278.2096, 
found 278.2070; IR (neat, NaCl, cm-1): 3364, 2971, 2930, 2848, 1682, 1526, 






tert-Butyl (trans-4-Hexylcyclohexyl)carbamate (6-2).  After chromatographic 
purification, a white solid was obtained (78%, mp: 77 - 78 °C).  1H NMR (CDCl3, 
400 MHz, ppm): δ 4.44 (s, 1H), 3.35 (s, 1H), 1.96 (d, J = 12.2 Hz, 2H), 1.74 (d, J 
= 12.2 Hz, 2H), 1.43 (s, 9H), 1.24 (m, 8H), 1.15 - 0.92 (m, 7H), 0.86 (t, J = 6.5 
Hz, 3H); 13C NMR (CDCl3, 400 MHz, ppm): δ 154.0, 77.7, 50.0, 48.8, 38.1, 35.7, 
32.4, 30.6, 28.8, 27.2, 26.0, 21.7, 14.7; ESI-HRMS: calc’d m/e for [M+Na+] 
C17H33NNaO2: 306.2409, found 306.2417; IR (neat, NaCl, cm-1): 3371, 2926, 
2850, 1683, 1522, 1451, 1389, 1366, 1321, 1270, 1247, 1239, 1178, 1092, 1044, 




General Procedure for the Synthesis of trans-4-Alkylcyclohexanamine 
Hydrochlorides 7.  The above carbamates were placed in a flame-dried flask 
and cooled to 0 °C.  To the solid material, 4M HCl in dioxane (5 equiv relative to 
6) was added.  The reaction was slowly stirred at 0 °C until all the start material 
was consumed.  The solvent was then removed under high vacuum, and the 











Methyl 6-O-tert-Butyldimethylsilyl-α-D-pyranoside (8). Methyl-alpha-D-
glucopyranoside (5.1 g, 26.3 mmol) was dissolved in anhydrous DMF (60 mL) 
and cooled to 0 °C.  Imidazole (4.4 g, 64.6 mmol) and tert-butyldimethylsilyl 
chloride (4.7 g, 31.2 mmol) were added to the solution in sequence.  The mixture 
was allowed to stir at room temperature overnight.  Upon the consumption of 
starting material, the solvent was removed under high vacuum and the residue 
was dissolved in EtOAc (400 mL).  The solution was washed with water (2 × 200 
mL) and brine (2 × 200 mL), dried over MgSO4 and concentrated in vacuo. The 
residue was purified by flash column chromatography on silica gel, using 100% 
EtOAc as the eluent.  After chromatographic purification, an amorphous solid 
was obtained (90%).  1H NMR (CDCl3, 400 MHz, ppm): δ 4.75 (d, J = 3.9 Hz, 
1H), 3.89 (dd, J = 4.9, 10.6 Hz, 1H), 3.82 (dd, J = 5.2, 10.6 Hz, 1H), 3.74 (t, J = 
9.1 Hz, 1H), 3.61 (dd, J = 5.0, 9.7 Hz, 1H), 3.53 (t, J = 9.0 Hz, 1H), 3.51 (m, 1H), 
3.42 (s, 3H), 3.14 (s, 1H), 2.82 (s, 1H), 2.19 (d, J = 7.6 Hz, 1H), 0.91 (s, 9H), 0.10 
(s, 6H); 13C NMR (CDCl3, 400 MHz, ppm): δ 99.1, 74.8, 72.5, 72.2, 70.3, 64.3, 
55.3, 25.9, 18.3, -5.5; ESI-HRMS: calc’d m/e for [M+Na+] C13H28NaO6Si: 
309.1733, found 309.2209; IR (neat, NaCl, cm-1): 3474, 2954, 2929, 2858, 1655, 
1472, 1464, 1361, 1253, 1194, 1152, 1112, 1045, 1002, 903, 854, 837, 777, 749; 












Methyl 6-O-tert-butyldimethylsilyl-α-D-pyranoside (8) (7.0 g, 22.7 mmol) was 
dissolved in anhydrous DMF (100 mL) and cooled to 0 °C.  Sodium hydride (3.3 
g, 82.5 mmol) was added to the solution.  After the evolution of H2 ceased, 
benzyl bromide (12.2 mL, 102.6 mmol) was added to the reaction.  The mixture 
was stirred under an atmosphere of nitrogen overnight.  Upon the consumption of 
the starting material, the reaction was quenched with MeOH (10 mL), then 
poured into water (500 mL) and extracted with EtOAc (5 × 100 mL).  The 
combined organic layers were washed with water (2 × 200 mL) and brine (2 × 
200 mL), dried over MgSO4, and concentrated in vacuo.  The residue was 
purified by flash column chromatography on silica gel, using 10% EtOAc:hexanes 
(v/v) as the eluent.  After chromatographic purification, a colorless oil was 
obtained (85%).  1H NMR (CDCl3, 400 MHz, ppm): δ 7.32 - 7.21 (m, 15H), 4.93 
(d, J = 10.8 Hz, 1H), 4.84 (d, J = 10.9 Hz, 1H), 4.78 (d, J = 10.9 Hz, 1H), 4.76 (d, 
J = 12.1 Hz, 1H), 4.64 (d, J = 12.1 Hz, 1H), 4.60 (d, J = 11.0 Hz, 1H), 4.57 (d, J = 
3.6 Hz, 1H), 3.96 (t, J = 9.3 Hz, 1H), 3.75 (d, J = 3.2 Hz, 1H), 3.58 (dt, J = 3.7, 
10.0 Hz, 1H), 3.50 (d, J = 9.1 Hz, 1H), 3.48 (d, J = 3.6 Hz, 1H), 3.46 (d, J = 3.6 
Hz, 1H), 3.33 (s, 3H), 0.85 (s, 9H), 0.00 (d, J = 2.0 Hz, 6H); 13C NMR (CDCl3, 
400 MHz, ppm): δ 138.82, 138.53, 138.29, 128.51, 128.42, 128.40, 128.29, 
128.10, 128.06, 127.83, 127.67, 127.61, 126.12, 97.90, 82.18, 80.27, 77.78, 




m/e for [M+Na+] C34H46NaO6Si: 601.2961, found 601.2932;  IR (neat, NaCl, cm-
1): 3065, 3031, 2928, 2856, 1606, 1497, 1455, 1361, 1252, 1201, 1193, 1160, 









tert-butyldimethylsilyl-α-D-pyranoside (9) (11.5 g, 19.9 mmol) was dissolved in 
acetonitrile (120 mL).  H2O (25 mL) was added, and the pH of the solution 
adjusted to pH = 3 by the addition of p-toluenesulphonic acid.  The reaction 
mixture was stirred at room temperature overnight.  Upon the consumption of the 
starting material, EtOAc (300 mL) was added to the reaction mixture.  The 
mixture was washed with saturated aqueous sodium bicarbonate (2 × 150 mL) 
and brine (150 mL).  The organic layers were combined, dried over MgSO4 and 
concentrated in vacuo. The residue was purified by flash column chromatography 
on silica gel, using 30% EtOAc:hexanes (v/v) as the eluent. After 
chromatographic purification, a colorless oil was obtained (65%).  1H NMR 
(CDCl3, 400 MHz, ppm): δ 7.37 - 7.28 (m, 15H), 4.99 (d, J = 10.9 Hz, 1H), 4.88 
(d, J = 11.1 Hz, 1H), 4.84 (d, J = 10.9 Hz, 1H), 4.80 (d, J = 12.1 Hz, 1H), 4.65 (t, 
J = 12.2 Hz, 2H), 4.57 (d, J = 3.6 Hz, 1H), 4.00 (t, J = 9.3 Hz, 1H), 3.77 (m, 1H), 
3.69 (m, 1H), 3.65 (m, 1H), 3.53 (d, J = 9.2 Hz, 1H), 3.50 (dd, J = 3.6, 6.1 Hz, 
1H), 3.37 (s, 3H), 1.60 (dd, J = 5.3, 7.4 Hz, 1H); 13C NMR (CDCl3, 400 MHz, 




127.63, 98.21, 82.98, 80.02, 77.44, 75.76, 75.05, 73.45, 70.67, 61.93, 55.20; 
ESI-HRMS: calc’d m/e for [M+Na+] C28H32NaO6: 487.2097, found 487.2104; IR 
(neat, NaCl, cm-1): 3486, 3063, 3034, 2921, 1732, 1606, 1497, 1454, 1360, 1260, 









methoxytetrahydro-2H-pyran (11).  Triphenylphosphine (5.1 g, 19.4 mmol) and 
imidazole (1.8 g, 26.4 mmol) were successively dissolved in THF (150 mL).  The 
resultant mixture was cooled to 0 °C, and iodine (4.9 g, 19.3 mmol) was added in 
portions over 30 min.  A solution of 10 (6.0 g, 12.9 mmol) in THF (50 mL) was 
cannuled into the reaction flask.  The reaction was then heated to 66 °C and 
stirred at that temperature for 1 h.  The reaction was then cooled to room 
temperature and quenched with H2O (25 mL); the aqueous layer was extracted 
with EtOAc (250 mL × 2).  The organic layers were combined, washed with 10% 
sodium thiosulfate, dried over MgSO4 and concentrated in vacuo. The crude 
material was purified by flash column chromatography on silica gel, using 10% 
EtOAc:hexanes (v/v) as the eluent.  After chromatographic purification, a light 
yellow oil was obtained (97%).  1H NMR (CDCl3, 400 MHz, ppm): δ 7.37 - 7.27 
(m, 15H), 4.99 (d, J = 10.8 Hz, 1H), 4.94 (d, J = 11.0 Hz, 1H), 4.81 (d, J = 2.0 Hz, 
1H), 4.79 (d, J = 3.3 Hz, 1H), 4.67 (t, J = 11.0 Hz, 2H), 4.61 (d, J = 3.6 Hz, 1H), 




(t, J = 9.0 Hz, 1H), 3.29 (dd, J = 6.7, 11.0 Hz, 1H); 13C NMR (CDCl3, 400 MHz, 
ppm): δ 138.56, 138.05, 138.02, 128.53, 128.51, 128.45, 128.10, 128.01, 127.95, 
127.71, 98.13, 81.58, 81.51, 80.10, 75.80, 75.37, 73.46, 69.31, 55.52, 7.65; ESI-
HRMS: calc’d m/e for [M+Na+] C28H31INaO5: 597.1114, found 597.1162; IR (neat, 
NaCl, cm-1): 3062, 3030, 2909,  1496, 1454, 1359, 1260, 1196, 1120, 1102, 





(2R,3S,4R)-2,3,4-Tris(benzyloxy)hex-5-enal (12).  Compound 11 (4.6 g, 8.0 
mmol) was dissolved in a mixture of THF/H2O (9:1, 200 mL) and then activated 
zinc (5.2 g, 79.5 mmol) was added.  The flask was placed in an ultrasonic 
cleaner (Fisher, FS20H) and sonicated overnight.  The reaction progress was 
monitored by mass-spectroscopy due to the fact that the Rf value of the product 
is identical to that of the starting material on TLC.  Upon the consumption of the 
starting material, the reaction was diluted with EtOAc (50 mL), and the aqueous 
layer was extracted with EtOAc (50 mL × 2).  The organic layers were combined, 
washed with sodium bicarbonate (20 mL), brine (20 mL) and dried over MgSO4.  
The solvent was removed in vacuo and the residue was purified by flash column 
chromatography on silica gel, using 10% EtOAc:hexanes (v/v) as the eluent.  
After chromatographic purification, a colorless oil was obtained (94%).  1H NMR 
(CDCl3, 400 MHz, ppm): δ 9.63, 9.57 (rotamer, 1H), 7.29 - 7.21 (m, 15H), 5.76  




= 2.2, 10.0 Hz, 1H), 4.60 (t, J = 13.1 Hz, 1H), 4.54 (m, 1H), 4.50 (m, 1H), 4.44 
(dd, J = 8.0, 19.8 Hz, 1H), 4.30 (dd, J = 3.3, 11.9 Hz, 1H), 4.04 (m, 1H), 3.91 (t, J 
= 6.8 Hz, 1H), 3.78 (m, 1H); 13C NMR (CDCl3, 400 MHz, ppm): δ 201.24 (201.60, 
201.98), 140.93, 138.35, 138.23, 138.09, 138.06, 137.84, 137.70, 137.22, 
134.80, 134.40, 128.56, 128.50, 128.45, 128.40, 128.38, 128.34, 128.30, 128.25, 
128.17, 128.12, 128.02, 127.98, 127.93, 127.91, 127.79, 127.68, 127.64, 127.60, 
126.98, 119.44, 82.40, 80.26, 79.95, 75.94, 74.50, 73.19, 70.85; ESI-HRMS: 
calc’d m/e for [M+Na+] C27H28NaO4: 439.1885, found 439.1954; IR (neat, NaCl, 
cm-1): 3064, 3031, 2866, 1727, 1497, 1454, 1393, 1352, 1208, 1071, 1027, 932, 






(2S,3S,4R)-2,3,4-Tris(benzyloxy)hex-5-enal Oxime (13).  Aldehyde 12 (3.8 g, 
9.1 mmol) was dissolved in MeOH (40 mL).  To the stirring solution, 
hydroxylamine hydrochloride (2.5 g, 36.0 mmol) was added.  The suspension 
was neutralized with sodium bicarbonate (4.3 g, 40.6 mmol).  The solution was 
then stirred under refluxing conditions for 6 h.  Upon the consumption of the 
starting material, the solvent was removed in vacuo.  The residue was dissolved 
in EtOAc, washed with 10% HCl solution, saturated sodium bicarbonate and 
brine in sequence and dried over MgSO4.  The solvent was removed to yield an 




using 25% EtOAc:hexanes (v/v) as the eluent.  After chromatographic 
purification, a mixture of inseparable E/Z isomers as a light green oil was 
obtained (85%).  1H NMR (CDCl3, 400 MHz, ppm, major): δ 7.46 (d, J = 7.8 Hz, 
1H), 7.31 (m, 15H), 5.76 (m, 1H), 5.24 (m, 1H), 5.20 (d, J = 5.2 Hz, 1H), 4.84 (m, 
1H), 4.80 (d, J = 11.5 Hz, 1H), 4.70 (d, J = 11.4 Hz, 1H), 4.60 (d, J = 3.7 Hz, 1H), 
4.57 (d, J = 3.7 Hz, 1H), 4.38 (d, J = 9.2 Hz, 1H), 4.35 (d, J = 9.3 Hz, 1H), 4.15 
(m, 1H), 3.58 (t, J = 4.7 Hz, 1H); 13C NMR (CDCl3, 400 MHz, ppm): δ 150.5, 
140.4, 138.6, 137.6, 135.1, 128.45, 128.43, 128.27, 128.32, 128.25, 127.96, 
127.74, 127.67, 127.47, 121.3, 120.9, 82.5, 81.1, 76.4, 75.1, 71.2, 70.8; ESI-
HRMS: calc’d m/e for [M+Na+] C27H29NNaO4: 454.1994, found 454.2014; IR 
(neat, NaCl, cm-1): 3331, 3088, 3064, 3031, 2870, 1642, 1606, 1497, 1454, 1422, 








(14).  A stirring solution of oxime 13 (970.5 mg, 2.2 mmol) in dry toluene (35 mL) 
was heated at reflux for 15 h under nitrogen.  Upon the consumption of the 
starting material, the reaction was cooled; and the solvent was removed in 
vacuo.  The crude product was purified by flash column chromatography on silica 
gel, using 40% EtOAc/hexanes as the eluent.  After chromatographic purification, 
a yellow oil was obtained (70%).  1H NMR (CDCl3, 400 MHz, ppm): δ 7.38 - 7.28 




Hz, 1H), 4.69 (d, J = 6.2 Hz, 1H), 4.58 (d, J = 11.8 Hz, 1H), 3.94 (t, J = 8.4 Hz, 
1H), 3.87 (t, J = 5.8 Hz, 1H), 3.85 (m, 1H), 3.83 (t, J = 6.6 Hz, 1H), 3.68 (t, J = 7.4 
Hz, 1H), 3.46 (t, J = 6.9 Hz, 1H), 2.91 (dd, J = 5.5, 7.0 Hz, 1H); 13C NMR (CDCl3, 
400 MHz, ppm): δ 138.52, 138.25, 138.04, 128.50, 128.36, 128.33, 127.86, 
127.76, 127.75, 127.69, 127.60, 127.53, 86.0, 85.6, 84.7, 76.0, 72.7, 72.4, 72.3, 
66.3, 49.6; ESI-HRMS: calc’d m/e for [M+Na+] C27H29NNaO4: 454.1994, found 
454.1996;  IR (neat, NaCl, cm-1): 3435, 3031, 2922, 2863, 1742, 1724, 1497, 









To a stirring solution of 14 (675.0 mg, 1.6 mmol) in 85% acetic acid in H2O (25 
mL), active zinc dust (510.0 mg, 8.0 mmol) was added.  The reaction was then 
stirred at 55 °C for 2 h.  Upon the consumption of the starting material, the 
mixture was cooled to room temperature and the zinc dust was filtered off.  The 
filtrate was diluted with H2O (25 mL) and basified with 1M NaOH.  The resultant 
solution was extracted with CH2Cl2 (3 x 25 mL); the organic layers were 
combined, dried over MgSO4 and concentrated in vacuo.  The crude product was 
purified by flash column chromatography on silica gel, using 10% MeOH/CH2Cl2 
+ 1% NH4OH as the eluent.  After chromatographic purification, a colorless oil 




5.56 - 5.23 (br s, 3H), 4.68 (d, J = 12.0 Hz, 1H), 4.64 (d, J = 11.1 Hz, 1H), 4.54 
(m, 2H), 4.53 (d, J = 11.6 Hz, 1H), 4.48 (d, J = 11.6 Hz, 1H), 4.02 (t, J = 5.7 Hz, 
1H), 3.92 (t, J = 4.4 Hz, 1H), 3.87 (t, J = 5.0 Hz, 1H), 3.82 (m, 1H), 3.69 (t, J = 6.7 
Hz, 1H), 2.46 (m, 1H), 2.02 (m, 1H); 13C NMR (CDCl3, 400 MHz, ppm): δ 137.88, 
127.84, 137.63, 128.44, 127.93, 127.85, 127.81, 87.3, 85.3, 82.7, 72.4, 72.1, 
71.9, 60.7, 55.5, 45.0; ESI-HRMS: calc’d m/e for [M+H+] C27H32NO4: 434.2326, 
found 434.2295;  IR (neat, NaCl, cm-1): 3308, 3063, 3030, 2927, 2871, 1496, 
1454, 1363, 1207, 1091, 1071, 1028, 735, 697. 
To prepare the HCl salt of the hydroxycyclopentamine, pure 15 was 
dissolved in ether and 2M HCl in ether was added at 0 °C.  A white solid 
precipitated out instantly, and the solvent was removed in vacuo to afford the HCl 








General Procedure for the Synthesis of ((1R,2R,3S,4S,5R)-2,3,4-
Tris(benzyloxy)-5-(alkylamino)cyclopentyl)methanols 16.  To a suspension of 
the HCl salt of the above amine 15, an equal molar amount of triethylamine was 
added, followed by the addition with the corresponding aldehyde (0.95 equiv).  
After 10 min, sodium triacetoxyborohydride (2.0 equiv) was added to the mixture, 
and the reaction was stirred at room temperature for 2 h.  Upon the consumption 




bicarbonate solution and extracted with CH2Cl2 (2 x 20 mL).  The organic layers 
were combined, dried over MgSO4, and concentrated in vacuo.  The crude 
product was purified by flash column chromatography on silica gel, using 5% 









(butylamino)cyclopentyl)methanol (16-1).  After chromatographic purification, 
a colorless oil was obtained (73%).  1H NMR (CDCl3, 400 MHz, ppm): δ 7.38 - 
7.29 (m, 15 H), 7.02 - 6.30 (br s, 2H), 4.66 (d, J = 11.5 Hz, 1H), 4.60 (d, J = 7.9 
Hz, 1H), 4.58 (d, J = 4.5 Hz, 1H), 4.55 (d, J = 8.0 Hz, 1H), 4.48 (d, J = 8.0 Hz, 
1H), 4.45 (d, J = 8.0 Hz, 1H), 4.27 (t, J = 6.8 Hz, 1H), 3.93 (m, 1H), 3.89 (m, 1H), 
3.73 (t, J = 3.0 Hz, 1H), 3.53 (t, J = 7.8 Hz, 1H), 2.93 (m, 2H), 2.68 (m, 1H), 2.02 
(s, 2H), 1.62 (m, 2H), 1.28 (m, 2H), 0.87 (t, J = 7.3 Hz, 3H); 13C NMR (CDCl3, 
400 MHz, ppm): δ 137.70, 137.53, 137.45, 128.52, 128.48, 128.45, 127.96, 
127.90, 127.86, 87.58, 84.3, 82.2, 72.4, 72.0, 71.6, 62.4, 61.0, 48.3, 44.0, 29.3, 
19.9, 13.6; ESI-HRMS: calc’d m/e for [M+H+] C31H40NO4: 490.2957, found 
490.2950; IR (neat, NaCl, cm-1): 3308, 3063, 3030, 2927, 2871, 1496, 1454, 












(nonylamino)cyclopentyl)methanol (16-2).  After chromatographic purification, 
a colorless oil was obtained (70%).  1H NMR (CDCl3, 400 MHz, ppm): δ 7.35 - 
7.28 (m, 15 H), 4.70 (d, J = 11.8 Hz, 1H), 4.61 (d, J = 8.9 Hz, 1H), 4.58 (d, J = 
6.3 Hz, 1H), 4.56 (d, J = 9.3 Hz, 1H), 4.53 (d, J = 11.6 Hz, 2H), 3.96 (t, J = 4.5 
Hz, 1H), 3.82 (m, 4H), 3.26 (t, J = 7.3 Hz, 1H), 2.61 (t, J = 7.3 Hz, 2H), 2.39 (m, 
1H), 1.41 (m, 2H), 1.24 (m, 13H), 0.88 (t, J = 6.7 Hz, 3H); 13C NMR (CDCl3, 400 
MHz, ppm): δ 138.20, 138.07, 137.94, 128.49, 128.43, 127.84, 127.81, 127.76, 
88.4, 85.0, 83.2, 72.06, 72.00, 71.8, 63.3, 62.6, 49.3, 44.4, 31.9, 29.8, 29.51, 
29.46, 29.3, 27.1, 22.7, 14.1; ESI-HRMS: calc’d m/e for [M+H+] C36H50NO4: 
560.3734, found 560.3728; IR (neat, NaCl, cm-1): 3308, 3063, 3030, 2925, 2854, 









(17).  Method A: a mixture of the above tri-benzyl derivative, ammonium formate 
(10 equiv) and 10% palladium on carbon (0.3 g per mmol of O-benzyl group) was 




thin layer chromatography.  Upon consumption of the starting material, the 
catalyst was carefully filtered off by passing the reaction mixture through a Celite 
pad.  The solvent was subsequently removed under vacuum.  The neutral 
residue was purified by flash column chromatography on silica gel, using 10% 
MeOH/ CH2Cl2 + 1% NH4OH (v/v) as the eluent.  Method B: To a flask, fitted with 
a dry ice condenser, was charged with anhydrous liquid ammonia, then lithium 
metal was added until the blue color persisted.  A sample of the tri-benzyl 
derivative in 1,4-dioxane was added dropwise into the flask over 5 min.  After an 
additional 10 min, ammonium chloride was added to the solution until the blue 
color disappeared.  The dry ice condenser was then removed and the ammonia 
was allowed to evaporate.  The residue was extracted with EtOAc (2 x 20 mL).  
The organic layers were combined, dried over MgSO4, and concentrated in 
vacuo.  The crude product was purified by flash column chromatography on silica 









(17-1). Method A:  After chromatographic purification, a colorless viscous oil was 
obtained (42%).  1H NMR (MeOD, 400 MHz, ppm): δ 3.89 (t, J = 8.1 Hz, 1H), 
3.87 (t, J = 3.8 Hz, 1H), 3.77 (dd, J = 6.2, 11.4 Hz, 1H), 3.71 (t, J = 7.6 Hz, 1H), 




(m, 1H), 1.67 (m, 2H), 1.39 (m, 2H), 0.96 (t, J = 7.3 Hz, 3H); 13C NMR (MeOD, 
400 MHz, ppm): δ 82.2, 77.8, 75.0, 62.8, 59.6, 48.5, 45.6, 29.3, 20.9, 13.9; ESI-
HRMS: calc’d m/e for [M+H+] C10H22NO4: 220.1543, found 220.1546; [α]D25  6.4 (c 









(17-2). Method B:  After chromatographic purification, a colorless viscous oil was 
obtained (52%).  1H NMR (MeOD, 400 MHz, ppm): δ 3.96 (t, J = 8.0 Hz, 1H), 
3.93 (dd, J = 3.9, 11.8 Hz, 1H), 3.85 (dd, J = 6.3, 11.5 Hz, 1H), 3.77 (t, J = 7.6 
Hz, 1H), 3.65 (t, J = 7.7 Hz, 1H), 3.56 (t, J = 9.2 Hz, 1H), 3.26 (m, 1H), 3.07 (m, 
1H), 2.29 (m, 1H), 1.75 (m, 2H), 1.36 (m, 12H), 0.92 (t, J = 6.6 Hz, 3H); 13C NMR 
(MeOD, 400 MHz, ppm): δ 80.7, 76.3, 73.5, 61.3, 58.1, 47.2, 44.0, 31.5, 29.0, 
28.8, 28.7, 26.1, 25.7, 22.2, 12.9; ESI-HRMS: calc’d m/e for [M+H+] C15H32NO4: 





(S)-4-(Benzyloxy)-3-((tert-butoxycarbonyl)amino)butanoic Acid (18).  
Warning: Large amounts of diazomethane were used for this transformation. 




glassware used was free of cracks, scratches or ground-glass joints and a blast 
shield was used. 
 N-Boc-O-benzyl-D-serine (5.1 g, 17.2 mmol) was dissolved in 
tetrahydrofuran (50 mL) and cooled to 0 °C in an ice bath.  The solution was 
treated with triethylamine (2.5 mL, 17.2 mmol) and allowed to react for 15 min to 
fully deprotonate the carboxylic acid.  Subsequently, ethyl chloroformate (1.6 mL, 
17.2 mmol) was added slowly to the reaction at 0 °C. The resultant anhydride 
product precipitated out of solution as a thick white precipitate.  Stirring was 
continued for 15 min and then stopped.  In a separate flask, an ice-cold solution 
of diazomethane in ether was prepared (see procedure below) and, without 
stirring, was carefully transferred into the freshly prepared anhydrous reaction 
flask using a glass funnel.  The reaction solution was lightly stirred for 5 sec, then 
stirring was stopped.  The mixture was allowed to warm to room temperature and 
react overnight.  Any additional diazomethane was carefully quenched with 0.5 N 
acetic acid.   
On the following day, the reaction mixture was concentrated in vacuo, and 
the resultant residue was dissolved in chloroform.  The solution was washed with 
5% sodium bicarbonate (20 mL), 5% HCl (20 mL) and H2O (20 mL) in sequence.  
The organic layer was collected, dried over MgSO4, and concentrated in vacuo.  
The resultant crude diazo intermediate was then dissolved in water (7 mL) and 
tetrahydrofuran (80 mL); cooled to -25 °C and stirred for 30 min.  The reaction 
solution appeared thick and slurry.  Aluminum foil was used to cover the reaction 




g, 10 mol%), dissolved in triethylamine (7.5 mL, 51.6 mmol), was then added.  
The reaction temperature was allowed to slowly warm to room temperature and 
the solution was stirred overnight.  The reaction mixture was then transferred to a 
1 L flask, to which saturated sodium bicarbonate (100 mL) was added and stirred 
for 1 h.  The resultant black solution was partitioned with water and EtOAc.  The 
organic layer with the black suspension was collected and washed with brine 
once then twice with saturate sodium bicarbonate.  The organic phase was set 
aside and discarded.  All aqueous layers were combined in a large Erlenmeyer 
flask with a large stir bar and cooled to 0 °C.  The aqueous solution was then 
titrated with 5 N HCl until the pH value reached 2.  The solution was then 
extracted with EtOAc (100 mL × 3).  The organic layers were combined, dried 
over MgSO4, and concentrated in vacuo.  The resultant crude homologated 
product was purified by flash column chromatography on silica gel, using 30% 
EtOAc:hexanes (v/v) as the eluent.  
Diazomethane preparation: Warning: Glassware was free of cracks, scratches 
and ground glass joints.  
An ice-cold alkaline solution of potassium hydroxide (16.0 g, 2.9 mmol) in 
H2O (40 mL) was prepared, and cold ether (200 mL) followed by 1-methyl-3-nitro-
1-nitrosoguanidine (MNNG) (7.4 g, 50.0 mmol) was added.  The basic solution 
then turned clear and yellow and bubbled moderately as the reagent dissolved 
and volatile diazomethane was generated.  The solution was reacted for 2 min 
without stirring.  Using a glass funnel, the mixture was transferred into a 




negative pressure hood overnight.  The yellow organic layer was collected in an 
ice-cold Erlenmeyer flask, which was pre-charged with potassium hydroxide 
pellets to absorb any remaining moisture.  The diazomethane solution was used 
immediately after preparation.  The remaining aqueous layer was carefully 
quenched the following day with dilute acid.  All other glassware was allowed to 
sit in a negative pressure hood and was carefully washed with dilute acid.  After 
chromatographic purification, a hygroscopic light green oil was obtained (87%).  
1H NMR (CDCl3, 400 MHz, ppm): δ 10.38 (s, 1H), 7.36 - 7.24 (m, 5 H), 5.32 - 
5.30 (br s, 1H), 4.55 (s, 2H), 4.15 (m, 1H), 3.57 (m, 2H), 2.66 (d, J = 5.8 Hz, 2H), 
1.46 (s, 9H); 13C NMR (CDCl3, 400 MHz, ppm): δ 176.1, 156.2, 138.4, 128.7, 
128.5, 128.04, 128.00, 80.3, 73.6, 71.5, 47.9, 28.7; ESI-HRMS: calc’d m/e for 
[(M+H+] C16H24NO5: 310.1654, found 310.1651; IR (neat, NaCl, cm-1): 3325, 
2978, 2932, 1714, 1500, 1454, 1368, 1250, 1368, 1168, 1117, 1055, 1028, 906, 








carbamate (19).  Amino acid derivative 18 (812.3 mg, 2.6 mmol) was dissolved 
in anhydrous CH2Cl2 (15 mL) under a nitrogen atmosphere and cooled to -15 °C.  
To the solution, N,O-dimethylhydroxylamine•HCl (389.5 mg, 3.9 mmol) and N-
methylmorpholine (0.4 mL, 3.6 mmol) were added in sequence, followed by the 




then allowed to warm to room temperature.  Upon the consumption of the starting 
material, the reaction was cooled to 0 °C and quenched by the addition of an ice-
cold 10% HCl solution (5 mL).  The mixture was allowed to stir at 0 °C for 5 min 
and then diluted with H2O and extracted with CH2Cl2 (20 mL x 3).  The organic 
layers were combined, washed with saturated NaHCO3 (20 mL), dried over 
MgSO4, filtered and concentrated in vacuo.  The crude material was purified by 
flash column chromatography on silica gel, using 2% MeOH/CH2CH2 as the 
eluent.  After chromatographic purification, a colorless oil was obtained (91%).  
1H NMR (CDCl3, 400 MHz, ppm): δ 7.27 (m, 5H), 5.50 (d, J = 7.3 Hz, 1H), 4.47 
(s, 2H), 4.17 (s, 1H), 3.60 (s, 3H), 3.58 (m, 1H), 3.53 (m, J = 6.1 Hz, 1H), 3.10 (s, 
3H), 2.82 (d, J = 10.5 Hz, 1H), 2.64 (d, J = 10.4 Hz, 1H), 1.40 (s, 9H); 13C NMR 
(CDCl3, 400 MHz, ppm): δ 173.0, 155.8, 128.8, 128.0, 79.6, 73.5, 71.6, 61.6, 
47.5, 33.4, 32.4, 28.8; ESI-HRMS: calc’d m/e for [M+H+] C18H29N2O5: 353.2076, 
found 353.2066; IR (neat, NaCl, cm-1): 3342, 2976, 2934, 1710, 1654, 1497, 








(S)-4-(Benzyloxy)-N-methoxy-N-methyl-3-(nonylamino)butanamide (20).  To 
a flask containing the Weinreb amide derivative 19 (92.3 mg, 0.3 mmol), was 
added dropwise with 4M HCl in dioxane (2 mL) at 0 °C.  The ice bath was 




by TLC.  The solvent was removed in vacuo after all starting material was 
consumed. Dichloroethane (3 mL) was added to the resultant white solid material 
and neutralized with triethylamine (0.05 mL, 0.3 mmol).  To the stirring mixture, 
nonylaldehyde (45.0 µL, 0.2 mmol) was added and the pH value was adjusted to 
be slightly acidic with acetic acid.  The stirring continued for 30 min, and then 
sodium triacetoxyborohydride  (115.5 mg, 0.5 mmol) was added.  The stirring 
continued at room temperature.  Upon consumption of the starting material, the 
reaction was quenched with saturated sodium bicarbonate (30 mL), and 
extracted with CH2Cl2 (20 mL × 2).  The organic layers were combined, dried 
over MgSO4, and concentrated in vacuo.  The crude material was purified by 
flash column chromatography on silica gel, using 10% MeOH/CH2Cl2 + 1% 
NH4OH as the eluent.  After chromatographic purification, a light yellow oil was 
obtained (78%).  1H NMR (CDCl3, 400 MHz, ppm): δ 7.31 (m, 5H), 4.52 (s, 2H), 
3.66 (s, 3H), 3.55 (m, 2H), 3.30 (t, J = 5.6 Hz, 1H), 3.15 (s, 3H), 3.02 - 3.00 (br s, 
1H), 2.67 (m, 2H), 2.63 (t, J = 7.5 Hz, 2H), 1.49 (t, J = 6.6 Hz, 2H), 1.25 (m, 13H), 
0.87 (t, J = 7.2 Hz, 3H); 13C NMR (CDCl3, 400 MHz, ppm): δ 174.1, 138.6, 128.8, 
128.1, 105.0, 73.6, 72.1, 61.7, 54.8, 47.8, 32.3, 30.4, 30.1, 30.0, 29.9, 29.7, 27.7, 
23.1, 14.5; ESI-HRMS: calc’d m/e for [M+H+] C22H39N2O3: 379.2961, found 
379.2958; IR (neat, NaCl, cm-1): 2925, 2854, 1720, 1664, 1495, 1454, 1379, 











yl)(nonyl)carbamate (21).  The secondary amine 20 (77.8 mg, 0.2 mmol) was 
dissolved in anhydrous acetonitrile (10 mL).  To the solution, di-tert-butyl 
dicarbonate (297.3 mg, 1.2 mmol) and dimethylaminopyridine (61.4 mg, 0.5 
mmol) were added in sequence.  The mixture was stirred at room temperature 
overnight.  The reaction was then quenched by addition of saturated ammonium 
chloride (20 mL), and extracted with EtOAc (20 mL × 3).  The organic layers were 
combined, dried over MgSO4, and concentrated in vacuo.  The crude material 
was purified by flash column chromatography on silica gel, using 20% 
EtOAc/hexanes.  After chromatographic purification, a colorless oil was obtained 
(68%).  1H NMR (CDCl3, 400 MHz, ppm): δ 7.30 (m, 5H), 4.50 (s, 2H), 4.15 (m, 
1H), 3.70 (m, 2H), 3.64 (s, 3H), 3.21 (m, 2H), 3.14 (s, 3H), 3.06 (m, 1H), 2.75 (m, 
1H), 1.51 (s, 2H), 1.42 (s, 9H), 1.24 (m, 12H), 0.87 (t, J = 5.9 Hz, 3H); 13C NMR 
(CDCl3, 400 MHz, ppm): δ 172.0, 150.8, 128.2, 127.4, 82.6, 72.8, 31.9, 29.88, 
29.86, 29.7, 29.54, 29.48, 29.3, 28.4, 28.0, 27.7, 23.9, 22.7, 14.1; ESI-HRMS: 
calc’d m/e for [M+H+] C27H47N2O5: 501.3304, found 501.3311; IR (neat, NaCl, cm-
1): 2926, 2855, 1778, 1742, 1690, 1649, 1458, 1421, 1367, 1230, 1148; [α]D25  -





(S)-tert-Butyl (1-(Benzyloxy)-4-oxohex-5-yn-2-yl)(nonyl)carbamate (22).  




mL) under a nitrogen atmosphere and cooled to 0 °C.  To the stirring solution, a 
0.5M solution of ethynylmagnesium bromide (7.5 mL, 3.5 mmol) in THF was 
added dropwise.  The reaction was then allowed to warm to room temperature.  
The reaction was monitored by TLC.  Upon consumption of the starting material, 
the reaction was quenched with an ice-cold 10% HCl solution (5 mL) and allowed 
to stir at 0 °C for 5 min.  The mixture was then diluted with water and extracted 
with EtOAc (30 mL x 3).  The organic layers were combined, washed with 
saturated sodium bicarbonate solution  (20 mL), dried over MgSO4, filtered and 
concentrated in vacuo.  The crude material was purified by flash column 
chromatography on silica gel, using 10% EtOAc:hexanes (v/v) as the eluent.  
After chromatographic purification, a colorless oil was obtained (82%).  1H NMR 
(CDCl3, 400 MHz, ppm): δ 7.31 (m, 5H), 4.50 (s, 2H), 4.33 (m, 1H), 3.62 (m, 2H), 
3.14 (m, 5H), 1.44 (m, 11H), 1.26 (m, 12H), 0.90 (m, 3H); 13C NMR (CDCl3, 400 
MHz, ppm): δ 128.3, 127.5, 81.6, 78.7, 75.7, 72.9, 53.2, 39.7, 31.9, 29.85, 29.81, 
29.7, 29.53, 29.48, 29.3, 28.4, 27.7, 22.7, 14.1; ESI-HRMS: calc’d m/e for [M+H+] 
C27H42NO4: 466.2933, found 466.2926; IR (neat, NaCl, cm-1): 2926, 2855, 2092, 






(S)-2-((Benzyloxy)methyl)-1-nonyl-2,3-dihydropyridin-4(1H)-one (23).  Ynone 




mmol) and allowed to react for 15 min.  The dioxane and excess HCl were 
removed under reduced pressure and the residue was placed under high 
vacuum for another 15 min.  This material was then dissolved in MeOH (10 mL) 
and excess potassium carbonate (8.0 mmol) was added.  The reaction was 
monitored by TLC.  Upon consumption of the starting material, the reaction 
mixture was diluted with CH2Cl2, and the inorganic salts were filtered off.  The 
organic phase was concentrated in vacuo, the resultant residue was purified by 
flash column chromatography on silica gel, using 60% EtOAc:hexanes (v/v) as 
the eluent.  After chromatographic purification, a yellow oil was obtained (92%).  
1H NMR (CDCl3, 400 MHz, ppm): δ 7.36 - 7.28 (m, 5H), 6.95 (d, J = 7.4 Hz, 1H), 
4.88 (d, J = 7.3 Hz, 1H), 4.51 (s, 2H), 3.80 (dd, J = 8.8, 16.2 Hz, 1H), 3.77 (m, 
1H), 3.51 (dd, J = 4.0, 8.9 Hz, 1H), 3.42 (m, 1H), 3.20 (m, 1H), 2.77 (dd, J = 9.7, 
16.7 Hz, 1H), 2.42 (dd, J = 2.2, 16.5 Hz, 1H), 1.60 (t, J = 5.8 Hz, 2H), 1.28 (m, 
12H), 0.90 (t, J = 6.5 Hz, 3H); 13C NMR (CDCl3, 400 MHz, ppm): δ 189.9, 152.5, 
137.7, 128.4, 127.6, 96.4, 73.5, 68.3, 56.0, 55.2, 37.7, 31.8, 29.7, 29.4, 29.21, 
29.18, 26.5, 22.6, 14.1; ESI-HRMS: calc’d m/e for [M+H+] C22H34NO2: 366.2409, 
found 366.2415;  IR (neat, NaCl, cm-1): 3031, 2926, 2855, 1641, 1589, 1497, 
1454, 1411, 1375, 1350, 1288, 1220, 1177, 1115, 1028, 1025, 739, 698; [α]D25  -









(2S,4R)-2-(Hydroxymethyl)-1-nonylpiperidin-4-ol (24).  Method A: Enaminone 
23 (72.2 mg, 0.2 mmol) was dissolved in anhydrous ethanol (3 mL).  To the 
stirring solution, sodium borohydride (120.0 mg, 2.2 mmol) was added.  The 
mixture was allowed to stir for 48 h.  Upon the disappearance of the starting 
material on TLC, the solvent was removed in vacuo.  The resultant residue was 
dissolved in CH2Cl2 and washed with H2O; the aqueous layer was extracted with 
CH2Cl2 (20 mL × 2).  The organic layers were combined, dried over MgSO4 and 
concentrated in vacuo.  The crude material (59.2 mg) was dissolved in 
anhydrous MeOH (3 mL).  To the stirring solution, 10 wt% Pd/C (60.0 mg) was 
added carefully.  The mixture was allowed to react under hydrogen gas at 1 
atmosphere overnight.  Upon consumption of the starting material, the catalyst 
was filtered off by passing the reaction through a Celite pad, and then the filtrate 
was concentrated in vacuo.  The resultant residue was purified by flash column 
chromatography on silica gel, using 10% MeOH/CH2Cl2 + 1% NH4OH as the 
eluent.  After chromatographic purification, a viscous light yellow oil was obtained 
(45%).  1H NMR (CDCl3, 400 MHz, ppm): δ 3.89 (dd, J = 3.8, 11.1 Hz, 1H), 3.70 
(m, 1H), 3.43 (dd, J = 1.9, 10.9 Hz, 1H), 3.12 (dt, J = 3.4, 12 Hz, 1H), 2.77 (dt, J 
= 5.0, 12.4 Hz, 1H), 2.43 (s, 1H), 2.30 (m, 2H), 1.94 (m, 2H), 1.72 (d, J = 10.8 
Hz, 1H), 1.72 - 1.60 (br s, 2H), 1.66 (d, J = 10.7 Hz, 1H), 1.50 (m, 2H), 1.28 (m, 
12H), 0.90 (t, J = 6.5 Hz, 3H); 13C NMR (CDCl3, 400 MHz, ppm): δ 68.8, 63.1, 
60.1, 52.9, 50.1, 37.9, 34.6, 32.3, 30.01, 29.98, 29.7, 28.0, 26.3, 23.1, 14.5; ESI-
HRMS: calc’d m/e for [M+H+] C15H32NO2: 258.2433, found 258.2427;  IR (neat, 




1220, 1177, 1115, 1028, 1025, 739, 698; [α]D25 -22 (c = 0.75, MeOH). 
Method B: (2S,4R)-1-tert-Butyl 2-methyl 4-hydroxypiperidine-1,2-dicarboxylate 
(181.8 mg, 0.67 mM) was added to a dry flask and cooled to 0 °C.  To the flask 
was added 4 N HCl in dioxane (5 mL, 20 mM).  The reaction was then warmed to 
room temperature and the stirring continued for 30 min.  Solvent was then 
removed in vacuo and the crude material was used in the reductive alkylation 
without purification.  The HCl salt was dissolved in dichloroethane (5 mL) at room 
temperature.  To the flask, triethylamine (0.2 mL, 1.43 mM), sodium 
triacetoxyborohydride (203.0 mg, 0.96 mM) and nonylaldehyde (0.7 mL, 0.85 
mM) were added in sequence.  pH value of the reaction was adjusted to < 7 with 
acetic acid.  The stirring continued for 2 h, upon consumption of the starting 
material, the reaction was quenched with saturated sodium bicarbonate (20 mL), 
and extracted with CH2Cl2 (10 mL × 2).  The organic layers were combined, dried 
over MgSO4, and concentrated in vacuo.  The crude material was purified by 
flash column chromatography on silica gel, using 10% MeOH/CH2Cl2 + 1% 
NH4OH as the eluent.  After chromatographic purification, a light green oil was 
obtained (80%).  1H NMR (CDCl3, 400 MHz, ppm): δ 3.85 (s, 3H), 3.12 (m, 1H), 
2.50 (m, 1H), 2.25 (m, 1H), 2.16 (m, 1H), 2.09 (d, J = 12.1 Hz, 1H), 1.92 (d, J = 
10.7 Hz, 1H), 1.78 (m, 1H), 1.67 (m, 1H), 1.49 (s, 2H), 1.26 (s, 14H), 0.88 (t, J = 
6.4 Hz, 3H).  The N-alkylated methyl ester (130.0 mg, 0.46 mM) was dissolved in 
toluene (5 mL) and cooled to -60 °C.  To the stirring solution, DIBAL (1M in THF, 
4.5 mL, 4.5 mM) was added dropwise.  The stirring continued for 4 h and the 




continued for 15 min at 0 °C.  H2O (0.15 mL), 25% NaOH solution (75 µL) and 
H2O (0.30 mL) were added to the flask in sequence.  The aluminum salts were 
filtered, and the solvent was removed in vacuo for the filtrate. The crude material 
was purified by flash column chromatography on silica gel, using 10% 
MeOH/CH2Cl2 + 1% NH4OH as the eluent.  After chromatographic purification, a 
viscous light yellow oil was obtained (40%).  1H NMR (CDCl3, 400 MHz, ppm): δ 
3.89 (dd, J = 3.8, 11.1 Hz, 1H), 3.70 (m, 1H), 3.43 (dd, J = 1.9, 10.9 Hz, 1H), 
3.12 (dt, J = 3.4, 12 Hz, 1H), 2.77 (dt, J = 5.0, 12.4 Hz, 1H), 2.43 (s, 1H), 2.30 
(m, 2H), 1.94 (m, 2H), 1.72 (d, J = 10.8 Hz, 1H), 1.72 - 1.60 (br s, 2H), 1.66 (d, J 









yl)carbamate (25).  N-Boc-O-benzyl-D-serine (500.0 mg, 1.7 mmol) was 
dissolved in anhydrous CH2Cl2 (15 mL) under a nitrogen atmosphere and cooled 
to -15 °C.  To the stirring solution, N,O-dimethylhydroxylamine•HCl (214.0 mg, 
2.2 mmol) and N-methylmorpholine (0.3 mL, 2.4 mmol) were added, followed by 
addition of EDCI (454.4 mg, 2.4 mmol) in portions over 30 min.  The reaction was 
then allowed to warm to room temperature.  Upon consumption of the starting 
material, the reaction was cooled to 0 °C and quenched by the addition of an ice-
cold 10% HCl solution (5 mL).  The mixture was allowed to stir at 0 °C for 5 min 




organic layers were combined, washed with saturated NaHCO3 (20 mL), dried 
over MgSO4, filtered and concentrated in vacuo.  The crude material was purified 
by flash column chromatography on silica gel, using 25% EtOAc:hexanes (v/v) as 
the eluent.  After chromatographic purification, a colorless oil was obtained 
(90%).  1H NMR (CDCl3, 400 MHz, ppm): δ 7.31 (m, 5H), 5.42 (d, J = 9.2 Hz, 
1H), 4.88 (s, 1H), 4.57 (d, J = 12.3 Hz, 1H), 4.50 (d, J = 12.2 Hz, 1H), 3.71 (s, 
3H), 3.68 (t, J = 4.8 Hz, 2H), 3.21 (s, 3H), 1.44 (s, 9H); 13C NMR (CDCl3, 400 
MHz, ppm): δ 155.7, 128.4, 127.69, 127.65, 73.1, 70.0, 64.0, 61.5, 50.8, 37.9, 
28.4; ESI-HRMS: calc’d m/e for [M+H+] C17H27N2O5: 339.1920, found 339.1926; 
IR (neat, NaCl, cm-1): 3326, 2977, 2936, 2868, 1713, 1667, 1497, 1455, 1391, 








(R)-2-(Allylamino)-3-(benzyloxy)-N-methoxy-N-methylpropanamide (26).  To 
a flask containing the Weinreb amide 25 (525.0 mg, 1.6 mmol), 4M HCl in 
dioxane (5 mL, 20.0 mmol) was added dropwise at 0 °C.  The ice bath was 
removed after the addition was completed.  The reaction was monitored by TLC.  
The solvent was removed in vacuo after the starting material was consumed.  
The resultant amorphous solid material was then suspended in anhydrous MeOH 
(8 mL), basified with diisopropylethylamine (0.8 mL, 4.8 mmol) dropwise.  The 




mmol) was added slowly, and allowed to react at 50 °C for 6 h. Upon 
consumption of the starting material, the reaction was quenched with saturated 
ammonium chloride (15 mL), and extracted with CH2Cl2 (20 mL × 2).  The 
organic layers were combined, dried over MgSO4, filtered, and concentrated in 
vacuo.  The resultant crude material was purified by flash column 
chromatography on silica gel, using 5% MeOH/CH2Cl2 + 1% NH4OH as the 
eluent.  After chromatographic purification, a colorless oil was obtained (50%).  
1H NMR (CDCl3, 400 MHz, ppm): δ 7.34 - 7.23 (m, 5H), 5.87 (m, 1H), 5.18 (ddd, 
J = 1.6, 3.2, 17.2 Hz, 1H), 5.08 (dd, J = 1.5, 10.2 Hz, 1H), 4.53 (s, 2H), 3.96 (s, 
1H), 3.66 (s, 3H), 3.60 (m, 2H), 3.28 (ddt, J = 1.5, 5.8, 13.8 Hz, 1H), 3.22 (s, 3H), 
3.12 (ddt, J = 1.2, 6.3, 13.8 Hz, 1H), 2.04 (m, 1H); 13C NMR (CDCl3, 400 MHz, 
ppm): δ 172.8, 138.1, 136.7, 128.3, 127.62, 127.57, 116.3, 73.4, 71.3, 61.5, 56.7, 
50.7, 34.8; ESI-HRMS: calc’d m/e for [M+H+] C15H23N2O3: 279.1709, found 
279.1715; IR (neat, NaCl, cm-1): 3323, 2975, 2936, 2866, 1711, 1662, 1496, 
1454, 1389, 1366, 1251, 1173, 1107, 1028, 992, 922, 864, 821, 740, 700; [α]D25  









yl)carbamate (27).  The secondary amine 26 (180.0 mg, 0.6 mmol) was 
dissolved in freshly distilled EtOAc (10 mL).  To the stirring solution, di-tert-butyl 




room temperature for 36 h and monitored by TLC.  Upon consumption of the 
starting material, the reaction was quenched by addition of saturated ammonium 
chloride (20 mL), and extracted with EtOAc (20 mL × 3).  The organic layers were 
combined, dried over MgSO4, and concentrated in vacuo.  The crude material 
was purified by flash column chromatography on silica gel, using 50% 
EtOAc:hexanes (v/v) as the eluent.  After chromatographic purification, a 
colorless oil was obtained (94%).  1H NMR (CDCl3, 400 MHz, ppm): δ 7.32 - 7.26 
(m, 5H), 5.80 (m, 1H), 5.48 (s, 1H), 5.10 (m, 1H), 5.03 (t, J = 10.1 Hz, 1H), 4.59 
(d, J = 12.0 Hz, 1H), 4.48 (d, J = 12.0 Hz, 1H), 3.92 (m, 1H), 3.85 (d, J = 5.7 Hz, 
1H), 3.81 (d, J = 5.6 Hz, 1H), 3.72 (s, 3H), 3.60 (s, 1H), 3.17 (s, 3H), 1.45 (s, 9H); 
13C NMR (CDCl3, 400 MHz, ppm): δ 197.9, 155.5, 138.1, 135.7, 135.0, 128.3, 
127.6, 115.7, 80.1, 72.8, 67.5, 62.3, 53.4, 46.7, 31.5, 28.3; ESI-HRMS: calc’d 
m/e for [M+H+] C20H31N2O5: 379.2233, found 379.2229; IR (neat, NaCl, cm-1): 
2976, 2934, 2868, 1695, 1671, 1454, 1400, 1366, 1318, 1270, 1252, 1174, 1150, 







(R)-tert-Butyl Allyl(1-(benzyloxy)-3-oxopent-4-en-2-yl)carbamate (28).  
Weinreb amide 27 (230.0 mg, 0.6 mmol) was dissolved in anhydrous THF (15 
mL) under a nitrogen atmosphere and cooled to 0 °C.  To the stirring solution, a 
1.0M solution of vinylmagnesium bromide (3.1 mL, 3.1 mmol) in THF was added 




reaction was monitored by TLC.  Upon consumption of the starting material, the 
reaction was quenched with an ice-cold 10% HCl solution (5 mL) and allowed to 
stir at 0 °C for 5 min.  The reaction was diluted with water and extracted with 
EtOAc (30 mL x 3).  The organic layers were combined, washed with saturated 
sodium bicarbonate solution (20 mL), dried over MgSO4, filtered and 
concentrated in vacuo.  The crude material was purified by flash column 
chromatography on silica gel, using 20% EtOAc:hexanes (v/v) as the eluent.  
After chromatographic purification, a colorless oil was obtained (90%). 1H NMR 
(CDCl3, 400 MHz, ppm): δ 7.34 - 7.27 (m, 5H), 6.59 (m, 1H), 6.37 (dd, J = 5.9, 
16.6 Hz, 1H), 5.92 (m, 1H), 5.72 (t, J = 10.4 Hz, 1H), 5.20 (t, J = 9.8 Hz, 1H), 
5.08 (t, J = 10.2 Hz, 1H), 4.76 (d, J = 6.0 Hz, 0.4H), 4.58 (d, J = 10.9 Hz, 1H), 
4.49 (d, J = 11.5 Hz, 1H), 4.33 (dd, J = 4.6, 15.0 Hz, 0.6H), 4.10 (t, J = 7.2 Hz, 
1H), 3.96 (m, 1H), 3.79 (m, 2H), 1.45 (s, 4H), 1.25 (s, 5H); 13C NMR (CDCl3, 400 
MHz, ppm): δ 196.5, 195.6, 155.4, 154.3, 138.0, 134.8, 134.0, 133.2, 132.2, 
128.9, 128.5, 128.4, 128.3, 127.6, 127.5, 118.6, 116.7, 81.5, 80.6, 73.3, 73.1, 
68.7, 67.6, 64.2, 62.1, 51.1, 49.1, 28.3, 28.1; ESI-HRMS: calc’d m/e for [M+H+] 
C20H28NO4: 368.1853, found 368.1862; IR (neat, NaCl, cm-1): 2977, 2930, 2868, 
1699, 1614, 1454, 1401, 1367, 1251, 1169, 1152, 1103, 1028, 987, 773, 737, 











carboxylate (29).  To a solution of diene 28 (131.1 mg, 0.4 mmol) in CH2Cl2 (5 
mL), the second generation of Grubbs catalyst was added (32 mg, 10 mol%).  
After 2 h under reflux, the solvent was removed in vacuo, and the crude residue 
was purified by flash column chromatography on silica gel, using 25% 
EtOAc:hexanes (v/v) as the eluent.  After chromatographic purification, a 
colorless oil was obtained (75%).  1H NMR (CDCl3, 400 MHz, ppm): δ 7.31 (m, 
3H), 7.23 (m, 2H), 7.00 (m, 1H), 6.19 (d, J = 10.4 Hz, 1H), 4.68 (m, 2H), 4.46 (s, 
2H), 4.03 (m, 1H), 3.82 (d, J = 8.6 Hz, 1H), 3.68 (d, J = 7.4 Hz, 1H), 1.46 (s, 9H); 
13C NMR (CDCl3, 400 MHz, ppm): δ 194.7, 154.3, 147.5, 146.4, 137.8, 128.4, 
127.6, 127.2, 127.0, 80.9, 73.1, 71.4, 61.1, 59.8, 43.3, 42.3, 28.3; ESI-HRMS: 
calc’d m/e for [M+Na+] C18H23NNaO4: 340.1525, found 340.1543; IR (neat, NaCl, 
cm-1): 2976, 2930, 2863, 1685, 1475, 1454, 1412, 1381, 1367, 1353, 1311, 1238, 








1(2H)-carboxylate (30).  Enone 29 (134.0 mg, 0.4 mmol) was dissolved in 
anhydrous MeOH (8 mL), and cooled to -78 °C with a dry ice/acetone bath.  To 
the stirring solution, cerium chloride (156.0 mg, 0.6 mmol) was added.  After 15 
min, sodium borohydride (18.0 mg, 0.5 mmol) was added to the solution.  The  
reaction was completed within 15 min after the addition.  The excess sodium 




layer was extracted with EtOAc (20 mL × 3).  The organic layers were combined, 
dried over MgSO4, filtered and concentrated in vacuo.  The resultant residue was 
purified by flash column chromatography on silica gel, using 50% EtOAc:hexanes 
(v/v) as the eluent.  After chromatographic purification, a colorless oil was 
obtained (92%).  1H NMR (CDCl3, 400 MHz, ppm): δ 7.33 - 7.29 (m, 5H), 5.75 (d, 
J = 10.4 Hz, 1H), 5.66 (m, 1H), 5.00 - 4.60 (br s, 1H), 4.56 (d, J = 11.9 Hz, 1H), 
4.53 (m, 1H), 4.48 (d, J = 11.9 Hz, 1H), 4.09 (m, 1H), 3.78 (dd, J = 2.3, 9.7 Hz, 
1H), 3.54 (t, J = 7.2 Hz, 1H), 3.40 (d, J = 19.3 Hz, 1H), 3.13 (m, 1H), 1.46 (s, 9H); 
13C NMR (CDCl3, 400 MHz, ppm): δ 154.8, 137.7, 128.7, 128.4, 127.8, 127.6, 
123.7, 80.2, 73.2, 67.2, 66.7, 40.5, 28.4; ESI-HRMS: calc’d m/e for [M+Na+] 
C18H25NNaO4: 342.1681, found 340.1700; IR (neat, NaCl, cm-1): 3430, 2929, 
2977, 2863, 1694, 1676, 1477, 1454, 1415, 1366, 1316, 1249, 1170, 1121, 1076, 








1(2H)-carboxylate (5-epi-30).  Allylic alcohol 30 (54.3 mg, 0.17 mM) was 
dissolved in THF (6 mL).  To the stirring solution, triphenylphosphine (81 mg, 
0.31 mM), p-NO2-benzoic acid (35.0 mg, 0.20 mM) and diisopropyl 
azodicarboxylate (65 µL, 0.31 mM) were added in sequence.  The stirring 
continued for 2 h at room temperature.  The reaction was then quenched with 




organic layers were combined, dried over MgSO4, filtered and concentrated in 
vacuo.  The crude material was purified by flash column chromatography on 
silica gel, using 20% EtOAc:hexanes (v/v) as the eluent.  The resultant 
intermediate (64.3 mg, 0.14 mM, 81%) was then dissolved in MeOH (5 mL).  To 
the stirring solution, K2CO3 (100 mg, 0.69 mM) was added.  The stirring 
continued until all the starting material was consumed.  The salt was then filtered, 
and the filtrate was concentrated in vacuo.  The crude material was purified by 
flash column chromatography on silica gel, using 50% EtOAc:hexanes (v/v) as 
the eluent.  After chromatographic purification, a colorless oil was obtained 
(60%).  1H NMR (CDCl3, 400 MHz, ppm): δ 7.31 (m, 5H), 5.94 (m, 1H), 5.88 (s, 
1H), 4.56 (d, J = 12.0 Hz, 1H), 4.48 (d, J = 12.0 Hz, 1H), 4.35 - 4.18 (br m, 1H), 
4.11 (s, 1H), 3.48 (d, J = 19.6 Hz, 1H), 3.40 (d, J = 6.2 Hz, 2H), 1.70 - 1.60 (br s 
1H), 1.47 (s, 9H); 13C NMR (CDCl3, 400 MHz, ppm): δ 153.2, 138.9, 128.5, 
128.3, 127.6, 127.5, 121.8, 86.2, 72.6, 68.0, 63.0, 43.0, 28.4; ESI-HRMS: calc’d 










carboxylate (31).  Allyl alcohol 30 (103.0 mg, 0.3 mmol) was dissolved in CH2Cl2 
(3 mL).  To the stirring solution, a solution of N-methylmorpholine N-oxide (116.0 




To the mixture, OsO4 (0.17 mL, 2.5 wt%, 5 mol%) was added and the reaction 
was allowed to warm to room temperature and was stirred for 12 h.  Upon 
consumption of the starting material, the reaction was diluted with saturated 
ammonium chloride (10 mL) and extracted with CH2Cl2 (20 mL × 2).  The organic 
layers were combined, dried over MgSO4, filtered and concentrated in vacuo.  
The crude product was purified by flash column chromatography on silica gel, 
using 10% MeOH/CH2Cl2 as the eluent.  After chromatographic purification, a 
colorless oil was obtained (78%).  1H NMR (CDCl3, 400 MHz, ppm): δ 7.37 - 7.29 
(m, 5H), 4.80 - 4.60 (br s, 1H), 4.54 (d, J = 12.2 Hz, 1H), 4.50 (d, J = 12.0 Hz, 
1H), 4.30 - 4.10 (br s, 1H), 3.99 (dd, J = 3.5, 9.9 Hz, 2H), 3.81 (m, 1H), 3.77 (d, J 
= 5.3 Hz, 2H), 3.15 (d, J = 14.9 Hz, 1H), 2.82 (m, 1H), 2.55 (m, 1H), 2.25 - 2.10 
(br s, 1H), 1.45 (s, 9H); 13C NMR (CDCl3, 400 MHz, ppm): δ 156.0, 138.0, 128.4, 
127.6, 127.5, 80.5, 73.6, 73.2, 71.9, 68.5, 68.3, 66.5, 44.6, 28.4; ESI-HRMS: 
calc’d m/e for [M+Na+] C18H27NNaO6: 376.1736, found 376.1735; IR (neat, NaCl, 
cm-1): 3407, 2976, 2928, 1668, 1477, 1454, 1427, 1366, 1248, 1171, 1139, 1081, 









General Procedure for the Synthesis of (2R,3S,4S,5S)-1-Alkyl-2-
((benzyloxy)methyl)-piperidine-3,4,5-triols (32).  The triol derivative 31 was 




was allowed to stir for 3 h at room temperature.  Upon consumption of the 
starting material, the solvent was removed in vacuo, and the remaining residue 
was left on high vacuum for 1 h.  The residue was then charged with 
dichloroethane (20 mL per 1 mmol of starting material).  To the stirring 
suspension, was added triethylamine (2.0 equiv relative to the starting material) 
and the corresponding aldehyde (1.5 equiv).  The mixture was allowed to stir for 
15 min until it turned into a clear solution.  To the stirring solution, sodium 
triacetoxyborohydride (2.0 equiv) was added.  Acetic acid was added to adjust 
the pH of the reaction to be slightly acidic.  The mixture was allowed to react at 
room temperature overnight.  The reaction was then quenched with saturated 
sodium bicarbonate (10 mL) and extracted with CH2Cl2 (2 x 20 mL).  The organic 
layers were combined, dried over MgSO4, and concentrated in vacuo.  The crude 
product was purified by flash column chromatography on silica gel, using 10% 







(2R,3S,4S,5S)-2-((Benzyloxy)methyl)-1-butylpiperidine-3,4,5-triol (32-1).  
After chromatographic purification, a colorless oil was obtained (73%).  1H NMR 
(MeOD, 400 MHz, ppm): δ 7.37 - 7.30 (m, 5H), 4.56 (d, J = 11.7 Hz, 1H), 4.52 (d, 
J = 11.7 Hz, 1H), 4.03 (m, 1H), 3.94 (dd, J = 2.5, 5.0 Hz, 1H), 3.80 (dd, J = 1.6, 
4.6 Hz, 1H), 3.77 (d, J = 4.3 Hz, 2H), 3.17 (m, 1H), 2.81 (m, 4H), 1.54 (m, 2H), 




129.4, 129.1, 128.9, 74.3, 72.4, 71.6, 69.8, 66.3, 60.1, 54.8, 52.6, 27.1, 21.5, 
14.2; ESI-HRMS: calc’d m/e for [M+Na+] C17H28NO4: 310.2018, found 310.2003; 
IR (neat, NaCl, cm-1): 3380, 2956, 2929, 2863, 1454, 1366, 1092, 1073, 734, 








(2R,3S,4S,5S)-2-((Benzyloxy)methyl)-1-nonylpiperidine-3,4,5-triol (32-2).  
After chromatographic purification, a colorless oil was obtained (71%).  1H NMR 
(MeOD, 400 MHz, ppm): δ 7.36 - 7.30 (m, 5H), 4.56 (d, J = 11.8 Hz, 1H), 4.51 (d, 
J = 11.8 Hz, 1H), 3.99 (t, J = 4.8 Hz, 1H), 3.91 (dd, J = 2.4, 4.8 Hz, 1H), 3.78 (t, J 
= 3.3 Hz, 1H), 3.75 (d, J = 4.7 Hz, 2H), 3.06 (m, 1H), 2.75 (m, 4H), 1.54 (m, 2H), 
1.28 (m, 12H), 0.92 (t, J = 7.1 Hz, 3H); 13C NMR (MeOD, 400 MHz, ppm): δ 
129.4, 129.0, 128.8, 74.3, 72.4, 71.6, 69.8, 66.3, 60.1, 54.8, 52.6, 35.8, 33.1, 
30.7, 30.6, 30.4, 28.5, 23.7, 14.4; ESI-HRMS: calc’d m/e for [M+Na+] 
C22H37NNaO4: 402.2620, found 402.2607; IR (neat, NaCl, cm-1): 3339, 2925, 













mixture of the tertiary amine derivatives (32), ammonium formate (10 equiv) and 
10% palladium on carbon (0.3 g per mmol of O-benzyl group) was refluxed in 
MeOH in a sealed reaction vessel.  The reaction was monitored by thin layer 
chromatography.  After the starting material was consumed, the catalyst was 
carefully filtered off by passing the reaction mixture through a Celite pad.  The 
solvent was subsequently removed under vacuum.  The neutral residue was 
purified by flash column chromatography, using 10% MeOH/ CH2Cl2 + 1% 








(2R,3S,4S,5S)-1-Butyl-2-(hydroxymethyl)piperidine-3,4,5-triol (33-1).  After 
chromatographic purification, a colorless viscous oil was obtained (66%).  1H 
NMR (MeOD, 400 MHz, ppm): δ 4.22 (dt, J = 2.8, 8.0 Hz, 1H), 4.08 (m, 1H), 3.97 
(d, J = 3.8 Hz, 2H), 3.90 (dd, J = 1.7, 4.5 Hz, 1H), 3.50 (m, 1H), 3.29 (d, J = 8.4 
Hz, 2H), 3.21 (d, J = 9.8 Hz, 2H), 1.76 (m, 2H), 1.44 (m, 2H), 1.03 (t, J = 8.0 Hz, 
3H); 13C NMR (MeOD, 400 MHz, ppm): δ 72.0, 70.2, 64.1, 61.9, 60.5, 55.0, 51.1, 
27.7, 21.0, 13.9; ESI-HRMS: calc’d m/e for [M+H+] C10H22NO4: 220.1549, found 











(2R,3S,4S,5S)-2-(Hydroxymethyl)-1-nonylpiperidine-3,4,5-triol (33-2). After 
chromatographic purification, a colorless viscous oil was obtained (88%).  1H 
NMR (MeOD, 400 MHz, ppm): δ 4.24 (dt, J = 2.6, 7.8 Hz, 1H), 4.10 (d, J = 3.0 
Hz, 1H), 3.98 (d, J = 4.2 Hz, 2H), 3.92 (dd, J = 1.4, 6.2 Hz, 1H), 3.50 (m, 1H), 
3.30 (d, J = 8.6 Hz, 2H), 3.22 (d, J = 8.0 Hz, 2H), 1.79 (m, 2H), 1.40 - 1.34 (m, 
12H), 0.93 (t, J = 6.6 Hz, 3H); 13C NMR (MeOD, 400 MHz, ppm): δ 71.9, 70.2, 
64.0, 61.9, 60.7, 54.8, 51.1, 33.0, 30.5, 30.31, 30.25, 27.7, 23.7, 14.4; ESI-
HRMS: calc’d m/e for [M+H+] C15H32NO4: 290.2331, found 290.2321; [α]D25 -13 (c 
= 0.84, MeOH). 
 
OH  
Hex-5-en-2-yn-1-ol.  To a brine solution (120 mL), HCl (0.5 mL), copper bromide 
(5.8 g, 40.4 mmol) and propargyl alcohol (14.0 g, 249.7 mmol) were added in 
sequence at room temperature.  The pH value of the mixture was adjusted to 9 
with a NaOH solution (40% v/v, 15 mL).  The mixture was then heated to 70 °C, 
and a solution of allyl bromide in MeOH (64 : 40, v/v) was added dropwise via a 
syringe pump.  The pH value was kept between 8 and 9 with NaOH throughout 
the addition.  The mixture was stirred at 70 °C for 3.5 h after the addition was 
finished, and then cooled to room temperature.  The pH value was re-adjusted to 




layers were combined, dried over MgSO4, filtered and concentrated in vacuo.  
The crude material was purified by a bulb-to-bulb distillation (bp 68 - 70 °C, 10 
mmHg), to give a colorless water-like liquid (84%).  1H NMR (CDCl3, 400 MHz, 
ppm): δ 5.81 (m, 1H), 5.32 (dd, J = 1.7, 17 Hz, 1H), 5.13 (dd, J = 1.6, 10 Hz, 1H), 
4.30 (t, J = 2.2 Hz, 2H), 3.01 (m, 2H); 13C NMR (CDCl3, 400 MHz, ppm): δ 132.2, 
116.3, 83.0, 80.6, 51.4, 23.1. 
 
OH  
(E)-Hexa-2,5-dien-1-ol.  To a stirring mixture of lithium aluminum hydride (3.8 g, 
100.1 mmol) in THF (150 mL), a solution of hex-5-en-2-yn-1-ol (9.6 g, 99.9 mmol) 
in THF (50 mL) was added dropwise at 0 °C.  Upon completion of the addition, 
the reaction was allowed to warm to room temperature and stirred for 30 min.  
The reaction was heated to 45 °C for another 3 h and then cooled to 0 °C again.  
The mixture was quenched with a saturated ammonium chloride solution (100 
mL) and extracted with ether (20 mL × 3).  The organic layers were combined, 
dried over MgSO4, filtered and concentrated in vacuo.  The crude material was 
purified by distillation (bp 70 - 72 °C, 10 mmHg), to give a colorless oil (37%). 1H 
NMR (CDCl3, 400 MHz, ppm): δ 5.82 (m, 2H), 5.71 (m, 1H), 5.04 (m, 2H), 4.12 
(dd, J = 1.4, 2.5 Hz, 2H), 2.81 (m, 2H); 13C NMR (CDCl3, 400 MHz, ppm): δ 









was dissolved in anhydrous CH2Cl2 (120 mL) and cooled to -25 °C.  To the 
stirring solution, powdered 4 Å molecular sieves (1.0 g), diethyl-D-(-)-tartrate (0.7 
mL, 3.3 mmol) and titanium tetraisoproxide (1.0 mL, 3.3 mmol) were added.  The 
mixture was stirred at -25 °C for 30 min.  After the “aging”, a solution of cumene 
hydroperoxide (11 mL, 66.8 mmol) in CH2Cl2 (10 mL) was added to the reaction.  
The mixture was stirred at -20 °C for 12 h.  The reaction was quenched with a 
10% solution (3 mL) of NaOH saturated by NaCl (prepared by dissolving 10 g 
NaCl and 10 g NaOH in 95 mL of H2O, and pre-cooled).  Then the cooling bath 
was removed, and the reaction was warmed to 10 °C for 10 min.  The mixture 
was dried over MgSO4, filtered and concentrated in vacuo.  The crude material 
was purified by flash column chromatography on silica gel, using 60% 
ether:hexanes (v/v) as the eluent.  After chromatographic purification, a colorless 
oil was obtained (60%).  1H NMR (CDCl3, 400 MHz, ppm): δ 5.82 (m, 1H), 5.18 
(dd, J = 1.6, 3.2 Hz, 1H), 5.14 (m, 1H), 3.93 (dt, J = 1.8, 10.2 Hz, 1H), 3.66 (m, 
1H), 3.06 (dt, J = 2.3, 5.4 Hz, 1H), 2.97 (m, 1H), 2.37 (m, 2H); 13C NMR (CDCl3, 








tert-Butyl Allyl((2S,3S)-1,2-dihydroxyhex-5-en-3-yl)carbamate (34). ((2R,3R)-
3-Allyloxiran-2-yl)methanol (4.4 g, 38.5 mmol) was dissolved in CH2Cl2 (150 mL).  




allylamine (3.6 mL, 46.2 mmol) were added in sequence.  The mixture was 
stirred at reflux for 6 days.  Upon consumption of the starting material, the 
reaction was quenched with a solution of 10% NaOH in brine, and stirred at room 
temperature for 12 h.  The mixture was then filtered through a pad of Celite, 
washed with 10% HCl (30 mL); the aqueous phase was collected and basified 
with NaOH until pH = 8 - 9.  The aqueous layer was extracted with CH2Cl2 (20 
mL × 3) and the organic layers were combined, dried over MgSO4, filtered and 
concentrated in vacuo.  The crude material (2.9 g) was dissolved in MeOH (20 
mL), basified with sodium bicarbonate (4.3 g, 115.5 mmol) and then di-tert-butyl 
dicarbonate (4.7 mL, 46.2 mmol) was added.  The reaction vessel was then 
placed in an ultra-sonic cleaner and was allowed to react overnight.  After the 
starting material was consumed, the mixture was filtered, washed with saturated 
NH4Cl (20 mL), and extracted with EtOAc (20 mL × 3).  The organic layers were 
combined, dried over MgSO4, filtered and concentrated in vacuo.  The crude 
product was purified by flash column chromatography on silica gel, using 50% 
EtOAc:hexanes (v/v) as the eluent.  After chromatographic purification, a light 
yellow oil was obtained (33% over two steps).  1H NMR (CDCl3, 400 MHz, ppm): 
δ 5.82 - 5.70 (m, 2H), 5.15 (m, 2H), 5.07 (t, J = 8.4 Hz, 2H), 3.80 (m, 1H), 3.70 
(d, J = 6.2 Hz, 2H), 3.57 (m, 2H), 3.03 (m, 1H), 2.66 (m, 1H), 2.46 (m, 1H), 1.46 
(s, 9H); 13C NMR (CDCl3, 400 MHz, ppm): δ 157.3, 135.4, 135.0, 117.2, 117.0, 
80.9, 80.8, 73.5, 63.2, 58.2, 32.0, 28.4; ESI-HRMS: calc’d m/e for [M+Na+] 
C14H25NNaO4: 294.1681, found 294.1647; IR (neat, NaCl, cm-1): 3409, 3078, 











carboxylate (35).  To a solution of diene 34 (1.6 g, 5.9 mmol) in CH2Cl2 (60 mL), 
the second generation of Grubbs catalyst (500 mg, 10 mol%) was added.  After 
stirring at room temperature for 12 h, the solvent was removed in vacuo, and the 
crude residue was purified by flash column chromatography on silica gel, using 
75% EtOAc:hexanes (v/v) as the eluent.  After chromatographic purification, a 
colorless oil was obtained (74%).  1H NMR (CDCl3, 400 MHz, ppm): δ 5.81 (t, J = 
6.2 Hz, 1H,), 5.63 (dd, J = 2.6, 7.5 Hz, 1H), 4.14 (m, 2H), 3.64 - 3.52 (br s, 2H), 
3.50 (m, 1H), 3.44 (d, J = 11.6 Hz, 2H), 2.62 (dd, J = 5.0, 17.8 Hz, 1H), 2.37 (m, 
2H), 1.49 (s, 9H); 13C NMR (CDCl3, 400 MHz, ppm): δ 157.2, 123.4, 122.1, 81.0, 
69.7, 62.5, 48.5, 41.4, 28.4, 24.4; ESI-HRMS: calc’d m/e for [M+Na+] 
C12H21NNaO4: 266.1368, found 266.1360; IR (neat, NaCl, cm-1): 3403, 2976, 
2929, 1693, 1674, 1659, 1478, 1455, 1413, 1391, 1365, 1310, 1253, 1172, 1113, 






(S)-tert-Butyl 6-(Hydroxymethyl)-5,6-dihydropyridine-1(2H)-carboxylate (36).  




mL, 1:3, v/v).  To the stirring solution, sodium periodate (1.0 g, 4.8 mmol) was 
added in portions over 30 min and then stirred at room temperature for 2 h.  The 
reaction mixture was diluted with H2O (20 mL) and extracted with CH2Cl2 (20 mL 
× 3).  The organic layers were combined, dried over MgSO4, filtered and 
concentrated in vacuo.  The resultant residue was dissolved in anhydrous 
ethanol (15 mL), and cooled to 0 °C.  To the stirring solution, sodium borohydride 
(182.0 mg, 4.8 mmol) was added and the reaction was monitored by TLC.  Upon 
consumption of the starting material, the solvent was removed in vacuo, and the 
residue was dissolved with CH2Cl2 and washed with H2O.  The aqueous layer 
was extracted with CH2Cl2 (20 mL × 2); the organic layers were combined, dried 
over MgSO4, filtered and concentrated.  The crude material was purified by flash 
column chromatography on silica gel, using 50% EtOAc:hexanes (v/v) as the 
eluent.  After chromatographic purification, a colorless oil was obtained (60%).  
1H NMR (CDCl3, 400 MHz, ppm): δ 5.72 (m, 1H), 5.65 (m, 1H), 4.48 (m, 1H), 
4.18 (m, 1H), 3.62 (dd, J = 1.8, 10.7 Hz, 2H), 3.56 (m, 1H), 2.40 (m, 1H), 2.05 (m, 
1H), 1.49 (s, 9H); 13C NMR (CDCl3, 400 MHz, ppm): δ 154.1, 123.3, 122.6, 81.0, 
63.0, 52.6, 40.7, 28.5, 25.2; ESI-HRMS: calc’d m/e for [M+Na+] C11H19NNaO3: 
236.1263, found 236.1213; IR (neat, NaCl, cm-1): 3435, 2976, 2929, 1695, 1677, 













dihydroxypiperidine-1-carboxylate (37).  To a solution of compound 36 (478.0 
mg, 2.2 mmol) in CH2Cl2 and DMF (20 mL, 1:1, v/v), tert-butyldiphenylsilyl 
chloride (1.7 mL, 6.7 mmol) and imidazole (305.0 mg, 4.5 mmol) were added in 
sequence at 0 °C.  The mixture was then allowed to warm to room temperature 
and continued stirring for 2 hours.  Upon completion, the reaction was diluted 
with H2O (10 mL), and extracted with CH2Cl2 (20 mL × 2).  The organic layers 
were combined, dried over MgSO4, filtered and concentrated in vacuo.  The 
residue was dissolved in CH2Cl2 (7.5 mL) and cooled to 0 °C and a solution of N-
methylmorpholine N-oxide (300.0 mg, 6.7 mmol) in H2O (0.6 mL) was added.  To 
the stirring solution, OsO4 (0.42 mL, 2.5 wt%, 5 mol%) was added and the 
reaction was allowed to warm to room temperature and continued stirring for 12 
h.  Upon consumption of the starting material, the reaction was diluted with 
saturated ammonium chloride and extracted with CH2Cl2 (20 mL × 2).  The 
organic layers were combined, dried over MgSO4, filtered and concentrated in 
vacuo.  The crude product was purified by flash column chromatography on silica 
gel, using 75% EtOAc:hexanes (v/v) as the eluent.  After chromatographic 
purification, a colorless oil was obtained (60%).  1H NMR (CDCl3, 400 MHz, 
ppm): δ 7.64 (m, 4H), 7.41 (m, 6H), 4.44 (m, 1H), 4.19 (d, J = 13.8 Hz, 1H), 3.82 




1.87 (dd, J = 5.4, 11.6 Hz, 2H), 1.43 (s, 9H), 1.05 (s, 9H); 13C NMR (CDCl3, 400 
MHz, ppm): δ 135.58, 135.56, 133.14, 133.07, 129.8, 127.80, 127.79, 80.1, 67.6, 
66.5, 63.1, 45.0, 28.3, 28.2, 26.8, 19.1; ESI-HRMS: calc’d m/e for [M+Na+] 
C27H39NNaO5Si: 508.2495, found 508.2494; IR (neat, NaCl, cm-1): 3415, 2961, 
2931, 2858, 1473, 1428, 1391, 1365, 1248, 1173, 1137, 1113, 1077, 1022, 824, 








(38).  The diol derivative 37 (119.0 mg, 0.2 mmol) was dissolved in formic acid 
(10 mL per 1 mmol of starting material).  The mixture was allowed to stir for 3 h 
at room temperature.  Upon consumption of the starting material, the solvent was 
removed in vacuo, and the remaining residue was left on high vacuum for 1 h.  
The residue was then charged with dichloroethane (15 mL).  To the stirring 
suspension, triethylamine (30.0 µL, 0.2 mmol) and nonyl aldehyde (67.0 µL, 0.4 
mmol) were added in sequence.  The mixture was allowed to stir for 15 min until 
it turned into a clear solution. Next, sodium triacetoxyborohydride (109.7 mg, 0.5 
mmol) was added to the reaction.  The pH value of the reaction was adjusted to 
be slightly acidic by acetic acid.  The mixture was allowed to react at room 
temperature overnight.  The reaction was then quenched with saturated sodium 




combined, dried over MgSO4, and concentrated in vacuo.  The crude product 
was purified by flash column chromatography on silica gel, using 4% 
MeOH/CH2Cl2 + 1% NH4OH as the eluent.  After chromatographic purification, a 
colorless oil was obtained (67%).  1H NMR (CDCl3, 400 MHz, ppm): δ 7.64 (d, J 
= 7.6 Hz, 4H), 7.42 (m, 6H), 4.05 - 3.80 (br s, 2H), 3.67 (d, J = 8.9 Hz, 1H), 3.11 
(m, 2H), 2.86 (m, 4H), 1.93 (s, 2H), 1.55 (br, 2H), 1.24 (m, 12H), 1.06 (s, 9H), 
0.88 (t, J = 7.1 Hz, 3H); 13C NMR (CDCl3, 400 MHz, ppm): δ 135.5, 130.4, 128.0, 
126.7, 82.3, 77.7, 69.7, 67.1, 55.7, 51.0, 43.4, 34.9, 32.4, 31.8, 30.5, 29.7, 29.4, 
29.1, 26.8, 22.6, 14.4; ESI-HRMS: calc’d m/e for [M+H+] C31H50NO3Si: 512.3560, 
found 512.3592; IR (neat, NaCl, cm-1): 3369, 3046, 3044, 2927, 2856, 1638, 
1588, 1550, 1465, 1428, 1391, 1361, 1261, 1111, 1082, 823, 801, 740, 702; 







(3S,4R,6S)-6-(Hydroxymethyl)-1-nonylpiperidine-3,4-diol (39).  The silyl ether 
38 (81.0 mg, 0.2 mmol) was dissolved in THF (10 mL) and cooled to 0 °C.  To 
the stirring solution, 1M tetrabutylammonium fluoride (0.18 mL, 0.2 mmol) was 
added slowly.  The mixture was allowed to react for 1 h at 0 °C.  Upon 
completion of the reaction, the solvent was removed in vacuo, and the crude 
material was subjected to chromatography with 15% MeOH/CH2Cl2 as the eluent.  




tetrabutylammonium fluoride.  It was then loaded on a Dowex resin (acidic form) 
column and eluted with H2O.  Tubes containing the product were collected and 
the solvent was removed in vacuo to yield the desired product as a colorless oil 
(96%).  1H NMR (MeOD, 400 MHz, ppm): δ 3.97 (dd, J = 3.5, 6.7 Hz, 1H), 3.67 
(m, 1H), 3.61 (t, J = 3.7 Hz, 2H), 2.81 (m, 1H), 2.77 (dd, J = 4.4, 6.2 Hz, 2H), 
2.62 (t, J = 10.1 Hz, 2H), 1.90 (m, 1H), 1.68 (m, 1H), 1.56 (m, 2H), 1.32 (m, 12H), 
0.92 (t, J = 6.6 Hz, 3H); 13C NMR (MeOD, 400 MHz, ppm): δ 79.5, 73.9, 69.0, 
64.4, 57.9, 50.2, 44.1, 33.5, 33.0, 30.7, 30.6, 30.5, 30.4, 23.7, 14.4; ESI-HRMS: 










tetrakis(benzyloxy)-5-oxohexanal (431.0 mg, 0.8 mmol) obtained from 1 by 
oxidation (see synthesis of compound 2) was dissolved in MeOH (5 mL 4Å 
molecular sieves (300 mg) were added.  A solution of Boc-protected-1,5-
pentadiamine (0.5 mL, 2.4 mmol) in MeOH was then added to the reaction.  
Next, sodium cyanoborohydride (140.0 mg, 2.1 mmol) was added, and the pH 
of the reaction was kept < 7 by adding acetic acid.  The reaction was stirred at 




was filtered through a pad of Celite.  The filtrated was diluted with H2O (40 mL) 
and extracted with CH2Cl2.  The filtrate was dried over MgSO4 and the solvent 
was removed under reduced pressure.  The crude products was purified by 
flash column chromatography on silica gel, using 60% EtOAc:hexanes (v/v) as 
the eluent.  After purification, a colorless oil was obtained (52%).  1H NMR 
(CDCl3, 400 MHz, ppm): δ 7.32 - 7.28 (m, 18H), 7.14 (d, J = 6.5 Hz, 2H), 4.95 (d, 
J = 11.1 Hz, 1H), 4.87 (d, J = 10.8 Hz, 1H), 4.81 (d, J = 11.1 Hz, 1H), 4.69 (d, J = 
11.5 Hz, 1H), 4.64 (d, J = 11.5 Hz, 1H), 4.49 (d, J = 12.3 Hz, 1H), 4.45 (m, 1H), 
4.41 (d, J = 10.8 Hz, 1H), 3.64 (m, 2H), 3.58 (t, J = 9.3 Hz, 1H), 3.52 (d, J = 10.2 
Hz, 1H), 3.45 (t, J = 9.1 Hz, 1H), 3.06 (dd, J = 4.8, 11.1 Hz, 3H), 2.65 (m, 1H), 
2.54 (m, 1H), 2.28 (d, J = 9.5 Hz, 1H), 2.20 (t, J = 10.8 Hz, 1H), 1.45 (s, 9H), 1.39 
(t, J = 7.4 Hz, 2H), 1.32 - 1.09 (m, 5H); 13C NMR (CDCl3, 400 MHz, ppm): δ 
155.9 139.0, 138.5, 137.8, 128.5, 128.37, 128.33, 128.31, 127.86, 127.84, 127.6, 
127.5, 127.4, 87.4, 78.6, 78.5, 75.3, 75.2, 73.4, 72.8, 65.2, 63.7, 54.4, 52.1, 40.5, 















yl)pentyl)pentanamide (41).  The carbamate 40 (164.6 mg, 0.2 mmol) was 




in dioxane (4.0 mL, 16.0 mmol).  The solvent was removed under reduced 
pressure after the reaction was completed.  The crude material was dissolved in 
anhydrous dimethylformamide (1 mL) and N-methylmorpholine (0.2 mL, 1.8 
mmol) was added.  To the stirring solution, a solution of biotin (60 mg, 1.0 equiv) 
in DMF (3 mL) was added, followed by the addition of the coupling reagent O-(7-
azabenzotriazol-1-yl)-N,N,N’,N’-tetramethyluronium hexafluorophosphate(HATU, 
90 mg, 0.2 mmol).  The mixture was allowed to stir at room temperature for 2 
days.  The mixture was then washed with H2O and the aqueous phase was 
extracted with EtOAc (20 mL × 2).  The organic layers were combined, dried over 
MgSO4, filtered and concentrated.  The crude product was purified by flash 
column chromatography on silica gel, using 10% MeOH/CH2Cl2 + 1% NH4OH as 
the eluent.  After purification, a yellow oil was obtained (92%).  1H NMR (CDCl3, 
400 MHz, ppm): δ 7.32 - 7.18 (m, 20H), 6.45 (s, 1H), 5.86 (s, 1H), 5.32 - 4.15 (m, 
10H), 3.96 - 3.62 (m, 5H), 3.17 - 3.05 (m, 6H), 2.75 - 2.52 (m, 3H), 2.17 (s, 2H), 
















yl)pentyl)pentanamide (42).  The benzylated compound 41 (400 mg, 0.5 mmol) 




solution, palladium chloride (348.0 mg, 2.1 mmol) was added carefully.  The 
mixture was allowed to stir at room temperature under hydrogen gas (1 
atmosphere) for 2 days.  Upon completion of the reaction, the catalyst was 
filtered off by passing the reaction mixture through a Celite pad.  The solvent was 
then removed in vacuo and the crude product was purified by flash column 
chromatography on silica gel, using 10% MeOH/CH2Cl2 + 1% NH4OH as the 
eluent.  After purification, an amorphous solid (31%) was obtained.  1H NMR 
(D2O, 400 MHz, ppm): δ 7.80 - 7.65 (br s, 1H), 4.96 (m, 1H), 3.77 (m, 1H), 4.19 
(m, 4H), 4.01 (m, 2H), 3.72 (m, 2H), 3.55 (m, 1H), 2.38 (m, 1H), 3.12 (m, 1H), 
2.95 (m, 1H), 2.62 (m, 4H), 2.27 (m, 2H), 1.94 (m, 5H), 1.66 (m, 5H); ESI-HRMS: 









tetrakis(benzyloxy)-5-oxohexanal (60.3 mg, 0.1 mmol) generated from the Swern 
oxidation was dissolved in MeOH (5 mL) and 3Å molecular sieves (50.0 mg) 
were added.  A solution of the Boc-protected-1,3-propyldiamine HCl (71.5 mg, 
0.3 mmol) and triethylamine (46 µL, 0.3 mmol) in MeOH were then added to the 
reaction in sequence.  Next, sodium cyanoborohydride (18.2 mg, 0.3 mmol) 




reaction was stirred at 50 °C overnight, and quenched with 1 M NaOH (5 mL).  
The reaction mixture was filtered through a pad of Celite.  The filtrated was 
diluted with H2O (40 mL) and extracted with CH2Cl2.  The organic layers were 
combined and dried over MgSO4.  The solvent was removed under reduced 
pressure and the crude residue was purified by flash column chromatography 
on silica gel, using 60% EtOAc:hexanes (v/v) as the eluent.  After purification, a 
colorless oil was obtained (58%).  1H NMR (CDCl3, 400 MHz, ppm): δ 7.32 - 7.28 
(m, 18H), 7.10 (dd, J = 2.5, 7.7 Hz, 2H), 5.26 - 5.20 (br s, 1H), 4.96 (d, J = 11.1 
Hz, 1H), 4.84 (d, J = 10.8 Hz, 1H), 4.80 (d, J = 11.1 Hz, 1H), 4.70 (d, J = 11.6 Hz, 
1H), 4.63 (d, J = 11.5 Hz, 1H,), 4.54 (d, J = 12.2 Hz, 1H), 4.45 (d, J = 12.2 Hz, 
1H), 4.33 (d, J = 10.8 Hz, 1H), 3.66 (dd, J = 2.1, 10.4 Hz, 1H), 3.60 (d, J = 2.3 
Hz, 1H), 3.57 (d, J = 3.3 Hz, 1H), 3.54 (d, J = 9.3 Hz, 1H), 3.46 (t, J = 8.9 Hz, 
1H), 3.16 (m, 1H), 3.04 (dd, J = 4.8, 11.2 Hz, 1H), 2.98 (m, 1H), 2.81 (m, 1H), 
2.34 (m, 1H), 2.24 (d, J = 9.3 Hz, 1H), 2.02 (m, 1H), 1.42 (s, 9H), 1.25 (t, J = 7.2 
Hz, 1H); 13C NMR (CDCl3, 400 MHz, ppm): δ 156.2 139.0, 138.5, 128.4, 128.3, 
128.0, 127.9, 127.84, 127.80, 127.7, 127.6, 127.5, 127.4, 87.3, 78.6, 75.3, 75.2, 












formate (80.0 mg, 0.6 mmol) and 10% palladium on carbon (45.0 mg, 0.3 g per 
mM of O-benzyl group) was refluxed in MeOH in a sealed reaction vessel.  The 
reaction was monitored by TLC, and upon completion of the reaction, the catalyst 
was carefully filtered off by passing the mixture through a Celite pad.  The 
solvent was subsequently removed in vacuo.  The neutral residue was purified by 
flash column chromatography, using 10% MeOH/ CH2Cl2 + 1% NH4OH (v/v) as 
the eluent.  After purification, a colorless oil was obtained (77%).  1H NMR 
(MeOD, 400 MHz, ppm): δ 3.97 (d, J = 12.2 Hz, 1H), 3.87 (d, J = 11.0 Hz, 1H), 
3.58 (m, 1H), 3.47 (t, J = 9.5 Hz, 1H), 3.25 (m, 1H), 3.22 (t, J = 4.8 Hz, 1H), 3.15 
(m, 1H), 3.09 (t, J = 6.7 Hz, 2H), 2.92 (m, 1H), 2.63 (d, J = 7.1 Hz, 1H), 2.59 (t, J 
= 11.2 Hz, 1H), 1.79 (m, 2H), 1.42 (s, 9H), 1.26 (s, 1H); 13C NMR (MeOD, 400 




























yl)benzamide (45).  The aminosugar derivative 44 (3.5 mg, 0.01 mmol) was 




when starting material was completely consumed.  The residue was then 
dissolved in DMSO (1 mL) and stirred in a reaction vessel that was wrapped in 
aluminum foil to exclude light.  To the stirring mixture, Sulfo-SBED (10 mg, 0.01 
mmol) was added to generate the photoaffinity label 45.  The sample was 
submitted for the biological assay in the form of a 0.01 M solution in DMSO, 
(95%). ESI-HRMS: calc’d m/e for [M+H+] C37H59N10O9S3: 883.3629, found 
883.3623. 
 
3.3.2 Chapter 2 
General Procedure for the Synthesis of bis-Addition Products of 
Enaminones with Aldehydes (Table 4): The enaminone was dissolved in THF 
or CH2Cl2 (5 mL per 0.1 mmol), and stirred at room temperature.  To the stirring 
solution, trimethylsilyl chloride (1 equiv relative to the enaminone) was added, 
followed by the addition of the aldehyde (1 equiv).  The reaction was monitored 
by TLC and quenched with saturated sodium bicarbonate when the starting 
material was consumed.  The organic layer was separated and the aqueous 
phase was extracted with EtOAc (10 mL × 2).  The organic layers were 
combined, dried over MgSO4, filtered and concentrated in vacuo.  The crude 
product was purified by flash column chromatography on silica gel, using 75% 











5,5'-(Butane-1,1-diyl)bis(1-benzyl-2,3-dihydropyridin-4(1H)-one).  After 
chromatographic purification, a viscous yellow oil was obtained (86%).  1H NMR 
(CDCl3, 400 MHz, ppm): δ 7.51 (s, 2H), 7.37 - 7.26 (m, 10H), 4.33 (s, 4H), 3.28 
(t, J = 7.8 Hz, 1H), 3.20 (t, J = 7.7 Hz, 4H), 2.38 (t, J = 8.0 Hz, 4H), 1.79 (dd, J = 
7.6, 15.6 Hz, 2H), 1.26 (m, 2H), 0.90 (t, J = 7.3 Hz, 3H); ESI-HRMS: calc’d m/e 









5,5'-(Phenylmethylene)bis(1-benzyl-2,3-dihydropyridin-4(1H)-one).  After 
chromatographic purification, a viscous yellow oil was obtained (90%).  1H NMR 
(CDCl3, 400 MHz, ppm): δ 7.37 - 7.30 (m, 9H), 7.25 (s, 2H), 7.22 - 7.20 (m, 6H), 
5.20 (s, 1H), 4.28 (s, 4H), 3.29 (t, J = 7.8 Hz, 4H), 2.46 (t, J = 8.3 Hz, 4H); 13C 
NMR (CDCl3, 400 MHz, ppm): δ 199.9, 155.5, 136.1, 128.9, 128.3, 128.1, 127.9, 
127.7, 125.5, 111.5, 60.2, 46.6, 41.5, 36.1; ESI-HRMS: calc’d m/e for [M+Na+] 









5,5'-(2-Tolylmethylene)bis(1-benzyl-2,3-dihydropyridin-4(1H)-one).  After 




400 MHz, ppm): δ 7.35 - 7.26 (m, 7H), 7.20 - 7.08 (m, 8H), 6.88 (s, 2H), 5.15 (s, 
1H), 4.22 (d, J = 2.9 Hz, 4H), 3.27 (t, J = 7.8 Hz, 4H), 2.46 (t, J = 3.6 Hz, 4H), 
2.24 (s, 3H), 3.29 (t, J = 7.8 Hz, 4H), 2.46 (t, J = 8.3 Hz, 4H); 13C NMR (CDCl3, 
400 MHz, ppm): δ 189.3, 154.1, 142.1, 136.4, 136.1, 130.4, 128.8, 128.1, 127.6, 
127.4, 125.8, 125.4, 110.7, 60.1, 46.8, 38.0, 36.1, 19.5; ESI-HRMS: calc’d m/e 











After chromatographic purification, a yellow oil was obtained (75%). 1H NMR 
(CDCl3, 400 MHz, ppm): δ 8.10 (dd, J = 1.7, 7.0 Hz, 2H), 7.41 - 7.33 (m, 8H), 
7.25 - 7.21 (m, 6H), 5.01 (s, 1H), 4.32 (s, 4H), 3.34 (t, J = 7.7 Hz, 4H), 2.47 (t, J = 
8.1 Hz, 4H); 13C NMR (CDCl3, 400 MHz, ppm): δ 189.1, 155.2, 152.7, 145.9, 
135.8, 129.0, 128.8, 128.3, 127.8, 123.2, 110.4, 60.4, 60.2, 46.6, 41.8, 35.9; ESI-














After chromatographic purification, two isomers were obtained (1:2, 99%, 
combined yield).  Isomer 1, yellow oil (Rf 0.38, 75% EtOAc/hexane): 1H NMR 
(CDCl3 400 MHz, ppm): δ 7.34 - 7.23 (m, 23H), 7.02 (m, 4H), 5.03 (s, 1H), 4.41 
(t, J = 7.3 Hz, 2H), 4.24 (d, J = 15.1 Hz, 2H), 4.03 (d, J = 15.1 Hz, 2H), 2.82 (dd, 
J = 6.8, 16.2 Hz, 2H), 2.70 (dd, J = 8.3, 16.2 Hz, 2H); 13C NMR (CDCl3, 400 MHz, 
ppm): δ 188.3, 155.3, 143.6, 138.7, 136.2, 128.9, 128.7, 128.5, 128.03, 127.97, 
127.95, 127.8, 127.2, 125.6, 111.7, 60.4, 57.5, 44.3, 41.8;  
Isomer 2, yellow oil (Rf 0.25, 75% EtOAc/hexane): 1H NMR (CDCl3, 400 MHz, 
ppm): δ 7.34 - 7.18 (m, 23H), 7.05 - 6.99 (m, 4H), 5.04 (s, 1H), 4.43 (m, 2H), 4.25 
(m, 2H), 4.03 (m, 2H), 2.81 (m, 2H), 2.69 (m, 2H); 3.83 (d, J = 13.5 Hz, 2H), 3.58 
(dd, J = 3.7, 10.9 Hz, 2H), 3.22 (m, 2H), 2.93 (d, J = 13.5 Hz, 2H), 2.66 (m, 4H), 
2.54 (m, 2H), 2.38 (m, 1H), 2.33 (m, 3H); 13C NMR (CDCl3, 400 MHz, ppm): δ 
188.7, 188.3, 188.1, 155.5, 155.2, 155.1, 143.7, 138.74, 138.68, 136.3, 136.19, 
136.17, 128.9, 128.7, 128.5, 128.3, 128.1, 128.0, 127.99, 127.95, 127.85, 
127.83, 127.29, 127.25, 125.6, 125.5, 112.1, 111.7, 111.1, 60.7, 60.6, 60.4, 57.6, 
57.5, 57.4, 44.6, 44.4, 44.2, 41.8, 41.5;  
 
General Procedure for the Synthesis of β-Elimination Products: The 
enaminone was dissolved in CH2Cl2 (10 mL per 0.1 mmol), and stirred at room 
temperature.  To the stirring solution, trimethylsilyl chloride (1 equiv relative to the 
enaminone) was added, followed by the addition of isobutylaldehyde and 
Ti(OiPr)4 (1 equiv).  The reaction vessel was then sealed, heated to 60 °C and 




starting material was completely consumed.  The organic layer was separated 
and the aqueous phase was extracted with CH2Cl2 (10 mL × 2).  The organic 
layers were combined, dried over MgSO4, filtered and concentrated in vacuo.  
The crude product was purified by flash column chromatography on silica gel, 






1-Benzyl-5-(2-methylprop-1-en-1-yl)-2,3-dihydropyridin-4(1H)-one.  After 
chromatographic purification, a yellow oil was obtained (44%).  1H NMR (CDCl3, 
400 MHz, ppm): δ 7.41 - 7.34 (m, 3H), 7.28 (d, J = 1.9 Hz, 2H), 7.14 (s, 1H), 5.90 
(s, 1H), 4.39 (s, 2H), 3.38 (t, J = 7.6 Hz, 2H), 2.48 (t, J = 7.9 Hz, 2H), 1.81 (d, J = 
0.8 Hz, 3H), 1.71 (d, J = 0.7 Hz, 3H); 13C NMR (CDCl3, 400 MHz, ppm): δ 153.6, 
118.4, 110.8, 60.2, 46.7, 35.9, 26.3, 19.7; ESI-HRMS: calc’d m/e for [M+H+] 








After chromatographic purification, a yellow oil was obtained (77%).  1H NMR 
(CDCl3, 400 MHz, ppm): δ 7.37 - 7.25 (m, 9H), 7.16 - 7.14 (m, 2H), 5.90 (s, 1H), 




(dd, J = 6.9, 16.4 Hz, 1H), 2.73 (dd, J = 8.0, 16.4 Hz, 1H), 1.82 (s, 3H), 1.73 (s, 
3H); 13C NMR (CDCl3, 400 MHz, ppm): δ 189.1, 153.2, 138.6, 136.1, 132.3, 
129.0, 128.9, 128.3, 128.2, 127.8, 127.1, 118.2, 109.0, 60.6, 57.5, 43.8, 26.3, 
19.8; ESI-HRMS: calc’d m/e for [M+H+] C22H24NO: 318.1858, found 318.0979. 
 
General Procedure for the Synthesis of Alkyl Products 46 (Table 5): The 
enaminone was dissolved in CH2Cl2 (10 mL per 0.1 mmol), and stirred at room 
temperature.  To the stirring solution, trifluoroacetic acid (4 equiv relative to the 
enaminone) was added, followed by the addition of triethylsilane and the 
aldehyde (1 equiv, respectively).  The reaction was heated to 60 °C in a sealed 
vessel and monitored by TLC.  The reaction was quenched with saturated 
sodium bicarbonate when all starting material was consumed.  The organic layer 
was separated and the aqueous phase was extracted with CH2Cl2 (10 mL × 2).  
The organic layers were combined, dried over MgSO4, filtered and concentrated 
in vacuo.  The crude product was purified by flash column chromatography on 





1-Benzyl-5-butyl-2,3-dihydropyridin-4(1H)-one (46a).  After chromatographic 
purification, a yellow oil was obtained (81%).  1H NMR (CDCl3, 400 MHz, ppm): δ 




= 7.7 Hz, 2H), 2.37 (t, J = 7.6 Hz, 2H), 2.05 (t, J = 6.8 Hz, 2H), 1.33 - 1.21 (m, 
4H), 0.83 (t, J = 7.2 Hz, 3H); 13C NMR (CDCl3, 400 MHz, ppm): δ 189.8, 151.5, 
135.3, 127.9, 127.7, 127.1, 126.9, 126.6, 109.8, 58.9, 46.1, 35.1, 31.0, 26.1, 






1,5-Dibenzyl-2,3-dihydropyridin-4(1H)-one (46b).  After chromatographic 
purification, a yellow oil was obtained (85%).  1H NMR (CDCl3, 400 MHz, ppm): δ 
7.37 - 7.15 (m, 10H), 6.90 (s, 1H), 4.25 (s, 2H), 3.50 (s, 2H), 3.30 (t, J = 7.8 Hz, 
2H), 2.48 (t, J = 8.0 Hz, 2H); 13C NMR (CDCl3, 400 MHz, ppm): δ 190.1, 153.4, 
141.6, 136.0, 128.9, 128.7, 128.3, 128.2, 127.6, 125.7, 110.1, 59.9, 46.9, 35.8, 







1-Benzyl-5-butyl-2-phenyl-2,3-dihydropyridin-4(1H)-one (46c). After 
chromatographic purification, a yellow oil was obtained (92%).  1H NMR (CDCl3, 
400 MHz, ppm): δ 7.35 - 7.30 (m, 6H), 7.25 - 7.22 (m, 2H), 7.14 (s, 1H), 7.11 (m, 




2.73 (m, 2H), 2.16 (m, 2H), 1.42 (m, 2H), 1.34 (m, 2H), 0.91 (t, J = 7.2 Hz, 2H); 
13C NMR (CDCl3, 400 MHz, ppm): δ 189.8, 152.4, 139.0, 136.4, 128.9, 128.8, 
128.2, 128.0, 127.7, 127.2, 110.0, 61.2, 57.0, 44.2, 32.1, 27.0, 22.4, 14.0; ESI-







1,5-Dibenzyl-2-phenyl-2,3-dihydropyridin-4(1H)-one (46d). After 
chromatographic purification, a yellow oil was obtained (86%).  1H NMR (CDCl3, 
400 MHz, ppm): δ 7.34 - 7.17 (m, 13H), 7.03 (s, 2H), 7.01 (s, 1H), 4.43 (dd, J = 
2.2, 9.0 Hz, 1H), 4.22 (d, J = 15.1 Hz, 1H), 4.03 (d, J = 15.1 Hz, 1H), 3.57 (d, J = 
15.7 Hz, 1H), 3.52 (d, J = 15.0 Hz, 1H), 2.82 (dd, J = 6.8, 16.4 Hz, 1H), 2.73 (dd, 
J = 9.2, 16.4 Hz, 2H); 13C NMR (CDCl3, 400 MHz, ppm): δ 189.1, 153.5, 141.5, 
138.7, 136.0, 129.0, 128.8, 128.7, 128.3, 128.2, 128.1, 127.7, 127.2, 125.8, 
110.5, 61.1, 57.2, 44.0, 32.7; ESI-HRMS: calc’d m/e for [M+H+] C25H24NO: 







1-Benzyl-5-nonyl-2-phenyl-2,3-dihydropyridin-4(1H)-one (46e). After 




400 MHz, ppm): δ 7.33 - 7.11 (m, 11H), 4.42 (t, J = 7.8 Hz, 1H), 4.30 (d, J = 15.1 
Hz, 1H), 4.06 (d, J = 15.0 Hz, 1H), 2.73 (m, 2H), 2.15 (d, J = 5.3 Hz, 2H), 1.42 (s, 
2H), 1.27 (s, 14H), 0.89 (t, J = 6.1 Hz, 3H); 13C NMR (CDCl3, 400 MHz, ppm): δ 
189.8, 152.5, 139.0, 136.4, 128.9, 128.8, 128.2, 128.0, 127.7, 127.2, 111.0, 61.2, 
57.0, 44.2, 31.9, 29.9, 29.7, 29.6, 29.4, 29.37, 27.3, 22.7, 14.1; ESI-HRMS: 







1-Benzyl-5-isobutyl-2-phenyl-2,3-dihydropyridin-4(1H)-one (46f). After 
chromatographic purification, a yellow oil was obtained (93%).  1H NMR (CDCl3, 
400 MHz, ppm): δ 7.36 - 7.30 (m, 6H), 7.25 - 7.22 (m, 2H), 7.12 (m, 2H), 7.11 (s, 
1H), 4.43 (dd, J = 2.0, 8.9 Hz, 1H), 4.31 (d, J = 15.1 Hz, 1H), 4.08 (d, J = 15.2 
Hz, 1H), 2.78 (dd, J = 6.8, 16.4 Hz, 1H), 2.69 (dd, J = 9.1, 16.4 Hz, 1H), 2.01 (m, 
2H), 1.76 (m, 1H), 0.89 (d, J = 3.9 Hz, 3H), 0.87 (d, J = 3.8 Hz, 3H); 13C NMR 
(CDCl3, 400 MHz, ppm): δ 189.8, 153.1, 138.9, 136.4, 128.9, 128.8, 128.1, 
128.0, 127.7, 127.2, 109.9, 61.1, 57.1, 44.2, 36.7, 28.3, 22.4, 22.3; ESI-HRMS: 









chromatographic purification, a colorless oil was obtained (88%).  1H NMR 
(CDCl3, 400 MHz, ppm): δ 6.64 (s, 1H), 3.26 (dt, J = 2.0, 12.4 Hz, 1H), 3.10 (m, 
1H), 2.80 (dt, J = 2.9, 12.6 Hz, 1H), 2.36 (dd, J = 5.2, 16.2 Hz, 1H), 2.26 (dd, J = 
13.8, 16.2 Hz, 1H), 2.02 (m, 2H), 1.77 (m, 1H), 1.67 (m, 2H), 1.51 (dddt, J = 4.2, 
12.8, 12.8, 12.8 Hz, 1H), 1.39 (m, 1H), 1.32 - 1.17 (m, 5H), 0.81 (t, J = 7.1 Hz, 
3H); 13C NMR (CDCl3, 400 MHz, ppm): δ 192.0, 153.2, 112.1, 57.7, 52.8, 43.7, 
32.1, 31.6, 26.8, 25.6, 23.2, 22.4, 14.0; ESI-HRMS: calc’d m/e for [M+H+] 





3-Benzyl-7,8,9,9a-tetrahydro-1H-quinolizin-2(6H)-one (46h). After 
chromatographic purification, a colorless oil was obtained (93%).  1H NMR 
(CDCl3, 400 MHz, ppm): δ 7.20 - 7.06 (m, 5H), 6.54 (s, 1H), 3.42 (d, J = 15.3 Hz, 
1H), 3.36 (d, J = 15.3 Hz, 1H), 3.21 - 3.11 (m, 2H), 2.79 (dt, J = 2.9, 12.6 Hz, 
1H), 2.42 (dd, J = 5.2, 16.3 Hz, 1H), 2.29 (dd, J = 13.8, 16.3 Hz, 1H), 1.77 - 1.61 
(m, 3H), 1.52 - 1.18 (m, 3H); 13C NMR (CDCl3, 400 MHz, ppm): δ 191.3, 154.1, 
141.6, 128.7, 128.3, 125.7, 111.2, 57.5, 52.9, 43.4, 32.6, 31.7, 25.6, 23.1; ESI-









3-Butyl-4-(pyrrolidin-1-yl)furan-2(5H)-one (46i).  After chromatographic 
purification, a colorless oil was obtained (89%).  1H NMR (CDCl3, 400 MHz, 
ppm): δ 4.53 (s, 2H), 3.44 (s, 4H), 2.30 (t, J = 7.2 Hz, 2H), 1.97 (t, J = 6.7 Hz, 
4H), 1.41 (m, 2H), 1.34 (m, 2H), 0.90 (t, J = 7.2 Hz, 3H); 13C NMR (CDCl3, 400 
MHz, ppm): δ 176.1, 158.9, 92.5, 65.4, 47.3, 33.1, 24.2, 22.1, 21.6, 13.0; ESI-






3-Benzyl-4-(pyrrolidin-1-yl)furan-2(5H)-one (46j).  After chromatographic 
purification, a colorless oil was obtained (98%).  1H NMR (CDCl3, 400 MHz, 
ppm): δ 7.21 - 7.09 (m, 5H), 4.57 (s, 2H), 3.67 (s, 2H), 3.33 (s, 4H), 1.83 (t, J = 
6.6 Hz, 4H); 13C NMR (CDCl3, 400 MHz, ppm): δ 177.4, 161.5, 141.9, 128.6, 
128.5, 128.2, 127.8, 125.9, 66.6, 48.5, 28.6, 25.1; ESI-HRMS: calc’d m/e is 






3-Isobutyl-4-(pyrrolidin-1-yl)furan-2(5H)-one (46k).  After chromatographic 
purification, a colorless oil was obtained (88%).  1H NMR (CDCl3, 400 MHz, 




4H), 1.76 (m, 1H), 0.90 (s, 3H), 0.89 (s, 3H); 13C NMR (CDCl3, 400 MHz, ppm): δ 
177.4, 160.5, 66.5, 48.5, 32.1, 30.1, 27.3, 25.2, 22.3; ESI-HRMS: calc’d [m/e] is 






3-(2-Methylbenzyl)-4-(pyrrolidin-1-yl)furan-2(5H)-one (46l). After 
chromatographic purification, a colorless oil was obtained (97%). 1H NMR 
(CDCl3, 400 MHz, ppm): δ 7.14 - 7.08 (m, 3H), 6.97 (d, J = 7.4 Hz, 1H), 4.71 (s, 
2H), 3.65 (s, 2H), 3.35 (t, J = 6.4 Hz, 4H), 2.32 (s, 3H), 1.86 (t, J = 6.6 Hz, 4H); 
13C NMR (CDCl3, 400 MHz, ppm): δ 177.6, 162.1, 139.2, 135.5, 129.9, 126.9, 
126.1, 125.9, 66.7, 48.1, 26.0, 25.1, 19.7; ESI-HRMS: calc’d m/e for [M+Na+] 







3-(4-Chlorobenzyl)-4-(pyrrolidin-1-yl)furan-2(5H)-one (46m). After 
chromatographic purification, a colorless oil was obtained (96%).  1H NMR 
(CDCl3, 400 MHz, ppm): δ 7.23 (t, J = 8.4 Hz, 2H), 7.13 (d, J = 8.4 Hz, 2H), 4.64 
(s, 2H), 3.69 (s, 2H), 3.39 (s, 4H), 1.91 (m, 4H); 13C NMR (CDCl3, 400 MHz, 




HRMS: calc’d m/e for [M+Na+] C15H16ClNNaO2: 300.0767, found 300.0742. 
 
General Procedure for the Synthesis of Aminomethylation Products 47 
(Table 6): The enaminone was dissolved in dichloroethane (10 mL per 0.1 
mmol), and stirred at room temperature.  To the stirring solution, lithium 
perchlorate (1.2 equiv relative to the enaminone) was added, followed by the 
addition of the carbamate (2.0 equiv) and paraformaldehyde (2.0 equiv) in 
sequence.  The reaction was heated to 90 °C in a sealed vessel and monitored 
by TLC and quenched with saturated sodium bicarbonate when the starting 
material was completely consumed.  The organic layer was separated and the 
aqueous phase was extracted with CH2Cl2 (10 mL × 2).  The organic layers were 
combined, dried over MgSO4, filtered and concentrated in vacuo.  The crude 
product was purified by flash column chromatography on silica gel, using 100% 












(47a).  After chromatographic purification, a white gel was obtained (74%).  1H 
NMR (CDCl3, 400 MHz, ppm): δ 5.21 (s, 1H), 4.59 (s, 2H), 4.07 (d, J = 5.8 Hz, 
2H), 3.90 - 3.10 (br s, 4H), 2.00 (s, 4H), 1.42 (s, 9H); 13C NMR (CDCl3, 400 MHz, 
















(47b).  After chromatographic purification, a white gel was obtained (99%).  1H 
NMR (CDCl3, 400 MHz, ppm): δ 7.34 (t, J = 7.7 Hz, 2H), 7.18 (t, J = 7.3 Hz, 1H), 
7.11 (d, J = 7.7 Hz, 2H), 5.86 (s, 1H), 4.62 (s, 2H), 4.20 (d, J = 6.0 Hz, 2H), 4.05 - 
3.10 (br s, 4H), 1.98 (s, 4H); 13C NMR (CDCl3, 400 MHz, ppm): δ 176.8, 160.1, 
154.6, 151.0, 129.3, 125.3, 121.7, 89.6, 66.8, 60.4, 48.8, 34.8; ESI-HRMS: calc’d 












yl)methyl)carbamate (47c).  After chromatographic purification, a yellow gel was 
obtained (86%).  1H NMR (CDCl3, 400 MHz, ppm): δ 7.26 - 7.08 (m, 10H), 5.13 
(s, 2H), 4.48 (s, 2H), 4.29 (s, 2H), 4.08 (s, 2H), 3.60 - 2.80 (br s, 4H), 1.86 -1.58 
(br s, 4H); 13C NMR (CDCl3, 400 MHz, ppm): δ 176.9, 162.6, 156.0, 140.0, 139.6, 
136.7, 128.4, 128.0, 127.5, 127.1, 126.5, 87.7, 67.2, 66.1, 64.4, 49.5, 48.4, 40.2; 














yl)methyl)carbamate (47d).  After chromatographic purification, a white gel was 
obtained (99%).  1H NMR (CDCl3, 400 MHz, ppm): δ 7.25 - 7.19 (m, 5H), 5.95 (s, 
1H), 5.30 (m, 1H), 5.21 (m, 1H), 4.66 (s, 2H), 4.56 (s, 2H), 4.35 (s, 2H), 4.19 (m, 
2H), 3.60 - 3.20 (br s, 4H), 1.89 (s, 4H); 13C NMR (CDCl3, 400 MHz, ppm): δ 
176.9, 162.6, 156.0, 139.6, 132.9, 128.0, 127.2, 126.6, 117.5, 87.8, 66.1, 49.6, 












yl)methyl)carbamate (47e).  After chromatographic purification, a white gel was 
obtained (74%).  1H NMR (CDCl3, 400 MHz, ppm): δ 7.36 - 7.34 (m, 5H), 5.81 (s, 
1H), 5.13 (s, 2H), 5.11 (m, 2H), 4.56 (s, 2H), 4.29 (s, 2H), 3.97 (d, J = 5.5 Hz, 
2H), 3.96 - 3.02(br s, 4H), 1.94 (s, 4H); 13C NMR (CDCl3, 400 MHz, ppm): δ 
162.3, 156.0, 136.8, 134.0, 128.4, 127.9, 127.7, 116.2, 88.2, 67.0, 66.4, 48.7, 















yl)methyl)carbamate (47f).  After chromatographic purification, a white gel was 
obtained (51%).  1H NMR (CDCl3, 400 MHz, ppm): δ 7.35 - 7.27 (m, 5H), 5.13 (s, 
2H), 4.57 (s, 2H), 4.29 (s, 2H), 3.80 -2.98 (br s, 4H), 3.29 (t, J = 7.6 Hz, 2H), 1.93 
(br, 4H), 1.54 (t, J = 7.1 Hz, 2H), 1.26 (m, 2H), 0.88 (m, 3H); 13C NMR (CDCl3, 
400 MHz, ppm): δ 176.9, 162.3, 156.1, 137.0, 128.4, 127.8, 127.7, 87.9, 66.3, 
48.7, 45.2, 39.0, 30.3, 29.7, 25.1, 20.1, 13.9; ESI-HRMS: calc’d m/e for [M+H+] 











(47g).  After chromatographic purification, a yellow oil was obtained (54%).  1H 
NMR (CDCl3, 400 MHz, ppm): δ 7.43 (s, 1H), 7.39 - 7.33 (m, 5H), 7.24 (m, 2H), 
7.17 (t, J = 6.4 Hz, 1H), 7.12 (d, J = 7.4 Hz, 2H), 5.73 (s, 1H), 4.30 (s, 2H), 3.82 
(d, J = 6.0 Hz, 2H), 3.27 (t, J = 9.6 Hz, 2H), 2.40 (t, J = 7.8 Hz, 2H); 13C NMR 




127.7, 125.1, 121.9, 121.7, 106.9, 60.0, 46.5, 39.3, 35.3, 29.7; ESI-HRMS: calc’d 











yl)methyl)carbamate (47h).  After chromatographic purification, a yellow oil was 
obtained (68%).  1H NMR (CDCl3, 400 MHz, ppm): δ 7.48 (s, 1H), 7.32 - 7.21 (m, 
12H), 7.17 (m, 2H), 7.00 (m, 1H), 5.10 (s, 2H), 4.55 (s, 2H), 4.26 (s, 1H), 3.90 (s, 
1H), 3.87 (d, J = 5.0 Hz, 2H), 3.16 (m, 2H), 2.30 (m, 2H); 13C NMR (CDCl3, 400 
MHz, ppm): δ 190.0, 156.1, 138.8, 138.6, 136.9, 135.8, 135.7, 135.6, 129.0, 
128.6, 128.4, 128.3, 128.2, 128.1, 127.7, 127.6, 127.5, 127.1, 126.9, 106.5, 67.1, 
60.0, 50.6, 46.3, 43.7, 35.3; ESI-HRMS: calc’d m/e for [M+Na+] C28H28N2NaO3: 









methoxybenzyl)carbamate (47i).  After chromatographic purification, a yellow 
oil was obtained (51%).  1H NMR (CDCl3, 400 MHz, ppm): δ 7.48 (s, 1H), 7.29 - 




3.89 (s, 2H), 3.84 (s, 1H), 3.71 (s, 3H), 3.17 (m, 2H), 2.32 (m, 2H); 13C NMR 
(CDCl3, 400 MHz, ppm): δ 190.0, 158.7, 156.6, 156.1, 155.2, 136.9, 135.8, 
130.8, 129.8, 129.2, 129.0, 128.6, 128.4, 128.38, 128.3, 128.2, 127.9, 127.8, 
127.7, 127.4, 114.0, 113.7, 106.7, 106.5, 67.1, 60.0, 55.3, 50.0, 46.3, 43.2, 42.2, 
35.4, 29.7; ESI-HRMS: calc’d m/e for [M+Na+] C29H30N2NaO4: 493.2103, found 
493.2121. 
 
General Method for the Reaction of Enaminones with Malonates and 
Formaldehyde to form Methylmalonates 48 (Table 8).  A suspension of 
enaminone, LiClO4 (1.0 equiv), malonate diester (1.5 equiv) and acetic anhydride 
(1.0 equiv) in acetonitrile (10 mL) was stirred and pre-heated in a sealed screw-
cap vial until the reaction mixture turned into a clear solution.  To the reaction 
medium was then added paraformaldehyde (2.0 equiv), sealed and stirred at 60 
°C.  The reaction was monitored by TLC.  The reaction was completed within 0.5 
to 3 h.  The reaction medium was then allowed to cool and washed with H2O (20 
mL).  The aqueous phase was extracted with EtOAc (3 x 10 mL).  The organic 
layers were combined, washed with brine and MgSO4.  The organic solvent was 
then removed under reduced pressure and the residue was purified by flash 
column flash column chromatography on silica gel, using 50% acetone/hexanes 









Dimethyl 2-((2-(Benzylamino)-6-oxocyclohex-1-enyl)methyl)malonate (48a).  
After chromatographic purification, a viscous colorless oil was obtained (93%).  
1H NMR (CDCl3, 400 MHz, ppm): δ 7.38 - 7.34 (m, 2H), 7.30 - 7.26 (m, 3H), 6.35 
(m, 1H), 4.43 (d, J = 6.1 Hz, 2H), 3.81(t, J = 7.2 Hz, 1H), 3.69 (s, 6H), 2.83 (d, 
7.2 Hz, 2H), 2.39 (t, J = 6.2 Hz, 2H), 2.26 (t, J = 6.2 Hz, 2H), 1.84 (m, 2H); 13C 
NMR (CDCl3, 400 MHz, ppm): δ 194.9, 171.1, 162.7, 138.4, 129.0, 127.7, 126.9, 
105.8, 52.7, 50.6, 47.2, 36.3, 25.8, 23.5, 21.2; ESI-HRMS: calc’d m/e for [M+Na+] 
C19H23NNaO5: 368.1474, found 368.1484; IR (neat, NaCl, cm-1): 2951, 1733, 






Dimethyl 2-((6-Oxo-2-(phenylamino)cyclohex-1-enyl)methyl)malonate (48b).  
After chromatographic purification, a viscous colorless oil was obtained (90%).  
1H NMR (CDCl3, 400 MHz, ppm): δ 8.04 (s, 1H), 7.34 (m, 2H), 7.16 (m, 1H), 7.08 
(m, 2H), 3.83 (t, J = 7.2 Hz, 1H), 3.76 (s, 6H), 2.92 (d, J = 7.2 Hz, 2H), 2.50 (t, J = 
6.0 Hz, 2H), 2.37 (t, J = 6.0 Hz, 2H), 1.87 (m, 2H); 13C NMR (CDCl3, 400 MHz, 
ppm): δ 195.9, 171.3, 160.6, 139.3, 129.3, 125.0, 124.1, 109.0, 52.9, 50.9, 36.9, 
27.4, 23.8, 22.2; ESI-HRMS: calc’d m/e for [M+H+] C18H22NO5: 332.1498, found 
332.1505; IR (neat, NaCl, cm-1): 2593, 1733, 1567, 1499, 1435, 1398, 1306, 









Dibenzyl 2-((6-Oxo-2-(phenylamino)cyclohex-1-enyl)methyl)malonate (48c).  
After chromatographic purification, a viscous light yellow oil was obtained (97%).  
1H NMR (CDCl3, 400 MHz, ppm): δ 7.89 (s, 1H), 7.35-7.29 (m, 12H), 7.15 (m, 
1H), 7.01 (m, 2H), 5.14 (q-like, J = 12.4 Hz, 4H), 3.95 (t, 1H, J = 7.4 Hz), 2.95 (d, 
2H J = 7.4 Hz), 2.39 (t, J= 6.0 Hz, 2H), 2.32 (t, J = 6.0 Hz, 2H), 1.76 (m, 2H); 13C 
NMR (CDCl3, 400 MHz, ppm): δ 196.0, 170.5, 160.8, 139.1, 135.6, 129.3, 128.6, 
128.4, 128.1, 125.1, 124.2,108.6, 67.4, 51.1, 36.8, 27.3, 23.7, 22.0; ESI-HRMS: 
calc’d m/e for  [M+H+] C30H30NO5: 484.2124, found 484.2118; IR (neat, NaCl, cm-








enyl)methyl)malonate (48d).  After chromatographic purification, a viscous light 
yellow oil was obtained (73%).  1H NMR (CDCl3, 400 MHz, ppm): δ 7.36 - 7.24 
(m, 10H), 6.24 (t, J = 6.2 Hz, 1H), 5.15 (q-like, J= 12.4 Hz, 2H), 4.36 (d, J = 6.1 
Hz, 2H), 3.89 (t, J = 7.6 Hz, 1H), 3.67 (s, 3H), 2.84 (m, 2H), 2.33 (m, 2H), 2.24 
(m, 2H), 1.81 (m, 2H); 13C NMR (CDCl3, 400 MHz, ppm): δ 194.9, 170.7, 162.7, 




47.2, 36.3, 25.8, 23.6, 21.2; ESI-HRMS: calc’d m/e for [M+H+] C25H28NO5: 
422.1967, found 422.1973; IR (neat, NaCl, cm-1): 2949, 1732, 1575, 1497, 1455, 






Dibenzyl 2-((2-(Benzylamino)-6-oxocyclohex-1-enyl)methyl)malonate (48e).  
After chromatographic purification, a viscous light yellow oil was obtained (90%).  
1H NMR (CDCl3, 400 MHz, ppm): δ 7.36 - 7.22 (m, 15H), 6.20 (t, J = 6.1 Hz, 1H), 
5.12 (q-like, J = 12.4 Hz, 4H), 4.30 (d, J = 6.1 Hz, 2H), 3.95 (t, J = 7.3 Hz, 1H), 
2.87 (d, J = 7.3 Hz, 2H), 2.28 (t, J = 6.2 Hz, 2H), 2.22 (t, J = 6.3 Hz, 2H), 1.77 (m, 
2H); 13C NMR (CDCl3, 400 MHz, ppm): 194.9, 170.4, 162.7, 138.3, 135.7, 129.0, 
128.6, 128.3, 128.1, 127.7, 127.0, 105.6, 67.2, 50.7, 47.1, 36.3, 25.7, 23.5, 21.1; 
ESI-HRMS: calc’d m/e for [M+H+] C31H32NO5: 498.2280, found 498.2275; IR 
(neat, NaCl, cm-1): 2945, 1731, 1577, 1497, 1456, 1434, 1372, 1356, 1295, 1200, 






Dimethyl 2-((2-(Butylamino)-6-oxocyclohex-1-enyl)methyl)malonate (48f).  
After chromatographic purification, a viscous colorless oil (66%) was obtained.  




6H), 3.18 (m, 2H), 2.76 (d, J = 7.1 Hz, 2H), 2.41 (t, J = 6.2 Hz, 2H), 2.26 (t, J = 
6.3 Hz, 2H), 1.87 (m, 2H), 1.57 (m, 2H), 1.40 (m, 2H), 0.95 (t, J = 7.3 Hz, 3H); 
13C NMR (CDCl3, 400 MHz, ppm): δ 194.4, 171.2, 163.0, 104.9, 52.8, 52.7, 50.6, 
43.2, 36.3, 32.4, 25.8, 23.4, 21.3, 20.1, 13.9; ESI-HRMS: calc’d m/e for [M+H+] 
C16H26NO5: 312.1811, found 312.1801; IR (neat, NaCl, cm-1): 2954, 1733, 1570, 






Dibenzyl 2-((2-(Butylamino)-6-oxocyclohex-1-enyl)methyl)malonate (48g).  
After chromatographic purification, a viscous colorless oil was obtained (83%).  
1H NMR (CDCl3, 400 MHz, ppm): δ 7.32 - 7.26 (m, 10H), 5.69 (t, J = 4.8 Hz, 1H), 
5.13 (q-like, J = 12.4 Hz, 4H), 3.92 (t, J = 7.4 Hz, 1H), 3.04 (m, 2H), 2.81 (d, J = 
7.3 Hz, 2H), 2.28 (t, J = 6.2 Hz, 2H), 2.22 (t, J = 6.1 Hz, 2H), 1.81 (m, 2H), 1.50 
(m, 2H), 1.37 (m, 2H), 0.94 (t, J = 7.3 Hz, 3H); 13C NMR (CDCl3, 400 MHz, ppm): 
δ 194.4, 170.6, 162.8, 135.8, 128.6, 128.3, 128.1, 104.7, 67.1, 50.7, 43.1, 36.3, 
32.3, 25.8, 23.4, 21.2, 20.1, 13.79; ESI-HRMS: calc’d m/e for [M+H+] C28H34NO5: 
464.2437, found 464.2444; IR (neat, NaCl, cm-1): 2955, 1731, 1575, 1438, 1413, 












(48h).  After chromatographic purification, a viscous light yellow oil was obtained 
(72%).  1H NMR (CDCl3, 400 MHz, ppm): δ 6.78 (s, 1H), 3.77 (t, J = 7.2 Hz, 1H), 
3.76 (s, 4H), 3.71 (s, 6H), 2.76 (s, 4H), 2.74 (d, J = 7.2 Hz, 2H), 2.64 (t, J = 6.2 
Hz, 2H), 2.27 (t, J = 6.2 Hz, 2H), 1.86 (m, 2H); 13C NMR (CDCl3, 400 MHz, ppm): 
δ 195.6, 171.1, 162.6, 103.6, 66.7, 56.9, 52.7, 50.6, 36.7, 25.2, 23.2, 21.4; ESI-
HRMS: calc’d m/e for [M+H+] C16H25N2O6: 341.1713, found 341.1699; IR (neat, 
NaCl, cm-1): 2953, 2857, 1733, 1583, 1438, 1403, 1303, 1267, 1243, 1201, 1157, 









(48i).  After chromatographic purification, a viscous light yellow oil was obtained 
(86%).  1H NMR (CDCl3, 400 MHz, ppm): δ 7.33 - 7.25 (m, 10H), 6.64 (s, 1H), 
5.14 (q-like, J = 12.5 Hz, 4H), 3.94 (t, J = 7.4 Hz, 1H), 3.90 - 3.40 (br s, 4H), 2.78 




1.82 (m, 2H); 13C NMR (CDCl3, 400 MHz, ppm): δ 195.5, 170.4, 162.6, 135.8, 
128.6, 128.3, 127.9, 103.5, 67.2, 66.6, 56.7, 50.8, 36.7, 25.2, 23.1, 21.3; ESI-
HRMS: calc’d m/e for [M+H+] C28H33N2O6: 493.2339, found 493.2342; IR (neat, 
NaCl, cm-1): 2917, 2850, 1732, 1584, 1497, 1455, 1402, 1385, 1266, 1233, 1200, 







malonate (48j).  After chromatographic purification, a viscous colorless oil was 
obtained (83%).  1H NMR (CDCl3, 400 MHz, ppm): δ 7.94 (s, 1H), 7.35 (m, 2H), 
7.16 (m, 1H), 7.06 (m, 2H), 3.88 (t, J = 7.4 Hz, 1H), 3.75 (s, 6H), 2.93 (d, J = 7.4 
Hz, 2H), 2.36 (s, 2H), 2.23 (s, 2H), 0.97 (s, 6H); 13C NMR (CDCl3, 400 MHz, 
ppm): δ 195.5, 171.3, 158.4, 139.3, 129.4, 124.9, 123.9, 108.0, 52.9, 50.7, 50.5, 
40.8, 32.8, 28.1, 23.8; ESI-HRMS: calc’d m/e for [M+H+] C20H26NO5: 314.1392, 
found 314.1385; IR (neat, NaCl, cm-1): 2954, 1735, 1579, 1498, 1436, 1395, 











was obtained (90%).  1H NMR (CDCl3, 400 MHz, ppm): δ 7.90 (s, 1H), 7.34 (m, 
2H), 7.29 (m, 10H), 7.16 (m, 1H), 7.00 (m, 2H), 5.16 (dt, J = 3.2, 14.0 Hz, 4H), 
3.99 (t, J = 7.5 Hz, 1H), 2.95 (d, J = 7.5 Hz, 2H), 2.27 (s, 2H), 2.18 (s, 2H), 0.91 
(s, 6H); 13C NMR (CDCl3, 400 MHz, ppm): δ 195.5, 170.5, 158.4, 139.3, 135.5, 
129.3, 128.7, 128.4, 128.2, 124.9, 124.0, 107.9, 67.4, 51.0, 50.5, 40.7, 32.7, 
28.1, 23.7; ESI-HRMS: calc’d m/e for [M+H+] C32H34NO5: 512.2437, found 
512.2431; IR (neat, NaCl, cm-1): 2956, 1733, 1579, 1498, 1455, 1395, 1384, 







malonate (48l).  After chromatographic purification, a viscous colorless oil was 
obtained (95%).  1H NMR (CDCl3, 400 MHz, ppm): δ 7.37 (m, 2H), 7.9 (m, 3H), 
6.20 (m, 1H), 4.43 (d, J = 6.2 Hz, 2H), 3.82 (t, J = 7.4 Hz, 1H), 3.69 (s, 6H), 2.84 
(d, J= 7.3 Hz, 2H), 2.24 (s, 2H), 2.16 (s, 2H), 0.96 (s, 6H); 13C NMR (CDCl3, 400 
MHz, ppm): δ 194.4, 171.1, 161.0, 138.5, 129.0, 127.8, 126.9, 104.5, 52.7, 50.5, 
50.0, 47.1, 39.3, 31.8, 28.5, 23.4; ESI-HRMS: ESI-HRMS: calc’d m/e for [M+H+] 
C21H28NO5: 374.1967, found 374.1964; IR (neat, NaCl, cm-1): 2953, 1732, 1576, 










enyl)methyl)malonate (48m).  After chromatographic purification, a viscous light 
yellow oil was obtained (88%).  1H NMR (CDCl3, 400 MHz, ppm): δ 7.37 - 7.23 
(m, 15H), 6.10 (t, J = 6.5 Hz, 1H), 5.11 (q-like, J = 12.4 Hz, 4H), 4.32 (d, J = 6.3 
Hz, 2H), 3.95 (t, J = 7.4 Hz, 1H), 2.87 (d, J = 7.4 Hz, 2H), 2.13 (s, 2H), 2.10 (s, 
2H), 0.92 (s, 6H); 13C NMR (CDCl3, 400 MHz, ppm): δ 194.4, 170.4, 160.9, 
138.5, 135.6, 129.0, 128.6, 128.3, 128.2, 127.7, 126.9, 104.3, 67.2, 50.8, 49.9, 
47.0, 39.2, 31.8, 28.5, 23.3; ESI-HRMS: calc’d m/e for [M+H+] C33H36NO5: 
526.2593, found 526.2586; IR (neat, NaCl, cm-1): 2955, 1731, 1577, 1497, 1455, 







enyl)methyl)malonate (48n).  After chromatographic purification, a viscous 
colorless oil was obtained (88%).  1H NMR (CDCl3, 400 MHz, ppm): δ 5.73 (s, 
1H), 3.77 (t, J = 7.3 Hz, 1H), 3.69 (s, 6H), 3.18 (m, 2H), 2.77 (d, J = 7.3 Hz, 2H), 
2.25 (s, 2H), 2.16 (s, 2H), 1.57 (m, 2H), 1.40 (m, 2H), 1.02 (s, 6H), 0.96 (t, 7.3 
Hz, 3H); 13C NMR (CDCl3, 400 MHz, ppm): δ 193.8, 171.2, 161.1, 103.5, 52.6, 




for [M+H+] C18H30NO5: 374.1967, found 374.1964; IR (neat, NaCl, cm-1): 2953, 








(48o).  After chromatographic purification, a viscous colorless oil was obtained 
(96%).  1H NMR (CDCl3, 400 MHz, ppm): δ 8.20 (s, 1H), 7.34 (t, J = 7.7 Hz, 2H), 
7.14 (m, 3H), 3.75 (s, 6H), 3.72 (t, J = 7.2 Hz, 1H), 2.78 (d, J= 7.0 Hz, 2H), 2.70 
(s, 2H), 2.37 (s, 2H); 13C NMR (CDCl3, 400 MHz, ppm): δ 202.9, 171.5, 170.8, 
139.3, 129.5, 124.9, 122.3, 111.6, 52.9, 50.3, 33.2, 26.3, 21.7; ESI-HRMS: calc’d 
m/e for [M+H+] C17H20NO5: 318.1341, found 318.1344; IR (neat, NaCl, cm-1): 







Dimethyl 2-((2-(Benzylamino)-5-oxocyclopent-1-enyl)methyl)malonate (48p).  
After chromatographic purification, a viscous colorless oil was obtained (94%).  
1H NMR (CDCl3, 400 MHz, ppm): δ 7.36 (m, 2H), 7.29 (m, 3H), 6.43 (s, 1H), 4.47 
(d, J = 6.4 Hz, 2H), 3.71 (t, J = 6.9 Hz, 1H), 2.69 (d, J= 7.2 Hz, 2H), 2.54 (s, 2H), 
2.33 (s, 2H); 13C NMR (CDCl3, 400 MHz, ppm): δ 202.3, 174.1, 170.6, 138.0, 




m/e for [M+H+] C18H22NO5: 332.1498, found 332.1492; IR (neat, NaCl, cm-1): 
2952, 1733, 1669, 1594, 1578, 1496, 1436, 1353, 1279, 1238, 1156, 1118, 1077, 
1056, 1030. 
 
Mechanistic Studies for the LiClO4-mediated Formation of Enaminone 




Dimethyl 2-Methylenemalonate. Dimethyl malonate (11.5 mL, 100.0 mmol) 
was dissolved in acetic acid (45 mL).  The reaction was then heated at 100 °C for 
3-4 h.  After cooling, the salts were filtered off and acetic acid was removed, 
using bulb-to-bulb distillation (bp 50-60 °C, 100 mmHg). Further distillation (bp 
120-130 °C, 20 mmHg missing) gave a colorless oil (3.7 g, 25%).  The product 
was taken into the reaction with the enaminone immediately after it was isolated, 
in order to avoid polymerization.  1H NMR (CDCl3, 400 MHz, ppm): δ 6.56 (s, 
2H), 3.83 (s, 6H); Polymer: δ 3.75 (s, 3H), 3.40 (s, 1H); 13C NMR (CDCl3, 400 
MHz, ppm): δ 167.1, 135.2, 52.7; ESI-HRMS: calc’d m/e for [M+H+] C6H9O4: 





Dimethyl 2-Benzylidenemalonate. To a solution of benzaldehyde (6.6 mL, 60 




was stirred for 5 min before the addition of dimethyl malonate (13.7 mL, 120 
mmol).  After stirring at room temperature for 24 h, the reaction was diluted with  
EtOAc (60 mL) and washed with water (60 mL × 2).  The combined organic layer 
was dried over Na2SO4 and the solvent was removed under reduced pressure.  
The residue was purified by flash column chromatography on silica gel, using 
50% acetone:hexanes (v/v) as the eluent.  After purification, a viscous oil was 
obtained (12.8 g, 98%).  1H NMR (CDCl3, 400 MHz, ppm): δ 7.78 (s, 1H), 7.42 - 
7.40 (m, 5H), 3.86 (s, 3H), 3.85 (s, 3H); 13C NMR (CDCl3, 400 MHz, ppm): δ 
167.3, 164.6, 143.1, 132.9, 130.8, 129.5, 129.0, 125.6, 52.8; ESI-HRMS: calc’d 
m/e for [M+H+] C12H13O4: 221.0814, found 221.0805. 
 
 Four reactions were set up parallely, utilizing the enaminone (3-
(benzylamino)cyclohex-2-enone) to react with dimethyl 2-methylenemalonate and 
dimethyl 2-benzylidenemalonate synthesized above, respectively:  
a) A solution of enaminone (50.2 mg, 0.25 mM), LiClO4 (30 mg, 0.25 mM), and 
dimethyl 2-methylenemalonate (54 mg, 0.38 mM) was heated in a sealed screw-
cap vial at 60 °C.  
b) A solution of enaminone (50.2 mg, 0.25 mM) and dimethyl 2-
methylenemalonate (54 mg, 0.38 mM) was heated in a sealed screw-cap vial at 
60 °C. 
c) A solution of enaminone (50.2 mg, 0.25 mM), LiClO4 (30 mg, 0.25 mM), and 
dimethyl 2-benzylidenemalonate (83 mg, 0.38 mM) was heated in a sealed 




d) A solution of enaminone (50.2 mg, 0.25 mM) and dimethyl 2-
benzylidenemalonate (83 mg, 0.38 mM) was heated in a sealed screw-cap vial at 
60 °C. 
The reactions were monitored by TLC for product formation.  After starting 
material was completely consumed, the reaction medium was then allowed to 
cool and washed with H2O (20 mL).  The aqueous phase was extracted with 
EtOAc (3 x 10 mL).  The organic layers were combined, washed with brine and 
MgSO4.  The organic solvent was then removed under reduced pressure and the 
residue was purified by flash column flash column chromatography on silica gel. 
Only reactions a and b yielded desired adducts in a yield of 90%, as the result of 
this study. 
 
General Method for the Synthesis of N-Substituted 2,5-Dioxo-1,2,3,4,5,6,7,8-
octahydroquinoline-3-carboxylates 49 (Table 9).  The methylmalonate 48 was 
dissolved (10 mL) in a screw-cap vial.  Dichloroethane was selected as the 
solvent for those compounds derived from dimethyl malonate, while toluene was 
used for those derived from dibenzyl malonate.  To the solution was then slowly 
added trifluoroacetic acid (30.0 equiv).  The vial was sealed and stirred at 90 °C.  
The reaction was monitored by TLC.  The reaction time varied from 0.5 to 3 hr.  
The reaction medium was then allowed to cool and washed with saturated 
NaHCO3 (20 mL).  The aqueous phase was extracted with CH2Cl2 or EtOAc (3 x 
10 mL).  The organic layers were combined and washed with brine and dried 




and the residue was purified by flash column flash column chromatography on 










(49a).  After chromatographic purification, a light yellow oil was obtained (79%).  
1H NMR (CDCl3, 400 MHz, ppm): δ 7.27 (m, 2H), 7.20 (m, 1H), 7.11 (m, 2H), 
4.96 (q-like, J = 16.4 Hz, 2H), 3.70 (s, 3H), 3.57 (t, J = 8.3 Hz, 1H), 3.00 (dd, J = 
8.4, 16.9 Hz, 1H), 2.78 (dd, J = 8.5, 16.9 Hz, 1H), 2.42 (t, J = 6.3 Hz, 2H), 2.28 (t, 
J = 6.2 Hz, 2H), 1.88 (m, 2H); 13C NMR (CDCl3, 400 MHz, ppm): δ 195.8, 169.6, 
167.2, 154.7, 136.7, 128.98, 127.7, 126.2, 115.0, 52.8, 47.4, 45.7, 36.0, 26.5, 
21.8, 20.8; ESI-HRMS: calc’d m/e for [M+H+] C18H20NO4: 360.1811, found 
360.1801; IR (neat, NaCl, cm-1): 2953, 1743, 1692, 1654, 1622, 1497, 1454, 










(49b).  After chromatographic purification, a light yellow oil was obtained (70%).  
1H NMR (CDCl3, 400 MHz, ppm): δ 7.37 -7.24 (m, 8H), 7.16 (m, 2H), 5.20 (q-like, 




J = 7.5, 16.8 Hz, 1H), 2.80 (dd, J = 6.6, 16.8 Hz, 1H), 2.41 (m, 2H), 2.26 (m, 2H), 
1.84 (m, 2H); 13C NMR (CDCl3, 400 MHz, ppm): δ 195.6, 168.9, 167.1, 154.7, 
136.6, 135.4, 129.0, 128.6, 128.4, 128.3, 127.5, 126.1, 115.0, 67.3, 47.5, 45. 6, 
35.9, 26.3, 21.6, 20.8; ESI-HRMS: calc’d m/e for [M+H+] C24H24NO4: 390.1705, 
found 390.1700; IR (neat, NaCl, cm-1): 2953, 1738, 1691, 1652, 1622, 1497, 










(49c).  After chromatographic purification, a white solid was obtained (84%, mp: 
120 - 121 °C).  1H NMR (CDCl3, 400 MHz, ppm): δ 7.48 - 7.40 (m, 3H), 7.17 (s, 
2H), 3.76 (s, 3H), 3.68 (t, J = 7.6 Hz, 1H), 3.18 (dd, J = 8.4, 17.0 Hz, 1H), 2.90 
(dd, J = 8.6, 17.0 Hz, 1H), 2.39 (t, J = 6.0 Hz, 2H), 2.09 (t, J = 6.0 Hz, 2H), 1.93 
(m, 2H); 13C NMR (CDCl3, 400 MHz, ppm): δ 196.0, 169.6, 167.1, 154.9, 137.0, 
129.7, 129.0, 113.9, 52.8, 47.6, 36.3, 28.0, 21.9, 21.1; ESI-HRMS: calc’d m/e for 
[M+H+] C17H18NO4: 300.1236, found 300.1228; IR (neat, NaCl, cm-1): 2953, 1742, 













(49d).  After chromatographic purification, a light yellow solid was obtained (49%, 
mp: 117 - 118 °C).  1H NMR (CDCl3, 400 MHz, ppm): δ 7.43 (m, 3H), 7.35 (m, 
5H), 7.09 (m, 2H), 5.20 (q-like, J = 12.1 Hz, 2H), 3.73 (t, J = 6.5 Hz, 1H), 3.30 
(dd, J = 6.5, 17.0 Hz, 1H), 2.85 (dd, J = 6.6, 16.9 Hz, 1H), 2.33 (m, 2H), 1.99 (m, 
2H), 1.81 (m, 2H); 13C NMR (CDCl3, 400 MHz, ppm): δ 195.8, 168.8, 167.0, 
154.8, 136.9, 135.3, 129.6, 128.9, 128.6, 128.5, 128.4, 113.8, 67.4, 47.6, 36.1, 
27.9, 21.7, 21.2; ESI-HRMS: calc’d m/e for [M+H+] C23H22NO4: 376.1549, found 
376.1546; IR (neat, NaCl, cm-1): 2951, 1740, 1704, 1652, 1624, 1595, 1491, 










(49e).  After chromatographic purification, a viscous yellow oil was obtained 
(57%).  1H NMR (CDCl3, 400 MHz, ppm): δ 3.74 (s, 3H), 3.69 (m, 2H), 3.48 (dd, J 
= 6.8, 9.3 Hz, 1H), 2.94 (dd, J = 9.3, 17.0 Hz, 1H), 2. 79 (dd, J = 6.8, 16.6 Hz, 
1H), 2.60 (m, 2H), 2.40 (t, J = 6.2 Hz, 2H), 2.07 (m, 2H), 1.54 (m, 2H), 1.35 (m, 
2H), 0.94 (t, J = 7.3 Hz, 2H); 13C NMR (CDCl3, 400 MHz, ppm): δ 195.66, 169.62, 
166.79, 154.34, 114.73, 52.60, 47.31, 42.60, 35.98, 31.24, 26.20, 21.84, 20.64, 




280.1544; IR (neat, NaCl, cm-1): 2957, 1744, 1690, 1652, 1618, 1435, 1393, 










(1f).  After chromatographic purification, a viscous colorless oil was obtained 
(60%).  1H NMR (CDCl3, 400 MHz, ppm): δ 7.36 - 7.29 (m, 5H), 5.16 (q-like, J = 
12.2 Hz, 2H), 3.68 (m, 2H), 3.52 (dd, J = 6.6, 8.0 Hz, 1H), 3.04 (dd, J = 8.0, 16.7 
Hz, 1H), 2.73 (dd, J = 6.4, 17.2 Hz, 1H), 2.51 (m, 2H), 2.34 (m, 2H), 1.96 (m, 2H), 
1.50 (m, 2H), 1.34 (m, 2H), 0.93 (t, J = 7.2 Hz, 3H); 13C NMR (CDCl3, 400 MHz, 
ppm): δ 195.55, 168.94, 166.72, 154.45, 135.43, 128.55, 128.37, 128.31, 114.66, 
67.18, 47.46, 42.56, 35.93, 31.18, 26.12, 21.74, 20.76, 20.06, 13.74; ESI-HRMS: 
calc’d m/e for [M+H+] C21H26NO4: 356.1862, found 356.1861; IR (neat, NaCl, cm-











3-carboxylate (49g).  After chromatographic purification, a viscous colorless oil 




1H), 7.17 (m, 2H), 5.00 (q-like, J = 16.4 Hz, 2H), 3.75 (s, 3H), 3.64 (t, J = 6.9 Hz, 
1H), 3.14 (dd, J = 7.2, 16.8 Hz, 1H), 2.80 (dd, J = 6.6, 16.8 Hz, 1H), 2.34 (s, 2H), 
2.22 (s, 2H), 0.95 (s, 3H), 0.92 (s, 3H); 13C NMR (CDCl3, 400 MHz, ppm): δ 
195.7, 169.6, 167.4, 152.9, 136.8, 129.1, 127.7, 126.1, 114.1, 52.8, 49.8, 47.5, 
45.6, 40.1, 33.2, 28.9, 27.5, 20.6; ESI-HRMS: calc’d m/e for [M+H+] C20H24NO4: 
342.1705, found 342.1698; IR (neat, NaCl, cm-1): 2956, 1741,1693, 1653, 1625, 










3-carboxylate (49h).  After chromatographic purification, a viscous colorless oil 
was obtained (64%).  1H NMR (CDCl3, 400 MHz, ppm): δ 7.35 - 7.25 (m, 8H), 
7.16 (m, 2H), 5.18 (q-like, J= 12.2 Hz, 2H), 5.00 (q-like, J = 16.6 Hz, 2H), 3.69 (t, 
J = 6.8 Hz, 1H), 3.19 (dd, J = 7.0, 16.8 Hz, 1H), 2.79 (dd, J = 4.7, 16.8 Hz, 1H), 
2.27 (q-like, J = 10.2 Hz, 2H), 2.15 (q-like, J = 16.3 Hz, 2H), 0.90 (s, 3H), 0.84 (s, 
3H); 13C NMR (CDCl3, 400 MHz, ppm): δ 195.6, 169.0, 167.3, 153.0, 136.7, 
135.4, 129.0, 128.7, 128.5, 128.4, 127.6, 126.0, 114.0, 67.4, 49.7, 47.6, 45.5, 
40.0, 33.0, 28.6, 27.7, 20.7; ESI-HRMS: calc’d m/e for [M+H+] C26H28NO4: 
418.2018, found 418.2021; IR (neat, NaCl, cm-1): 2959, 1739, 1694, 1653, 1625, 













3-carboxylate (49i).  After chromatographic purification, a white solid was 
obtained (64%, mp: 123 - 124 °C).  1H NMR (CDCl3, 400 MHz, ppm): δ 7.50 - 
7.42 (m, 3H), 7.21 - 7.10 (m, 2H), 3.75 (s, 3H), 3.69 (t, J = 5.8 Hz, 1H), 3.25 (dd, 
J = 6.6, 16.9 Hz, 1H), 2.86 (dd, J = 6.6, 16.9 Hz, 1H), 2.26 (s, 2H), 1.95 (q-like, J 
= 17.6 Hz, 2H), 0.97 (s, 3H), 0.95 (s, 3H); 13C NMR (CDCl3, 400 MHz, ppm): δ 
195.8, 169.5, 167.2, 153.0, 136.9, 129.7, 128.9, 128.5, 113.0, 52.7, 49.9, 47.5, 
41.5, 33.2, 28.8, 27.4, 20.8; ESI-HRMS: calc’d m/e for [M+H+] C19H22NO4: 
328.1549, found 328.1540; IR (neat, NaCl, cm-1): 2956, 1740, 1704, 1654, 1628, 










3-carboxylate (49j).  After chromatographic purification, a white solid was 
obtained (64%, mp: 126 - 127 °C).  1H NMR (CDCl3, 400 MHz, ppm): δ 7.43 (m, 
3H), 7.34 (m, 5H), 7.07 (m, 2H), 5.18 (q-like, J = 12.2 Hz, 2H), 3.73 (t, J = 6.3 Hz, 
1H), 3.33 (dd, J = 5.8, 16.9 Hz, 1H), 2.84 (dd, J = 6.3, 16.9 Hz, 1H), 2.19 (q-like, 
J = 16.4 Hz, 2H), 1.88 (q-like, J = 17.0 Hz, 2H), 0.94 (s, 3H), 0.86 (s, 3H); 13C 




128.9, 128.7, 128.5, 128.5, 112.8, 67.5, 49.8, 47.6, 41.4, 33.0, 28.6, 27.6, 20.9; 
ESI-HRMS: calc’d m/e for [M+H+] C25H26NO4: 404,1862, found 404.1864; IR 
(neat, NaCl, cm-1): 2958, 1740, 1705, 1654, 1628, 1596, 1492, 1455, 1379, 1351, 










carboxylate (49k).  After chromatographic purification, a viscous light yellow oil 
was obtained (62%).  1H NMR (CDCl3, 400 MHz, ppm): δ 3.71 (s, 3H), 3.68 (m, 
2H), 3.48 (dd, J = 6.6, 8.0 Hz, 1H), 3.00 (dd, J = 8.1, 16.7 Hz, 1H), 2.72 (dd, J = 
6.6, 16.8 Hz, 1H), 2.42 (s, 2H), 2.27 (s, 2H), 1.53 (m, 2H), 1.35 (m, 2H), 1.10 (s, 
3H), 1.07 (s, 3H), 0.94 (t, J = 7.3 Hz, 3H); 13C NMR (CDCl3, 400 MHz, ppm): δ 
195.6, 169.7, 167.1, 152.6, 113.8, 52.7, 49.8, 47.4, 42.5, 40.1, 33.2, 31.4, 29.0, 
27.9, 20.5, 20.2, 13.9; ESI-HRMS: calc’d m/e for [M+H+] C17H26NO4: 308.1862, 
found 308.1868; IR (neat, NaCl, cm-1): 2958, 2872, 1745, 1692, 1653, 1623, 














obtained (62%, mp: 134 - 135 °C).  1H NMR (CDCl3, 400 MHz, ppm): δ 7.37 - 
7.29 (m, 3H), 7.24 (m, 2H), 4.96 (q-like, J = 15.8 Hz, 2H), 3.77 (s, 3H), 3.72 (t, J 
= 7.6 Hz, 1H), 2.96 (dd, J = 7.3, 17.3 Hz, 1H), 2.75 (dd, J = 7.9, 17.0 Hz, 1H), 
2.65 (m, 2H), 2.46 (m, 2H); 13C NMR (CDCl3, 400 MHz, ppm): δ 201.5, 169.6, 
168.4, 167.4, 136.3, 129.1, 128.0, 126.9, 126.8, 116.9, 53.0, 47.5, 46.5, 34.3, 
25.4, 19.8; ESI-HRMS: calc’d m/e for [M+H+] C17H18NO4: 300.1236, found 
300.1230; IR (neat, NaCl, cm-1): 2953, 2928, 1742, 1687, 1640, 1496, 1437, 










3-carboxylate (49m).  After chromatographic purification, a white solid was 
obtained (49%, mp: 100 - 101 °C).  1H NMR (CDCl3, 400 MHz, ppm): δ 7.50 - 
7.44 (m, 3H), 7.24 (m, 2H), 3.79 (t, J = 6.4 Hz, 1H), 3.78 (s, 3H), 3.06 (dd, J = 
6.3, 17.1 Hz, 1H), 2.83 (dd, J = 7.8, 17.1 Hz, 1H), 2.45 (m, 2H), 2.33 (m, 2H); 13C 
NMR (CDCl3, 400 MHz, ppm): δ 201.9, 169.7, 168.6, 167.3, 136.1, 129.8, 129.4, 
128.3, 116.1, 53.1, 47.6, 34.3, 26.0, 20.1; ESI-HRMS: calc’d m/e for [M+H+] 
C16H16NO4: 286.1079, found 286.1074; IR (neat, NaCl, cm-1): 2954, 2929, 1743, 








2,2'-Methylenebis(3-(benzylamino)cyclohex-2-enone).  The enaminone was 
dissolved in acetonitrile, and paraformaldehyde and trimethylsilyl chloride (1.0 
equiv) were added.  The reaction was stirred 60 °C for 2 h.  Upon disappearance 
of the starting material, the solvent was removed in vacuo, and the crude 
material was purified by flash column flash column chromatography on silica gel, 
using 50% acetone:hexanes (v/v) as the eluent.  After purification, a light yellow 
oil was obtained (74%).  1H NMR (CDCl3, 400 MHz, ppm): δ 9.51 (s, 2H), 7.33 - 
7.20 (m, 10H), 4.48 (d, J= 6.4 Hz, 4H), rotomer (-CH2 bridge) [4.11, 3.77, 3.44], 
2.36 (s, 4H), 2.27 (s 4H), 1.82 (m, 4H); 13C NMR (CDCl3, 400 MHz, ppm): δ 
194.9, 166.9, 139.1, 128.8, 127.3, 126.7, 108.9, 63.8, 52.9, 46.8, 35.7, 25.6, 
21.5, 17.7; ESI-HRMS: calc’d m/e for [M+H+] C27H31N2O2: 415.2386, found 
415.2390; IR (neat, NaCl, cm-1): 3262, 3171, 3030, 2946, 1734, 1610, 1560, 
1478, 1433, 1355, 1317, 1201, 1127, 1106, 1051, 1011. 
 
General Procedure for the Oxidation of Methyl 2,5-Dioxo-1,2,3,4,5,6,7,8-
octahydroquinoline-3-carboxylates to Form 1-Substituted Methyl 2,5-Dioxo-
1,2,5,6,7,8-hexahydroquinoline-3-carboxylates 50. The 1-substituted methyl 
2,5-dioxo-1,2,3,4,5,6,7,8-octahydroquinoline-3-carboxylate 49 (1.4 mmol) was 
dissolved in MeOH (10 mL).  To the stirring solution, triethylamine (1.1 mL, 4.2 




cannula.  The mixture was then heated to 80 °C and allowed to react for 3 h.  
The reaction was then allowed to cool to room temperature, and the solvent was 
removed in vacuo.  The crude product was purified by flash column 









(50a).  After chromatographic purification, a yellow amorphous solid was 
obtained (94%).  1H NMR (CDCl3, 400 MHz, ppm): δ 8.79 (s, 1H), 7.35 - 7.28 (m, 
3H), 7.16 (d, J = 6.8 Hz, 2H), 5.42 (s, 2H), 3.90 (s, 3H), 2.91 (t, J = 6.2 Hz, 2H), 
2.52 (t, J = 6.4 Hz, 2H), 2.08 (m, 2H); 13C NMR (CDCl3, 400 MHz, ppm): δ 193.0, 
164.8, 160.8, 159.8, 141.6, 134.9, 129.1, 128.0, 126.5, 118.5, 114.0, 52.4, 47.6, 
36.1, 27.9, 21.0; ESI-HRMS: calc’d m/e for [M+H+] C18H18NO4: 312.1236, found 
312.1232; IR (neat, NaCl, cm-1): 2953, 1739, 1706, 1665, 1598, 1540, 1496, 
1438, 1388, 1357, 1338, 1318, 1249, 1233, 1192, 1147, 1116, 1047, 1017, 924, 












(50b).  After chromatographic purification, a white solid was obtained (24%, mp: 
142 - 144 °C).  1H NMR (CDCl3, 400 MHz, ppm): δ 8.81 (s, 1H), 7.55 - 7.49 (m, 
3H), 7.18 (m, 2H), 3.86 (s, 3H), 2.52 (t, J = 6.4 Hz, 2H), 2.48 (t, J = 6.2 Hz, 2H), 
2.03 (m, 2H); 13C NMR (CDCl3, 400 MHz, ppm): δ 193.2, 164.8, 164.7, 160.9, 
159.7, 142.0, 137.1, 130.1, 129.6, 129.1, 127.6, 119.2, 113.6, 52.3, 36.2, 29.5, 









(50c).  After chromatographic purification, a yellow oil was obtained (60%).  1H 
NMR (CDCl3, 400 MHz, ppm): δ 8.70 (s, 1H), 4.05 (t, J = 7.9 Hz, 2H), 3.86 (s, 
3H), 3.00 (t, J = 6.2 Hz, 2H), 2.55 (t, J = 7.2 Hz, 2H), 2.20 (m, 2H), 1.67 (m, 2H), 
1.42 (m, 2H), 0.96 (t, J = 7.3 Hz, 3H); 13C NMR (CDCl3, 400 MHz, ppm): δ 193.1, 
164.9, 159.9, 159.3, 141.2, 118.1, 113.8, 52.3, 44.9, 36.2, 30.3, 26.7, 21.1, 20.3, 











Methyl 2,5-Dioxo-1,2,5,6,7,8-hexahydroquinoline-3-carboxylate (50d).  After 
chromatographic purification, a white solid was obtained (25%, mp: 226 - 228 
°C).  1H NMR (MeOD, 400 MHz, ppm): δ 8.68 (s, 1H), 3.87 (s, 3H), 2.94 (t, J = 
6.2 Hz, 2H), 2.59 (t, J = 6.1 Hz, 2H), 2.18 (m, 2H); 13C NMR (MeOD, 400 MHz, 
ppm): δ 195.7, 166.0, 163.1, 162.1, 143.9, 119.1, 114.4, 52.5, 37.8, 28.0, 22.0; 
ESI-HRMS: calc’d m/e for [M+H+] C11H12NO4: 222.0766, found 222.0762.  
 
General Procedure for the Preparation of 3-Cyano-4,6,7,8-
tetrahydroquinoline-2,5-diones 51 (Table 10).  The enaminone was dissolved 
in acetonitrile (10 mL per 0.1 mmol), and stirred at room temperature.  To the 
stirring solution, lithium perchlorate (1 equiv relative to the enaminone) was 
added, followed by the addition of PPh3/PBu3 (0.5 equiv), methyl cyanoacetate 
(1.5 equiv) and paraformaldehyde (1.0 equiv) in sequence.  The reaction was 
heated to 60 °C in a sealed vessel and monitored by TLC.  When the starting 
material was completely consumed, the reaction was quenched with saturated 
sodium bicarbonate.  The organic layer was separated and aqueous phase was 
extracted with CH2Cl2 (10 mL × 2).  The organic layers were combined, dried 
over MgSO4, filtered and concentrated in vacuo.  The crude product was purified 












1-Benzyl-2,5-dioxo-1,2,3,4,5,6,7,8-octahydroquinoline-3-carbonitrile (51a).  
After chromatographic purification, a colorless oil was obtained (85%).  1H NMR 
(CDCl3, 400 MHz, ppm): δ 7.37 - 7.27 (m, 3H), 7.13 (m, 2H), 5.12 (d, J = 16.3 Hz, 
1H), 4.91 (d, 16.3 Hz, 1H), 3.75 (dd, J = 6.3, 11.3 Hz, 1H), 3.17 (ddd, J = 1.4, 
4.8, 15.3 Hz, 1H), 2.87 (m, 1H), 2.53 (m, 2H), 2.38 (t, J = 6.2 Hz, 2H), 1.99 (m, 
2H); 13C NMR (CDCl3, 400 MHz, ppm): δ 195.1, 163.0, 154.6, 135.8, 129.2, 
127.9, 126.1, 115.6, 114.6, 46.0, 35.7, 34.4, 26.3, 21.8, 21.5; ESI-HRMS: calc’d 
m/e for [M+H+] C17H17N2O2: 281.1290, found 281.1281; IR (neat, NaCl, cm-1): 
2959, 2890, 2256, 1756, 1700, 1655, 1627, 1497, 1454, 1387, 1307, 1255, 1249, 








2,5-Dioxo-1-phenyl-1,2,3,4,5,6,7,8-octahydroquinoline-3-carbonitrile (51b).  
After chromatographic purification, a yellow solid was obtained (65%, mp: 158 - 
160 °C).  1H NMR (CDCl3, 400 MHz, ppm): δ 7.57 - 7.46 (m, 3H), 7.15 (m, 2H), 
3.83 (dd, J = 6.4, 11.1 Hz, 1H), 3.24 (dd, J = 6.3, 15.2 Hz, 1H), 2.97 (m, 1H), 
2.42 (dt, J = 1.9, 6.4 Hz, 2H), 2.13 (m, 2H), 1.96 (m, 2H); 13C NMR (CDCl3, 400 




115.5, 113.6, 36.0, 34.7, 27.9, 22.1, 21.6; ESI-HRMS: calc’d m/e for [M+H+] 








1-Butyl-2,5-dioxo-1,2,3,4,5,6,7,8-octahydroquinoline-3-carbonitrile (51c).  
After chromatographic purification, a colorless oil was obtained (73%).  1H NMR 
(CDCl3, 400 MHz, ppm): δ 3.77 (m, 1H), 3.63 (m, 2H), 3.11 (dd, J = 6.3, 16.5 Hz, 
1H), 2.74 (m, 1H), 2.61 (m, 2H), 2.43 (t, J = 7.1 Hz, 2H), 2.11 (m, 2H), 1.53 (m, 
2H), 1.34 (m, 2H), 0.94 (t, J = 7.3 Hz, 3H); 13C NMR (CDCl3, 400 MHz, ppm): δ 
195.0, 162.5, 154.4, 115.7, 114.3, 43.1, 35.8, 34.4, 31.2, 26.2, 21.8, 21.7, 20.0, 









carbonitrile (51d).  After chromatographic purification, a colorless oil was 
obtained (68%). 1H NMR (CDCl3, 400 MHz, ppm): δ 7.37 - 7.30 (m, 3H), 7.12 (d, 
J = 7.3 Hz, 2H), 5.13 (d, J = 16.4 Hz, 1H), 4.89 (d, J = 16.4 Hz, 1H), 3.91 (s, 1H), 
3.74 (dd, J = 6.1, 10.0 Hz, 1H), 3.10 (dd, J = 6.0, 16.6 Hz, 1H), 2.96 (m, 1H), 




400 MHz, ppm): δ 195.1, 163.1, 152.7, 135.8, 129.2, 127.9, 126.0, 115.6, 113.6, 
49.5, 45.9, 39.9, 34.3, 33.0, 28.4, 27.8, 21.5; ESI-HRMS: calc’d m/e for [M+H+] 









carbonitrile (51e).  After chromatographic purification, a white solid was 
obtained (75%, mp: 136 - 137 °C).  1H NMR (CDCl3, 400 MHz, ppm): δ 3.67 (m, 
1H), 3.57 (m, 2H), 2.98 (dd, J = 6.3, 16.6 Hz, 1H), 2.76 (m, 1H), 2.43 (d, J = 17.0 
Hz, 1H), 2.36 (d, J = 16.9 Hz, 1H), 2.25 (d, J = 3.2 Hz, 2H), 1.53 (m, 2H), 1.08 (s, 
3H), 1.06 (s, 3H), 0.88 (t, J = 7.4 Hz, 3H); 13C NMR (CDCl3, 400 MHz, ppm): δ 
194.0, 161.7, 151.5, 114.8, 112.2, 48.5, 43.6, 38.9, 33.4, 32.1, 27.5, 27.3, 21.5, 












white solid was obtained (67%, mp: 77 - 79 °C)).  1H NMR (CDCl3, 400 MHz, 
ppm): δ 3.91 (m, 2H), 3.63 (dd, J = 6.2, 11.1 Hz, 1H), 3.52 (m, 2H), 3.28 (s, 3H), 
3.08 (dd, J = 6.2, 16.3 Hz, 1H), 2.80 (m, 1H), 2.61 (d, J = 17.2 Hz, 1H), 2.49 (d, J 
= 17.2 Hz, 1H), 2.28 (d, J = 3.0 Hz, 2H), 1.10 (s, 3H), 1.08 (s, 3H); 13C NMR 
(CDCl3, 400 MHz, ppm): δ 195.4, 163.1, 153.6, 115.7, 112.6, 70.3, 59.1, 49.5, 
43.3, 40.2, 34.4, 33.0, 28.4, 28.3, 21.5; ESI-HRMS: calc’d m/e for [M+H+] 
C15H21N2O3: 277.1552, found 277.1558. 
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